id	sid	tid	token	lemma	pos
dpc-5845	1	1	dermatology	dermatology	NOUN
dpc-5845	1	2	:	:	PUNCT
dpc-5845	1	3	practical	practical	ADJ
dpc-5845	1	4	and	and	CCONJ
dpc-5845	1	5	conceptual	conceptual	ADJ
dpc-5845	1	6	original	original	ADJ
dpc-5845	1	7	article	article	NOUN
dpc-5845	1	8	|	|	ADV
dpc-5845	1	9	dermatol	dermatol	ADJ
dpc-5845	1	10	pract	pract	NOUN
dpc-5845	1	11	concept	concept	NOUN
dpc-5845	1	12	.	.	PUNCT
dpc-5845	2	1	2025;15(3):5845	2025;15(3):5845	NUM
dpc-5845	2	2	1	1	NUM
dpc-5845	2	3	impact	impact	NOUN
dpc-5845	2	4	of	of	ADP
dpc-5845	2	5	disease	disease	NOUN
dpc-5845	2	6	activity	activity	NOUN
dpc-5845	2	7	-	-	PUNCT
dpc-5845	2	8	guided	guide	VERB
dpc-5845	2	9	dose	dose	NOUN
dpc-5845	2	10	reduction	reduction	NOUN
dpc-5845	2	11	on	on	ADP
dpc-5845	2	12	il-17	il-17	ADV
dpc-5845	2	13	and	and	CCONJ
dpc-5845	2	14	il-23	il-23	VERB
dpc-5845	2	15	inhibitors	inhibitor	NOUN
dpc-5845	2	16	in	in	ADP
dpc-5845	2	17	psoriasis	psoriasis	NOUN
dpc-5845	2	18	:	:	PUNCT
dpc-5845	2	19	a	a	DET
dpc-5845	2	20	real	real	ADJ
dpc-5845	2	21	-	-	PUNCT
dpc-5845	2	22	world	world	NOUN
dpc-5845	2	23	assessment	assessment	NOUN
dpc-5845	2	24	of	of	ADP
dpc-5845	2	25	efficacy	efficacy	NOUN
dpc-5845	2	26	,	,	PUNCT
dpc-5845	2	27	safety	safety	NOUN
dpc-5845	2	28	,	,	PUNCT
dpc-5845	2	29	and	and	CCONJ
dpc-5845	2	30	economic	economic	ADJ
dpc-5845	2	31	benefits	benefit	NOUN
dpc-5845	2	32	edoardo	edoardo	PROPN
dpc-5845	2	33	cammarata1	cammarata1	PROPN
dpc-5845	2	34	,	,	PUNCT
dpc-5845	2	35	chiara	chiara	PROPN
dpc-5845	2	36	airoldi2	airoldi2	PROPN
dpc-5845	2	37	,	,	PUNCT
dpc-5845	2	38	jacopo	jacopo	PROPN
dpc-5845	2	39	colombo1	colombo1	PROPN
dpc-5845	2	40	,	,	PUNCT
dpc-5845	2	41	andrealuna	andrealuna	PROPN
dpc-5845	2	42	ucciero3	ucciero3	PROPN
dpc-5845	2	43	,	,	PUNCT
dpc-5845	2	44	luca	luca	PROPN
dpc-5845	2	45	mastorino4	mastorino4	PROPN
dpc-5845	2	46	,	,	PUNCT
dpc-5845	2	47	veronica	veronica	PROPN
dpc-5845	2	48	arese5	arese5	PROPN
dpc-5845	2	49	,	,	PUNCT
dpc-5845	2	50	lorenza	lorenza	ADJ
dpc-5845	2	51	burzi6	burzi6	PROPN
dpc-5845	2	52	,	,	PUNCT
dpc-5845	2	53	franco	franco	PROPN
dpc-5845	2	54	castelli7	castelli7	PROPN
dpc-5845	2	55	,	,	PUNCT
dpc-5845	2	56	massimo	massimo	PROPN
dpc-5845	2	57	chiarpenello5	chiarpenello5	PROPN
dpc-5845	2	58	,	,	PUNCT
dpc-5845	2	59	francesca	francesca	PROPN
dpc-5845	2	60	graziola8	graziola8	PROPN
dpc-5845	2	61	,	,	PUNCT
dpc-5845	2	62	claudia	claudia	PROPN
dpc-5845	2	63	leporati6	leporati6	PROPN
dpc-5845	2	64	,	,	PUNCT
dpc-5845	2	65	michela	michela	PROPN
dpc-5845	2	66	ortoncelli4	ortoncelli4	PROPN
dpc-5845	2	67	,	,	PUNCT
dpc-5845	2	68	paolo	paolo	PROPN
dpc-5845	2	69	pella8	pella8	PROPN
dpc-5845	2	70	,	,	PUNCT
dpc-5845	2	71	ginevra	ginevra	PROPN
dpc-5845	2	72	pertusi9	pertusi9	PROPN
dpc-5845	2	73	,	,	PUNCT
dpc-5845	2	74	alessia	alessia	PROPN
dpc-5845	2	75	pisterna3	pisterna3	PROPN
dpc-5845	2	76	,	,	PUNCT
dpc-5845	2	77	pietro	pietro	PROPN
dpc-5845	2	78	quaglino4	quaglino4	PROPN
dpc-5845	2	79	,	,	PUNCT
dpc-5845	2	80	simone	simone	NOUN
dpc-5845	2	81	ribero4	ribero4	PROPN
dpc-5845	2	82	,	,	PUNCT
dpc-5845	2	83	gianluca	gianluca	PROPN
dpc-5845	2	84	rossotto10	rossotto10	VERB
dpc-5845	2	85	,	,	PUNCT
dpc-5845	2	86	rossana	rossana	PROPN
dpc-5845	2	87	tiberio9	tiberio9	PROPN
dpc-5845	2	88	,	,	PUNCT
dpc-5845	2	89	paolo	paolo	PROPN
dpc-5845	2	90	dapavo4	dapavo4	PROPN
dpc-5845	2	91	*	*	PROPN
dpc-5845	2	92	,	,	PUNCT
dpc-5845	2	93	paola	paola	PROPN
dpc-5845	2	94	savoia11	savoia11	PROPN
dpc-5845	2	95	*	*	PROPN
dpc-5845	2	96	1	1	NUM
dpc-5845	2	97	scdu	scdu	NOUN
dpc-5845	2	98	dermatologia	dermatologia	NOUN
dpc-5845	2	99	,	,	PUNCT
dpc-5845	2	100	aou	aou	PROPN
dpc-5845	2	101	maggiore	maggiore	PROPN
dpc-5845	2	102	della	della	PROPN
dpc-5845	2	103	carità	carità	PROPN
dpc-5845	2	104	,	,	PUNCT
dpc-5845	2	105	novara	novara	PROPN
dpc-5845	2	106	,	,	PUNCT
dpc-5845	2	107	italy	italy	PROPN
dpc-5845	2	108	2	2	NUM
dpc-5845	2	109	dept	dept	NOUN
dpc-5845	2	110	of	of	ADP
dpc-5845	2	111	translational	translational	ADJ
dpc-5845	2	112	medicine	medicine	NOUN
dpc-5845	2	113	,	,	PUNCT
dpc-5845	2	114	university	university	NOUN
dpc-5845	2	115	of	of	ADP
dpc-5845	2	116	eastern	eastern	PROPN
dpc-5845	2	117	piedmont	piedmont	PROPN
dpc-5845	2	118	,	,	PUNCT
dpc-5845	2	119	novara	novara	PROPN
dpc-5845	2	120	,	,	PUNCT
dpc-5845	2	121	italy	italy	PROPN
dpc-5845	2	122	3	3	NUM
dpc-5845	2	123	hospital	hospital	NOUN
dpc-5845	2	124	pharmacy	pharmacy	NOUN
dpc-5845	2	125	,	,	PUNCT
dpc-5845	2	126	aou	aou	PROPN
dpc-5845	2	127	maggiore	maggiore	PROPN
dpc-5845	2	128	della	della	PROPN
dpc-5845	2	129	carità	carità	PROPN
dpc-5845	2	130	,	,	PUNCT
dpc-5845	2	131	novara	novara	PROPN
dpc-5845	2	132	,	,	PUNCT
dpc-5845	2	133	italy	italy	PROPN
dpc-5845	2	134	4	4	NUM
dpc-5845	2	135	dermatologic	dermatologic	ADJ
dpc-5845	2	136	clinic	clinic	NOUN
dpc-5845	2	137	,	,	PUNCT
dpc-5845	2	138	department	department	NOUN
dpc-5845	2	139	of	of	ADP
dpc-5845	2	140	clinical	clinical	ADJ
dpc-5845	2	141	medicine	medicine	NOUN
dpc-5845	2	142	,	,	PUNCT
dpc-5845	2	143	university	university	PROPN
dpc-5845	2	144	of	of	ADP
dpc-5845	2	145	turin	turin	PROPN
dpc-5845	2	146	,	,	PUNCT
dpc-5845	2	147	turin	turin	PROPN
dpc-5845	2	148	,	,	PUNCT
dpc-5845	2	149	italy	italy	PROPN
dpc-5845	2	150	5	5	NUM
dpc-5845	2	151	ssd	ssd	PROPN
dpc-5845	2	152	dermatologia	dermatologia	NOUN
dpc-5845	2	153	,	,	PUNCT
dpc-5845	2	154	ao	ao	PROPN
dpc-5845	2	155	santa	santa	PROPN
dpc-5845	2	156	croce	croce	PROPN
dpc-5845	2	157	e	e	PROPN
dpc-5845	2	158	carle	carle	PROPN
dpc-5845	2	159	hospital	hospital	PROPN
dpc-5845	2	160	,	,	PUNCT
dpc-5845	2	161	cuneo	cuneo	PROPN
dpc-5845	2	162	,	,	PUNCT
dpc-5845	2	163	italy	italy	PROPN
dpc-5845	2	164	6	6	NUM
dpc-5845	2	165	ss	ss	NOUN
dpc-5845	2	166	dermatologia	dermatologia	NOUN
dpc-5845	2	167	,	,	PUNCT
dpc-5845	2	168	aou	aou	PROPN
dpc-5845	2	169	ss	ss	PROPN
dpc-5845	2	170	.	.	PUNCT
dpc-5845	3	1	antonio	antonio	PROPN
dpc-5845	3	2	e	e	PROPN
dpc-5845	3	3	biagio	biagio	PROPN
dpc-5845	3	4	e	e	PROPN
dpc-5845	3	5	cesare	cesare	PROPN
dpc-5845	3	6	arrigo	arrigo	PROPN
dpc-5845	3	7	,	,	PUNCT
dpc-5845	3	8	alessandria	alessandria	PROPN
dpc-5845	3	9	,	,	PUNCT
dpc-5845	3	10	italy	italy	PROPN
dpc-5845	3	11	7	7	NUM
dpc-5845	3	12	uo	uo	NOUN
dpc-5845	3	13	dermatologia	dermatologia	NOUN
dpc-5845	3	14	,	,	PUNCT
dpc-5845	3	15	ospedale	ospedale	PROPN
dpc-5845	3	16	koelliker	koelliker	NOUN
dpc-5845	3	17	,	,	PUNCT
dpc-5845	3	18	torino	torino	PROPN
dpc-5845	3	19	,	,	PUNCT
dpc-5845	3	20	italy	italy	PROPN
dpc-5845	3	21	8	8	NUM
dpc-5845	3	22	ssd	ssd	PROPN
dpc-5845	3	23	dermatologia	dermatologia	NOUN
dpc-5845	3	24	,	,	PUNCT
dpc-5845	3	25	ospedale	ospedale	PROPN
dpc-5845	3	26	degli	degli	NOUN
dpc-5845	3	27	infermi	infermi	PROPN
dpc-5845	3	28	,	,	PUNCT
dpc-5845	3	29	biella	biella	PROPN
dpc-5845	3	30	,	,	PUNCT
dpc-5845	3	31	italy	italy	PROPN
dpc-5845	3	32	9	9	NUM
dpc-5845	3	33	sc	sc	PROPN
dpc-5845	3	34	dermatologia	dermatologia	PROPN
dpc-5845	3	35	,	,	PUNCT
dpc-5845	3	36	s.	s.	PROPN
dpc-5845	3	37	andrea	andrea	PROPN
dpc-5845	3	38	hospital	hospital	PROPN
dpc-5845	3	39	,	,	PUNCT
dpc-5845	3	40	asl	asl	PROPN
dpc-5845	3	41	vercelli	vercelli	PROPN
dpc-5845	3	42	,	,	PUNCT
dpc-5845	3	43	vercelli	vercelli	PROPN
dpc-5845	3	44	10	10	NUM
dpc-5845	3	45	ssd	ssd	PROPN
dpc-5845	3	46	dermatologia	dermatologia	NOUN
dpc-5845	3	47	,	,	PUNCT
dpc-5845	3	48	cardinal	cardinal	ADJ
dpc-5845	3	49	massaia	massaia	PROPN
dpc-5845	3	50	hospital	hospital	PROPN
dpc-5845	3	51	,	,	PUNCT
dpc-5845	3	52	asti	asti	PROPN
dpc-5845	3	53	,	,	PUNCT
dpc-5845	3	54	italy	italy	PROPN
dpc-5845	3	55	11	11	NUM
dpc-5845	3	56	dept	dept	NOUN
dpc-5845	3	57	.	.	PROPN
dpc-5845	3	58	of	of	ADP
dpc-5845	3	59	health	health	NOUN
dpc-5845	3	60	science	science	NOUN
dpc-5845	3	61	,	,	PUNCT
dpc-5845	3	62	university	university	NOUN
dpc-5845	3	63	of	of	ADP
dpc-5845	3	64	eastern	eastern	PROPN
dpc-5845	3	65	piedmont	piedmont	PROPN
dpc-5845	3	66	,	,	PUNCT
dpc-5845	3	67	novara	novara	PROPN
dpc-5845	3	68	,	,	PUNCT
dpc-5845	3	69	italy	italy	PROPN
dpc-5845	3	70	*	*	PUNCT
dpc-5845	3	71	last	last	ADJ
dpc-5845	3	72	name	name	NOUN
dpc-5845	3	73	co	co	NOUN
dpc-5845	3	74	-	-	NOUN
dpc-5845	3	75	authorship	authorship	ADJ
dpc-5845	3	76	key	key	ADJ
dpc-5845	3	77	words	word	NOUN
dpc-5845	3	78	:	:	PUNCT
dpc-5845	3	79	cost	cost	NOUN
dpc-5845	3	80	-	-	PUNCT
dpc-5845	3	81	effectiveness	effectiveness	NOUN
dpc-5845	3	82	analysis	analysis	NOUN
dpc-5845	3	83	,	,	PUNCT
dpc-5845	3	84	dose	dose	NOUN
dpc-5845	3	85	reduction	reduction	NOUN
dpc-5845	3	86	,	,	PUNCT
dpc-5845	3	87	disease	disease	NOUN
dpc-5845	3	88	activity	activity	NOUN
dpc-5845	3	89	-	-	PUNCT
dpc-5845	3	90	guided	guide	VERB
dpc-5845	3	91	therapy	therapy	NOUN
dpc-5845	3	92	,	,	PUNCT
dpc-5845	3	93	il-17	il-17	ADV
dpc-5845	3	94	/	/	SYM
dpc-5845	3	95	il-23	il-23	NOUN
dpc-5845	3	96	inhibitors	inhibitor	NOUN
dpc-5845	3	97	,	,	PUNCT
dpc-5845	3	98	psoriasis	psoriasis	NOUN
dpc-5845	3	99	treatment	treatment	NOUN
dpc-5845	3	100	citation	citation	NOUN
dpc-5845	3	101	:	:	PUNCT
dpc-5845	3	102	cammarata	cammarata	PROPN
dpc-5845	3	103	e	e	NOUN
dpc-5845	3	104	,	,	PUNCT
dpc-5845	3	105	airoldi	airoldi	NOUN
dpc-5845	3	106	c	c	NOUN
dpc-5845	3	107	,	,	PUNCT
dpc-5845	3	108	colombo	colombo	PROPN
dpc-5845	3	109	j	j	PROPN
dpc-5845	3	110	,	,	PUNCT
dpc-5845	3	111	et	et	PROPN
dpc-5845	3	112	al	al	PROPN
dpc-5845	3	113	.	.	PROPN
dpc-5845	3	114	impact	impact	NOUN
dpc-5845	3	115	of	of	ADP
dpc-5845	3	116	disease	disease	NOUN
dpc-5845	3	117	activity	activity	NOUN
dpc-5845	3	118	-	-	PUNCT
dpc-5845	3	119	guided	guide	VERB
dpc-5845	3	120	dose	dose	NOUN
dpc-5845	3	121	reduction	reduction	NOUN
dpc-5845	3	122	on	on	ADP
dpc-5845	3	123	il-17	il-17	ADV
dpc-5845	3	124	and	and	CCONJ
dpc-5845	3	125	il-23	il-23	VERB
dpc-5845	3	126	inhibitors	inhibitor	NOUN
dpc-5845	3	127	in	in	ADP
dpc-5845	3	128	psoriasis	psoriasis	NOUN
dpc-5845	3	129	:	:	PUNCT
dpc-5845	3	130	a	a	DET
dpc-5845	3	131	real	real	ADJ
dpc-5845	3	132	-	-	PUNCT
dpc-5845	3	133	world	world	NOUN
dpc-5845	3	134	assessment	assessment	NOUN
dpc-5845	3	135	of	of	ADP
dpc-5845	3	136	efficacy	efficacy	NOUN
dpc-5845	3	137	,	,	PUNCT
dpc-5845	3	138	safety	safety	NOUN
dpc-5845	3	139	,	,	PUNCT
dpc-5845	3	140	and	and	CCONJ
dpc-5845	3	141	economic	economic	ADJ
dpc-5845	3	142	benefits	benefit	NOUN
dpc-5845	3	143	.	.	PUNCT
dpc-5845	4	1	dermatol	dermatol	NOUN
dpc-5845	4	2	pract	pract	PROPN
dpc-5845	4	3	concept	concept	NOUN
dpc-5845	4	4	.	.	PUNCT
dpc-5845	5	1	2025;15(3):5845	2025;15(3):5845	NUM
dpc-5845	5	2	.	.	PUNCT
dpc-5845	5	3	doi	doi	PROPN
dpc-5845	5	4	:	:	PUNCT
dpc-5845	6	1	https://doi	https://doi	PROPN
dpc-5845	6	2	.	.	PUNCT
dpc-5845	6	3	org/10.5826	org/10.5826	NUM
dpc-5845	6	4	/	/	SYM
dpc-5845	6	5	dpc.1503a5845	dpc.1503a5845	NOUN
dpc-5845	6	6	accepted	accept	VERB
dpc-5845	6	7	:	:	PUNCT
dpc-5845	6	8	june	june	PROPN
dpc-5845	6	9	12	12	NUM
dpc-5845	6	10	,	,	PUNCT
dpc-5845	6	11	2025	2025	NUM
dpc-5845	6	12	;	;	PUNCT
dpc-5845	6	13	published	publish	VERB
dpc-5845	6	14	:	:	PUNCT
dpc-5845	7	1	july	july	PROPN
dpc-5845	7	2	2025	2025	NUM
dpc-5845	7	3	copyright	copyright	NOUN
dpc-5845	7	4	:	:	PUNCT
dpc-5845	7	5	©	©	PROPN
dpc-5845	7	6	2025	2025	NUM
dpc-5845	7	7	cammarata	cammarata	NOUN
dpc-5845	7	8	et	et	PROPN
dpc-5845	7	9	al	al	PROPN
dpc-5845	7	10	.	.	PUNCT
dpc-5845	8	1	this	this	PRON
dpc-5845	8	2	is	be	AUX
dpc-5845	8	3	an	an	DET
dpc-5845	8	4	open	open	ADJ
dpc-5845	8	5	-	-	PUNCT
dpc-5845	8	6	access	access	NOUN
dpc-5845	8	7	article	article	NOUN
dpc-5845	8	8	distributed	distribute	VERB
dpc-5845	8	9	under	under	ADP
dpc-5845	8	10	the	the	DET
dpc-5845	8	11	terms	term	NOUN
dpc-5845	8	12	of	of	ADP
dpc-5845	8	13	the	the	DET
dpc-5845	8	14	creative	creative	ADJ
dpc-5845	8	15	commons	common	NOUN
dpc-5845	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5845	8	17	license	license	NOUN
dpc-5845	8	18	(	(	PUNCT
dpc-5845	8	19	by	by	ADP
dpc-5845	8	20	-	-	PUNCT
dpc-5845	8	21	nc-4.0	nc-4.0	NOUN
dpc-5845	8	22	)	)	PUNCT
dpc-5845	8	23	,	,	PUNCT
dpc-5845	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5845	8	25	,	,	PUNCT
dpc-5845	8	26	which	which	PRON
dpc-5845	8	27	permits	permit	VERB
dpc-5845	8	28	unrestricted	unrestricted	ADJ
dpc-5845	8	29	noncommercial	noncommercial	ADJ
dpc-5845	8	30	use	use	NOUN
dpc-5845	8	31	,	,	PUNCT
dpc-5845	8	32	distribution	distribution	NOUN
dpc-5845	8	33	,	,	PUNCT
dpc-5845	8	34	and	and	CCONJ
dpc-5845	8	35	reproduction	reproduction	NOUN
dpc-5845	8	36	in	in	ADP
dpc-5845	8	37	any	any	DET
dpc-5845	8	38	medium	medium	NOUN
dpc-5845	8	39	,	,	PUNCT
dpc-5845	8	40	provided	provide	VERB
dpc-5845	8	41	the	the	DET
dpc-5845	8	42	original	original	ADJ
dpc-5845	8	43	authors	author	NOUN
dpc-5845	8	44	and	and	CCONJ
dpc-5845	8	45	source	source	NOUN
dpc-5845	8	46	are	be	AUX
dpc-5845	8	47	credited	credit	VERB
dpc-5845	8	48	.	.	PUNCT
dpc-5845	9	1	funding	funding	NOUN
dpc-5845	9	2	:	:	PUNCT
dpc-5845	9	3	none	none	NOUN
dpc-5845	9	4	.	.	PUNCT
dpc-5845	10	1	competing	compete	VERB
dpc-5845	10	2	interests	interest	NOUN
dpc-5845	10	3	:	:	PUNCT
dpc-5845	10	4	none	none	NOUN
dpc-5845	10	5	.	.	PUNCT
dpc-5845	11	1	authorship	authorship	NOUN
dpc-5845	11	2	:	:	PUNCT
dpc-5845	11	3	all	all	DET
dpc-5845	11	4	authors	author	NOUN
dpc-5845	11	5	have	have	AUX
dpc-5845	11	6	contributed	contribute	VERB
dpc-5845	11	7	significantly	significantly	ADV
dpc-5845	11	8	to	to	ADP
dpc-5845	11	9	this	this	DET
dpc-5845	11	10	publication	publication	NOUN
dpc-5845	11	11	.	.	PUNCT
dpc-5845	12	1	corresponding	correspond	VERB
dpc-5845	12	2	author	author	NOUN
dpc-5845	12	3	:	:	PUNCT
dpc-5845	12	4	edoardo	edoardo	PROPN
dpc-5845	12	5	cammarata	cammarata	NOUN
dpc-5845	12	6	,	,	PUNCT
dpc-5845	12	7	aou	aou	PROPN
dpc-5845	12	8	maggiore	maggiore	PROPN
dpc-5845	12	9	della	della	PROPN
dpc-5845	12	10	carità	carità	PROPN
dpc-5845	12	11	,	,	PUNCT
dpc-5845	12	12	novara	novara	PROPN
dpc-5845	12	13	,	,	PUNCT
dpc-5845	12	14	italy	italy	PROPN
dpc-5845	12	15	;	;	PUNCT
dpc-5845	12	16	c.so	c.so	PROPN
dpc-5845	12	17	mazzini	mazzini	PROPN
dpc-5845	12	18	18	18	NUM
dpc-5845	12	19	,	,	PUNCT
dpc-5845	12	20	28100	28100	NUM
dpc-5845	12	21	novara	novara	PROPN
dpc-5845	12	22	,	,	PUNCT
dpc-5845	12	23	italy	italy	PROPN
dpc-5845	12	24	.	.	PUNCT
dpc-5845	13	1	orcid	orcid	PROPN
dpc-5845	13	2	:	:	PUNCT
dpc-5845	13	3	0000	0000	NUM
dpc-5845	13	4	-	-	PUNCT
dpc-5845	13	5	0002	0002	NUM
dpc-5845	13	6	-	-	PUNCT
dpc-5845	13	7	7844	7844	NUM
dpc-5845	13	8	-	-	PUNCT
dpc-5845	13	9	6954	6954	NUM
dpc-5845	13	10	.	.	PUNCT
dpc-5845	14	1	e	e	X
dpc-5845	14	2	-	-	NOUN
dpc-5845	14	3	mail	mail	NOUN
dpc-5845	14	4	:	:	PUNCT
dpc-5845	14	5	edoardocammarata@gmail.com	edoardocammarata@gmail.com	X
dpc-5845	14	6	2	2	NUM
dpc-5845	14	7	original	original	ADJ
dpc-5845	14	8	article	article	NOUN
dpc-5845	14	9	|	|	ADV
dpc-5845	14	10	dermatol	dermatol	ADJ
dpc-5845	14	11	pract	pract	NOUN
dpc-5845	14	12	concept	concept	NOUN
dpc-5845	14	13	.	.	PUNCT
dpc-5845	15	1	2025;15(3):5845	2025;15(3):5845	NUM
dpc-5845	15	2	introduction	introduction	NOUN
dpc-5845	15	3	psoriasis	psoriasis	NOUN
dpc-5845	15	4	is	be	AUX
dpc-5845	15	5	a	a	DET
dpc-5845	15	6	chronic	chronic	ADJ
dpc-5845	15	7	immune	immune	NOUN
dpc-5845	15	8	-	-	PUNCT
dpc-5845	15	9	mediated	mediate	VERB
dpc-5845	15	10	inflammatory	inflammatory	ADJ
dpc-5845	15	11	multisystem	multisystem	NOUN
dpc-5845	15	12	disease	disease	NOUN
dpc-5845	15	13	primarily	primarily	ADV
dpc-5845	15	14	characterized	characterize	VERB
dpc-5845	15	15	by	by	ADP
dpc-5845	15	16	cutaneous	cutaneous	ADJ
dpc-5845	15	17	manifestations	manifestation	NOUN
dpc-5845	15	18	,	,	PUNCT
dpc-5845	15	19	with	with	ADP
dpc-5845	15	20	chronic	chronic	ADJ
dpc-5845	15	21	plaque	plaque	NOUN
dpc-5845	15	22	psoriasis	psoriasis	NOUN
dpc-5845	15	23	accounting	account	VERB
dpc-5845	15	24	for	for	ADP
dpc-5845	15	25	approximately	approximately	ADV
dpc-5845	15	26	90	90	NUM
dpc-5845	15	27	%	%	NOUN
dpc-5845	15	28	of	of	ADP
dpc-5845	15	29	cases	case	NOUN
dpc-5845	15	30	.	.	PUNCT
dpc-5845	16	1	beyond	beyond	ADP
dpc-5845	16	2	skin	skin	NOUN
dpc-5845	16	3	lesions	lesion	NOUN
dpc-5845	16	4	,	,	PUNCT
dpc-5845	16	5	psoriasis	psoriasis	NOUN
dpc-5845	16	6	is	be	AUX
dpc-5845	16	7	often	often	ADV
dpc-5845	16	8	associated	associate	VERB
dpc-5845	16	9	with	with	ADP
dpc-5845	16	10	-	-	PUNCT
dpc-5845	16	11	comorbidities	comorbiditie	NOUN
dpc-5845	16	12	such	such	ADJ
dpc-5845	16	13	as	as	ADP
dpc-5845	16	14	cardiometabolic	cardiometabolic	NOUN
dpc-5845	16	15	disease	disease	NOUN
dpc-5845	16	16	and	and	CCONJ
dpc-5845	16	17	psoriatic	psoriatic	ADJ
dpc-5845	16	18	arthritis	arthritis	NOUN
dpc-5845	16	19	[	[	X
dpc-5845	16	20	1,2	1,2	NUM
dpc-5845	16	21	]	]	PUNCT
dpc-5845	16	22	.	.	PUNCT
dpc-5845	17	1	over	over	ADP
dpc-5845	17	2	the	the	DET
dpc-5845	17	3	past	past	ADJ
dpc-5845	17	4	decade	decade	NOUN
dpc-5845	17	5	,	,	PUNCT
dpc-5845	17	6	the	the	DET
dpc-5845	17	7	advent	advent	NOUN
dpc-5845	17	8	of	of	ADP
dpc-5845	17	9	biologic	biologic	NOUN
dpc-5845	17	10	therapies	therapy	NOUN
dpc-5845	17	11	for	for	ADP
dpc-5845	17	12	chronic	chronic	ADJ
dpc-5845	17	13	plaque	plaque	NOUN
dpc-5845	17	14	psoriasis	psoriasis	NOUN
dpc-5845	17	15	and	and	CCONJ
dpc-5845	17	16	psoriatic	psoriatic	ADJ
dpc-5845	17	17	arthritis	arthritis	NOUN
dpc-5845	17	18	have	have	AUX
dpc-5845	17	19	represented	represent	VERB
dpc-5845	17	20	a	a	DET
dpc-5845	17	21	groundbreaking	groundbreake	VERB
dpc-5845	17	22	advancement	advancement	NOUN
dpc-5845	17	23	in	in	ADP
dpc-5845	17	24	treatment	treatment	NOUN
dpc-5845	17	25	.	.	PUNCT
dpc-5845	18	1	recently	recently	ADV
dpc-5845	18	2	,	,	PUNCT
dpc-5845	18	3	new	new	ADJ
dpc-5845	18	4	therapeutic	therapeutic	ADJ
dpc-5845	18	5	options	option	NOUN
dpc-5845	18	6	for	for	ADP
dpc-5845	18	7	moderate	moderate	ADJ
dpc-5845	18	8	-	-	PUNCT
dpc-5845	18	9	to	to	ADP
dpc-5845	18	10	-	-	PUNCT
dpc-5845	18	11	severe	severe	ADJ
dpc-5845	18	12	psoriasis	psoriasis	NOUN
dpc-5845	18	13	have	have	AUX
dpc-5845	18	14	emerged	emerge	VERB
dpc-5845	18	15	,	,	PUNCT
dpc-5845	18	16	including	include	VERB
dpc-5845	18	17	il-17	il-17	NUM
dpc-5845	18	18	inhibitors	inhibitor	NOUN
dpc-5845	18	19	(	(	PUNCT
dpc-5845	18	20	il-17i	il-17i	X
dpc-5845	18	21	)	)	PUNCT
dpc-5845	18	22	(	(	PUNCT
dpc-5845	18	23	secukinumab	secukinumab	NOUN
dpc-5845	18	24	,	,	PUNCT
dpc-5845	18	25	ixekizumab	ixekizumab	NOUN
dpc-5845	18	26	,	,	PUNCT
dpc-5845	18	27	brodalumab	brodalumab	NOUN
dpc-5845	18	28	,	,	PUNCT
dpc-5845	18	29	and	and	CCONJ
dpc-5845	18	30	bimekizumab	bimekizumab	ADV
dpc-5845	18	31	)	)	PUNCT
dpc-5845	18	32	and	and	CCONJ
dpc-5845	18	33	il-23	il-23	ADJ
dpc-5845	18	34	inhibitors	inhibitor	NOUN
dpc-5845	18	35	(	(	PUNCT
dpc-5845	18	36	il-23i	il-23i	NOUN
dpc-5845	18	37	)	)	PUNCT
dpc-5845	18	38	(	(	PUNCT
dpc-5845	18	39	guselkumab	guselkumab	NOUN
dpc-5845	18	40	,	,	PUNCT
dpc-5845	18	41	risankizumab	risankizumab	NOUN
dpc-5845	18	42	,	,	PUNCT
dpc-5845	18	43	and	and	CCONJ
dpc-5845	18	44	tildrakizumab	tildrakizumab	NOUN
dpc-5845	18	45	)	)	PUNCT
dpc-5845	18	46	,	,	PUNCT
dpc-5845	18	47	which	which	PRON
dpc-5845	18	48	have	have	AUX
dpc-5845	18	49	demonstrated	demonstrate	VERB
dpc-5845	18	50	remarkable	remarkable	ADJ
dpc-5845	18	51	efficacy	efficacy	NOUN
dpc-5845	18	52	[	[	X
dpc-5845	18	53	1,2	1,2	NUM
dpc-5845	18	54	]	]	PUNCT
dpc-5845	18	55	.	.	PUNCT
dpc-5845	19	1	however	however	ADV
dpc-5845	19	2	,	,	PUNCT
dpc-5845	19	3	their	their	PRON
dpc-5845	19	4	high	high	ADJ
dpc-5845	19	5	cost	cost	NOUN
dpc-5845	19	6	imposes	impose	VERB
dpc-5845	19	7	a	a	DET
dpc-5845	19	8	significant	significant	ADJ
dpc-5845	19	9	burden	burden	NOUN
dpc-5845	19	10	on	on	ADP
dpc-5845	19	11	the	the	DET
dpc-5845	19	12	national	national	PROPN
dpc-5845	19	13	health	health	PROPN
dpc-5845	19	14	care	care	NOUN
dpc-5845	19	15	system	system	NOUN
dpc-5845	19	16	,	,	PUNCT
dpc-5845	19	17	necessitating	necessitate	VERB
dpc-5845	19	18	the	the	DET
dpc-5845	19	19	exploration	exploration	NOUN
dpc-5845	19	20	of	of	ADP
dpc-5845	19	21	strategies	strategy	NOUN
dpc-5845	19	22	to	to	PART
dpc-5845	19	23	reduce	reduce	VERB
dpc-5845	19	24	economic	economic	ADJ
dpc-5845	19	25	strain	strain	NOUN
dpc-5845	19	26	without	without	ADP
dpc-5845	19	27	compromising	compromise	VERB
dpc-5845	19	28	treatment	treatment	NOUN
dpc-5845	19	29	outcomes	outcome	NOUN
dpc-5845	19	30	.	.	PUNCT
dpc-5845	20	1	currently	currently	ADV
dpc-5845	20	2	,	,	PUNCT
dpc-5845	20	3	the	the	DET
dpc-5845	20	4	main	main	ADJ
dpc-5845	20	5	guidelines	guideline	NOUN
dpc-5845	20	6	for	for	ADP
dpc-5845	20	7	the	the	DET
dpc-5845	20	8	management	management	NOUN
dpc-5845	20	9	of	of	ADP
dpc-5845	20	10	psoriasis	psoriasis	NOUN
dpc-5845	20	11	[	[	X
dpc-5845	20	12	1,2	1,2	NUM
dpc-5845	20	13	]	]	PUNCT
dpc-5845	20	14	do	do	AUX
dpc-5845	20	15	not	not	PART
dpc-5845	20	16	include	include	VERB
dpc-5845	20	17	a	a	DET
dpc-5845	20	18	flexible	flexible	ADJ
dpc-5845	20	19	therapeutic	therapeutic	ADJ
dpc-5845	20	20	window	window	NOUN
dpc-5845	20	21	based	base	VERB
dpc-5845	20	22	on	on	ADP
dpc-5845	20	23	patients	patient	NOUN
dpc-5845	20	24	’	'	PUNCT
dpc-5845	20	25	clinical	clinical	ADJ
dpc-5845	20	26	response	response	NOUN
dpc-5845	20	27	,	,	PUNCT
dpc-5845	20	28	and	and	CCONJ
dpc-5845	20	29	biologic	biologic	NOUN
dpc-5845	20	30	therapies	therapy	NOUN
dpc-5845	20	31	are	be	AUX
dpc-5845	20	32	typically	typically	ADV
dpc-5845	20	33	prescribed	prescribe	VERB
dpc-5845	20	34	in	in	ADP
dpc-5845	20	35	fixed	fix	VERB
dpc-5845	20	36	doses	dose	NOUN
dpc-5845	20	37	,	,	PUNCT
dpc-5845	20	38	but	but	CCONJ
dpc-5845	20	39	“	"	PUNCT
dpc-5845	20	40	long	long	ADJ
dpc-5845	20	41	-	-	PUNCT
dpc-5845	20	42	term	term	NOUN
dpc-5845	20	43	responder	responder	NOUN
dpc-5845	20	44	”	"	PUNCT
dpc-5845	20	45	patients	patient	NOUN
dpc-5845	20	46	,	,	PUNCT
dpc-5845	20	47	achieving	achieve	VERB
dpc-5845	20	48	excellent	excellent	ADJ
dpc-5845	20	49	and	and	CCONJ
dpc-5845	20	50	sustained	sustained	ADJ
dpc-5845	20	51	responses	response	NOUN
dpc-5845	20	52	,	,	PUNCT
dpc-5845	20	53	may	may	AUX
dpc-5845	20	54	not	not	PART
dpc-5845	20	55	require	require	VERB
dpc-5845	20	56	the	the	DET
dpc-5845	20	57	standard	standard	ADJ
dpc-5845	20	58	regimen	regiman	NOUN
dpc-5845	20	59	,	,	PUNCT
dpc-5845	20	60	which	which	PRON
dpc-5845	20	61	could	could	AUX
dpc-5845	20	62	lead	lead	VERB
dpc-5845	20	63	to	to	ADP
dpc-5845	20	64	overtreatment	overtreatment	NOUN
dpc-5845	20	65	.	.	PUNCT
dpc-5845	21	1	this	this	PRON
dpc-5845	21	2	underscores	underscore	VERB
dpc-5845	21	3	the	the	DET
dpc-5845	21	4	importance	importance	NOUN
dpc-5845	21	5	of	of	ADP
dpc-5845	21	6	studies	study	NOUN
dpc-5845	21	7	focusing	focus	VERB
dpc-5845	21	8	on	on	ADP
dpc-5845	21	9	dose	dose	NOUN
dpc-5845	21	10	reduction	reduction	NOUN
dpc-5845	21	11	(	(	PUNCT
dpc-5845	21	12	dr	dr	PROPN
dpc-5845	21	13	)	)	PUNCT
dpc-5845	21	14	to	to	PART
dpc-5845	21	15	ensure	ensure	VERB
dpc-5845	21	16	cost	cost	NOUN
dpc-5845	21	17	-	-	PUNCT
dpc-5845	21	18	efficiency	efficiency	NOUN
dpc-5845	21	19	while	while	SCONJ
dpc-5845	21	20	maintaining	maintain	VERB
dpc-5845	21	21	high	high	ADJ
dpc-5845	21	22	effectiveness	effectiveness	NOUN
dpc-5845	21	23	.	.	PUNCT
dpc-5845	22	1	previous	previous	ADJ
dpc-5845	22	2	research	research	NOUN
dpc-5845	22	3	has	have	AUX
dpc-5845	22	4	demonstrated	demonstrate	VERB
dpc-5845	22	5	the	the	DET
dpc-5845	22	6	effectiveness	effectiveness	NOUN
dpc-5845	22	7	and	and	CCONJ
dpc-5845	22	8	safety	safety	NOUN
dpc-5845	22	9	of	of	ADP
dpc-5845	22	10	a	a	DET
dpc-5845	22	11	reduced	reduce	VERB
dpc-5845	22	12	dose	dose	NOUN
dpc-5845	22	13	compared	compare	VERB
dpc-5845	22	14	to	to	ADP
dpc-5845	22	15	the	the	DET
dpc-5845	22	16	standard	standard	NOUN
dpc-5845	22	17	dose	dose	PROPN
dpc-5845	22	18	(	(	PUNCT
dpc-5845	22	19	std	std	PROPN
dpc-5845	22	20	)	)	PUNCT
dpc-5845	22	21	in	in	ADP
dpc-5845	22	22	psoriasis	psoriasis	NOUN
dpc-5845	22	23	treatment	treatment	NOUN
dpc-5845	22	24	,	,	PUNCT
dpc-5845	22	25	with	with	ADP
dpc-5845	22	26	a	a	DET
dpc-5845	22	27	slightly	slightly	ADV
dpc-5845	22	28	increased	increase	VERB
dpc-5845	22	29	psoriasis	psoriasis	NOUN
dpc-5845	22	30	area	area	NOUN
dpc-5845	22	31	and	and	CCONJ
dpc-5845	22	32	severity	severity	NOUN
dpc-5845	22	33	index	index	NOUN
dpc-5845	22	34	(	(	PUNCT
dpc-5845	22	35	pasi	pasi	NOUN
dpc-5845	22	36	)	)	PUNCT
dpc-5845	22	37	while	while	SCONJ
dpc-5845	22	38	maintaining	maintain	VERB
dpc-5845	22	39	a	a	DET
dpc-5845	22	40	stable	stable	ADJ
dpc-5845	22	41	dermatology	dermatology	NOUN
dpc-5845	22	42	life	life	NOUN
dpc-5845	22	43	and	and	CCONJ
dpc-5845	22	44	quality	quality	NOUN
dpc-5845	22	45	index	index	NOUN
dpc-5845	22	46	(	(	PUNCT
dpc-5845	22	47	dlqi	dlqi	PROPN
dpc-5845	22	48	)	)	PUNCT
dpc-5845	23	1	[	[	X
dpc-5845	23	2	3	3	NUM
dpc-5845	23	3	-	-	SYM
dpc-5845	23	4	7	7	NUM
dpc-5845	23	5	]	]	PUNCT
dpc-5845	23	6	.	.	PUNCT
dpc-5845	24	1	consequently	consequently	ADV
dpc-5845	24	2	,	,	PUNCT
dpc-5845	24	3	dose	dose	NOUN
dpc-5845	24	4	reduction	reduction	NOUN
dpc-5845	24	5	(	(	PUNCT
dpc-5845	24	6	dr	dr	PROPN
dpc-5845	24	7	)	)	PUNCT
dpc-5845	24	8	,	,	PUNCT
dpc-5845	24	9	also	also	ADV
dpc-5845	24	10	referred	refer	VERB
dpc-5845	24	11	to	to	ADP
dpc-5845	24	12	as	as	ADP
dpc-5845	24	13	dose	dose	NOUN
dpc-5845	24	14	tapering	tapering	NOUN
dpc-5845	24	15	,	,	PUNCT
dpc-5845	24	16	appears	appear	VERB
dpc-5845	24	17	to	to	PART
dpc-5845	24	18	be	be	AUX
dpc-5845	24	19	a	a	DET
dpc-5845	24	20	promising	promising	ADJ
dpc-5845	24	21	strategy	strategy	NOUN
dpc-5845	24	22	.	.	PUNCT
dpc-5845	25	1	however	however	ADV
dpc-5845	25	2	,	,	PUNCT
dpc-5845	25	3	extending	extend	VERB
dpc-5845	25	4	the	the	DET
dpc-5845	25	5	therapeutic	therapeutic	ADJ
dpc-5845	25	6	window	window	NOUN
dpc-5845	25	7	should	should	AUX
dpc-5845	25	8	be	be	AUX
dpc-5845	25	9	guided	guide	VERB
dpc-5845	25	10	by	by	ADP
dpc-5845	25	11	patient	patient	ADJ
dpc-5845	25	12	profiling	profiling	NOUN
dpc-5845	25	13	and	and	CCONJ
dpc-5845	25	14	tailored	tailor	VERB
dpc-5845	25	15	therapeutic	therapeutic	ADJ
dpc-5845	25	16	choices	choice	NOUN
dpc-5845	25	17	to	to	PART
dpc-5845	25	18	ensure	ensure	VERB
dpc-5845	25	19	optimal	optimal	ADJ
dpc-5845	25	20	outcomes	outcome	NOUN
dpc-5845	25	21	.	.	PUNCT
dpc-5845	26	1	in	in	ADP
dpc-5845	26	2	this	this	DET
dpc-5845	26	3	regard	regard	NOUN
dpc-5845	26	4	,	,	PUNCT
dpc-5845	26	5	these	these	DET
dpc-5845	26	6	inhibitors	inhibitor	NOUN
dpc-5845	26	7	have	have	AUX
dpc-5845	26	8	demonstrated	demonstrate	VERB
dpc-5845	26	9	significant	significant	ADJ
dpc-5845	26	10	efficacy	efficacy	NOUN
dpc-5845	26	11	in	in	ADP
dpc-5845	26	12	reducing	reduce	VERB
dpc-5845	26	13	disease	disease	NOUN
dpc-5845	26	14	severity	severity	NOUN
dpc-5845	26	15	;	;	PUNCT
dpc-5845	26	16	however	however	ADV
dpc-5845	26	17	,	,	PUNCT
dpc-5845	26	18	their	their	PRON
dpc-5845	26	19	pharmacodynamics	pharmacodynamic	NOUN
dpc-5845	26	20	differ	differ	VERB
dpc-5845	26	21	,	,	PUNCT
dpc-5845	26	22	making	make	VERB
dpc-5845	26	23	one	one	NUM
dpc-5845	26	24	drug	drug	NOUN
dpc-5845	26	25	class	class	NOUN
dpc-5845	26	26	potentially	potentially	ADV
dpc-5845	26	27	more	more	ADV
dpc-5845	26	28	suitable	suitable	ADJ
dpc-5845	26	29	than	than	ADP
dpc-5845	26	30	the	the	DET
dpc-5845	26	31	other	other	ADJ
dpc-5845	26	32	for	for	ADP
dpc-5845	26	33	dose	dose	NOUN
dpc-5845	26	34	spacing	spacing	NOUN
dpc-5845	26	35	.	.	PUNCT
dpc-5845	27	1	il-23i	il-23i	PRON
dpc-5845	27	2	provide	provide	VERB
dpc-5845	27	3	longer	long	ADV
dpc-5845	27	4	-	-	PUNCT
dpc-5845	27	5	lasting	last	VERB
dpc-5845	27	6	effects	effect	NOUN
dpc-5845	27	7	by	by	ADP
dpc-5845	27	8	targeting	target	VERB
dpc-5845	27	9	the	the	DET
dpc-5845	27	10	root	root	NOUN
dpc-5845	27	11	of	of	ADP
dpc-5845	27	12	the	the	DET
dpc-5845	27	13	inflammatory	inflammatory	ADJ
dpc-5845	27	14	cascade	cascade	NOUN
dpc-5845	27	15	,	,	PUNCT
dpc-5845	27	16	whereas	whereas	SCONJ
dpc-5845	27	17	il-17i	il-17i	PROPN
dpc-5845	27	18	act	act	VERB
dpc-5845	27	19	more	more	ADV
dpc-5845	27	20	immediately	immediately	ADV
dpc-5845	27	21	on	on	ADP
dpc-5845	27	22	downstream	downstream	ADJ
dpc-5845	27	23	inflammation	inflammation	NOUN
dpc-5845	27	24	[	[	X
dpc-5845	27	25	8	8	NUM
dpc-5845	27	26	]	]	PUNCT
dpc-5845	27	27	.	.	PUNCT
dpc-5845	28	1	the	the	DET
dpc-5845	28	2	aims	aim	NOUN
dpc-5845	28	3	of	of	ADP
dpc-5845	28	4	this	this	DET
dpc-5845	28	5	study	study	NOUN
dpc-5845	28	6	were	be	AUX
dpc-5845	28	7	to	to	PART
dpc-5845	28	8	contribute	contribute	VERB
dpc-5845	28	9	to	to	ADP
dpc-5845	28	10	the	the	DET
dpc-5845	28	11	understanding	understanding	NOUN
dpc-5845	28	12	of	of	ADP
dpc-5845	28	13	the	the	DET
dpc-5845	28	14	dr	dr	PROPN
dpc-5845	28	15	outcomes	outcome	NOUN
dpc-5845	28	16	in	in	ADP
dpc-5845	28	17	real	real	ADJ
dpc-5845	28	18	-	-	PUNCT
dpc-5845	28	19	life	life	NOUN
dpc-5845	28	20	settings	setting	NOUN
dpc-5845	28	21	and	and	CCONJ
dpc-5845	28	22	to	to	PART
dpc-5845	28	23	investigate	investigate	VERB
dpc-5845	28	24	whether	whether	SCONJ
dpc-5845	28	25	disease	disease	NOUN
dpc-5845	28	26	activity	activity	NOUN
dpc-5845	28	27	-	-	PUNCT
dpc-5845	28	28	guided	guide	VERB
dpc-5845	28	29	dr	dr	PROPN
dpc-5845	28	30	of	of	ADP
dpc-5845	28	31	il-17i	il-17i	PROPN
dpc-5845	28	32	and	and	CCONJ
dpc-5845	28	33	il-23i	il-23i	PRON
dpc-5845	28	34	could	could	AUX
dpc-5845	28	35	be	be	AUX
dpc-5845	28	36	a	a	DET
dpc-5845	28	37	suitable	suitable	ADJ
dpc-5845	28	38	option	option	NOUN
dpc-5845	28	39	for	for	ADP
dpc-5845	28	40	selected	select	VERB
dpc-5845	28	41	psoriasis	psoriasis	NOUN
dpc-5845	28	42	patients	patient	NOUN
dpc-5845	28	43	.	.	PUNCT
dpc-5845	29	1	the	the	DET
dpc-5845	29	2	secondary	secondary	ADJ
dpc-5845	29	3	aim	aim	NOUN
dpc-5845	29	4	was	be	AUX
dpc-5845	29	5	to	to	PART
dpc-5845	29	6	analyse	analyse	VERB
dpc-5845	29	7	potential	potential	ADJ
dpc-5845	29	8	differences	difference	NOUN
dpc-5845	29	9	in	in	ADP
dpc-5845	29	10	effectiveness	effectiveness	NOUN
dpc-5845	29	11	and	and	CCONJ
dpc-5845	29	12	safety	safety	NOUN
dpc-5845	29	13	between	between	ADP
dpc-5845	29	14	il-17i	il-17i	PROPN
dpc-5845	29	15	and	and	CCONJ
dpc-5845	29	16	il-23i	il-23i	NOUN
dpc-5845	29	17	during	during	ADP
dpc-5845	29	18	dr	dr	PROPN
dpc-5845	29	19	.	.	PROPN
dpc-5845	29	20	materials	material	NOUN
dpc-5845	29	21	and	and	CCONJ
dpc-5845	29	22	methods	method	NOUN
dpc-5845	29	23	study	study	NOUN
dpc-5845	29	24	design	design	VERB
dpc-5845	29	25	the	the	DET
dpc-5845	29	26	psored	psore	VERB
dpc-5845	29	27	study	study	NOUN
dpc-5845	29	28	(	(	PUNCT
dpc-5845	29	29	study	study	NOUN
dpc-5845	29	30	number	number	NOUN
dpc-5845	29	31	ce	ce	PROPN
dpc-5845	29	32	102/2023	102/2023	NUM
dpc-5845	29	33	)	)	PUNCT
dpc-5845	29	34	was	be	AUX
dpc-5845	29	35	conducted	conduct	VERB
dpc-5845	29	36	by	by	ADP
dpc-5845	29	37	the	the	DET
dpc-5845	29	38	university	university	PROPN
dpc-5845	29	39	of	of	ADP
dpc-5845	29	40	eastern	eastern	PROPN
dpc-5845	29	41	piedmont	piedmont	PROPN
dpc-5845	29	42	and	and	CCONJ
dpc-5845	29	43	included	include	VERB
dpc-5845	29	44	the	the	DET
dpc-5845	29	45	primary	primary	ADJ
dpc-5845	29	46	prescribing	prescribing	NOUN
dpc-5845	29	47	centers	center	NOUN
dpc-5845	29	48	for	for	ADP
dpc-5845	29	49	biological	biological	ADJ
dpc-5845	29	50	drugs	drug	NOUN
dpc-5845	29	51	in	in	ADP
dpc-5845	29	52	piedmont	piedmont	PROPN
dpc-5845	29	53	.	.	PUNCT
dpc-5845	30	1	this	this	DET
dpc-5845	30	2	prospective	prospective	ADJ
dpc-5845	30	3	observational	observational	ADJ
dpc-5845	30	4	open	open	ADJ
dpc-5845	30	5	-	-	PUNCT
dpc-5845	30	6	label	label	NOUN
dpc-5845	30	7	study	study	NOUN
dpc-5845	30	8	was	be	AUX
dpc-5845	30	9	conducted	conduct	VERB
dpc-5845	30	10	from	from	ADP
dpc-5845	30	11	march	march	PROPN
dpc-5845	30	12	2023	2023	NUM
dpc-5845	30	13	to	to	ADP
dpc-5845	30	14	december	december	PROPN
dpc-5845	30	15	2024	2024	NUM
dpc-5845	30	16	to	to	PART
dpc-5845	30	17	investigate	investigate	VERB
dpc-5845	30	18	the	the	DET
dpc-5845	30	19	efficacy	efficacy	NOUN
dpc-5845	30	20	and	and	CCONJ
dpc-5845	30	21	safety	safety	NOUN
dpc-5845	30	22	of	of	ADP
dpc-5845	30	23	reduced	reduce	VERB
dpc-5845	30	24	-	-	PUNCT
dpc-5845	30	25	dose	dose	VERB
dpc-5845	30	26	(	(	PUNCT
dpc-5845	30	27	rd	rd	NOUN
dpc-5845	30	28	)	)	PUNCT
dpc-5845	30	29	,	,	PUNCT
dpc-5845	30	30	an	an	DET
dpc-5845	30	31	off	off	ADP
dpc-5845	30	32	-	-	PUNCT
dpc-5845	30	33	label	label	NOUN
dpc-5845	30	34	treatment	treatment	NOUN
dpc-5845	30	35	strategy	strategy	NOUN
dpc-5845	30	36	for	for	ADP
dpc-5845	30	37	secukinumab	secukinumab	NOUN
dpc-5845	30	38	,	,	PUNCT
dpc-5845	30	39	brodalumab	brodalumab	NOUN
dpc-5845	30	40	,	,	PUNCT
dpc-5845	30	41	introduction	introduction	NOUN
dpc-5845	30	42	:	:	PUNCT
dpc-5845	30	43	psoriasis	psoriasis	NOUN
dpc-5845	30	44	is	be	AUX
dpc-5845	30	45	a	a	DET
dpc-5845	30	46	chronic	chronic	ADJ
dpc-5845	30	47	inflammatory	inflammatory	ADJ
dpc-5845	30	48	multisystem	multisystem	NOUN
dpc-5845	30	49	disease	disease	NOUN
dpc-5845	30	50	for	for	ADP
dpc-5845	30	51	which	which	PRON
dpc-5845	30	52	il-17	il-17	ADV
dpc-5845	30	53	and	and	CCONJ
dpc-5845	30	54	il-23	il-23	NOUN
dpc-5845	30	55	inhibitors	inhibitor	NOUN
dpc-5845	30	56	have	have	AUX
dpc-5845	30	57	transformed	transform	VERB
dpc-5845	30	58	treatment	treatment	NOUN
dpc-5845	30	59	.	.	PUNCT
dpc-5845	31	1	however	however	ADV
dpc-5845	31	2	,	,	PUNCT
dpc-5845	31	3	high	high	ADJ
dpc-5845	31	4	costs	cost	NOUN
dpc-5845	31	5	and	and	CCONJ
dpc-5845	31	6	the	the	DET
dpc-5845	31	7	possibility	possibility	NOUN
dpc-5845	31	8	of	of	ADP
dpc-5845	31	9	overtreatment	overtreatment	NOUN
dpc-5845	31	10	in	in	ADP
dpc-5845	31	11	patients	patient	NOUN
dpc-5845	31	12	with	with	ADP
dpc-5845	31	13	excellent	excellent	ADJ
dpc-5845	31	14	and	and	CCONJ
dpc-5845	31	15	sustained	sustained	ADJ
dpc-5845	31	16	responses	response	NOUN
dpc-5845	31	17	have	have	AUX
dpc-5845	31	18	driven	drive	VERB
dpc-5845	31	19	interest	interest	NOUN
dpc-5845	31	20	in	in	ADP
dpc-5845	31	21	dose	dose	NOUN
dpc-5845	31	22	reduction	reduction	NOUN
dpc-5845	31	23	(	(	PUNCT
dpc-5845	31	24	dr	dr	PROPN
dpc-5845	31	25	)	)	PUNCT
dpc-5845	31	26	to	to	PART
dpc-5845	31	27	lower	low	ADJ
dpc-5845	31	28	expenses	expense	NOUN
dpc-5845	31	29	without	without	ADP
dpc-5845	31	30	compromising	compromise	VERB
dpc-5845	31	31	efficacy	efficacy	NOUN
dpc-5845	31	32	.	.	PUNCT
dpc-5845	32	1	materials	material	NOUN
dpc-5845	32	2	&	&	CCONJ
dpc-5845	32	3	methods	method	NOUN
dpc-5845	32	4	:	:	PUNCT
dpc-5845	32	5	we	we	PRON
dpc-5845	32	6	conducted	conduct	VERB
dpc-5845	32	7	a	a	DET
dpc-5845	32	8	multicenter	multicenter	ADJ
dpc-5845	32	9	observational	observational	ADJ
dpc-5845	32	10	trial	trial	NOUN
dpc-5845	32	11	assessing	assess	VERB
dpc-5845	32	12	the	the	DET
dpc-5845	32	13	efficacy	efficacy	NOUN
dpc-5845	32	14	and	and	CCONJ
dpc-5845	32	15	safety	safety	NOUN
dpc-5845	32	16	of	of	ADP
dpc-5845	32	17	drs	dr	NOUN
dpc-5845	32	18	for	for	ADP
dpc-5845	32	19	secukinumab	secukinumab	NOUN
dpc-5845	32	20	,	,	PUNCT
dpc-5845	32	21	brodalumab	brodalumab	NOUN
dpc-5845	32	22	,	,	PUNCT
dpc-5845	32	23	guselkumab	guselkumab	NOUN
dpc-5845	32	24	,	,	PUNCT
dpc-5845	32	25	and	and	CCONJ
dpc-5845	32	26	risankizumab	risankizumab	NOUN
dpc-5845	32	27	in	in	ADP
dpc-5845	32	28	adults	adult	NOUN
dpc-5845	32	29	with	with	ADP
dpc-5845	32	30	stable	stable	ADJ
dpc-5845	32	31	plaque	plaque	NOUN
dpc-5845	32	32	psoriasis	psoriasis	NOUN
dpc-5845	32	33	.	.	PUNCT
dpc-5845	33	1	eligible	eligible	ADJ
dpc-5845	33	2	participants	participant	NOUN
dpc-5845	33	3	were	be	AUX
dpc-5845	33	4	adults	adult	NOUN
dpc-5845	33	5	with	with	ADP
dpc-5845	33	6	low	low	ADJ
dpc-5845	33	7	disease	disease	NOUN
dpc-5845	33	8	activity	activity	NOUN
dpc-5845	33	9	(	(	PUNCT
dpc-5845	33	10	pasi	pasi	NOUN
dpc-5845	33	11	≤	≤	ADV
dpc-5845	33	12	3	3	NUM
dpc-5845	33	13	,	,	PUNCT
dpc-5845	33	14	dlqi	dlqi	VERB
dpc-5845	33	15	≤	≤	NUM
dpc-5845	33	16	3	3	NUM
dpc-5845	33	17	for	for	ADP
dpc-5845	33	18	at	at	ADV
dpc-5845	33	19	least	least	ADJ
dpc-5845	33	20	9	9	NUM
dpc-5845	33	21	months	month	NOUN
dpc-5845	33	22	)	)	PUNCT
dpc-5845	33	23	.	.	PUNCT
dpc-5845	34	1	dr	dr	PROPN
dpc-5845	34	2	involved	involve	VERB
dpc-5845	34	3	lengthening	lengthen	VERB
dpc-5845	34	4	intervals	interval	NOUN
dpc-5845	34	5	to	to	ADP
dpc-5845	34	6	approximately	approximately	ADV
dpc-5845	34	7	67	67	NUM
dpc-5845	34	8	%	%	NOUN
dpc-5845	34	9	of	of	ADP
dpc-5845	34	10	the	the	DET
dpc-5845	34	11	authorized	authorize	VERB
dpc-5845	34	12	standard	standard	PROPN
dpc-5845	34	13	dose	dose	PROPN
dpc-5845	34	14	.	.	PUNCT
dpc-5845	35	1	from	from	ADP
dpc-5845	35	2	the	the	DET
dpc-5845	35	3	361	361	NUM
dpc-5845	35	4	enrolled	enrol	VERB
dpc-5845	35	5	(	(	PUNCT
dpc-5845	35	6	march	march	PROPN
dpc-5845	35	7	2023	2023	NUM
dpc-5845	35	8	–	–	PUNCT
dpc-5845	35	9	january	january	NOUN
dpc-5845	35	10	2025	2025	NUM
dpc-5845	35	11	)	)	PUNCT
dpc-5845	35	12	,	,	PUNCT
dpc-5845	35	13	we	we	PRON
dpc-5845	35	14	analyzed	analyze	VERB
dpc-5845	35	15	data	datum	NOUN
dpc-5845	35	16	on	on	ADP
dpc-5845	35	17	156	156	NUM
dpc-5845	35	18	participants	participant	NOUN
dpc-5845	35	19	with	with	ADP
dpc-5845	35	20	≥12	≥12	NOUN
dpc-5845	35	21	months	month	NOUN
dpc-5845	35	22	of	of	ADP
dpc-5845	35	23	follow	follow	NOUN
dpc-5845	35	24	-	-	PUNCT
dpc-5845	35	25	up	up	NOUN
dpc-5845	35	26	or	or	CCONJ
dpc-5845	35	27	early	early	ADJ
dpc-5845	35	28	discontinuation	discontinuation	NOUN
dpc-5845	35	29	due	due	ADP
dpc-5845	35	30	to	to	ADP
dpc-5845	35	31	dr	dr	PROPN
dpc-5845	35	32	failure	failure	NOUN
dpc-5845	35	33	.	.	PUNCT
dpc-5845	36	1	results	result	NOUN
dpc-5845	36	2	:	:	PUNCT
dpc-5845	36	3	seventy	seventy	NUM
dpc-5845	36	4	of	of	ADP
dpc-5845	36	5	these	these	DET
dpc-5845	36	6	patients	patient	NOUN
dpc-5845	36	7	(	(	PUNCT
dpc-5845	36	8	44.87	44.87	NUM
dpc-5845	36	9	%	%	NOUN
dpc-5845	36	10	)	)	PUNCT
dpc-5845	36	11	received	receive	VERB
dpc-5845	36	12	il-17	il-17	ADP
dpc-5845	36	13	inhibitors	inhibitor	NOUN
dpc-5845	36	14	,	,	PUNCT
dpc-5845	36	15	and	and	CCONJ
dpc-5845	36	16	86	86	NUM
dpc-5845	36	17	(	(	PUNCT
dpc-5845	36	18	55.13	55.13	NUM
dpc-5845	36	19	%	%	NOUN
dpc-5845	36	20	)	)	PUNCT
dpc-5845	36	21	received	receive	VERB
dpc-5845	36	22	il23	il23	PROPN
dpc-5845	36	23	inhibitors	inhibitor	NOUN
dpc-5845	36	24	.	.	PUNCT
dpc-5845	37	1	after	after	ADP
dpc-5845	37	2	52	52	NUM
dpc-5845	37	3	weeks	week	NOUN
dpc-5845	37	4	,	,	PUNCT
dpc-5845	37	5	the	the	DET
dpc-5845	37	6	overall	overall	ADJ
dpc-5845	37	7	dose	dose	NOUN
dpc-5845	37	8	-	-	PUNCT
dpc-5845	37	9	reduction	reduction	NOUN
dpc-5845	37	10	survival	survival	NOUN
dpc-5845	37	11	was	be	AUX
dpc-5845	37	12	0.75	0.75	NUM
dpc-5845	37	13	(	(	PUNCT
dpc-5845	37	14	95	95	NUM
dpc-5845	37	15	%	%	NOUN
dpc-5845	37	16	ci	ci	NOUN
dpc-5845	37	17	:	:	PUNCT
dpc-5845	37	18	0.69–0.82	0.69–0.82	NUM
dpc-5845	37	19	)	)	PUNCT
dpc-5845	37	20	.	.	PUNCT
dpc-5845	38	1	for	for	ADP
dpc-5845	38	2	il-23	il-23	NOUN
dpc-5845	38	3	inhibitor	inhibitor	NOUN
dpc-5845	38	4	and	and	CCONJ
dpc-5845	38	5	il-17	il-17	ADV
dpc-5845	38	6	inhibitor	inhibitor	NOUN
dpc-5845	38	7	cohorts	cohort	NOUN
dpc-5845	38	8	,	,	PUNCT
dpc-5845	38	9	the	the	DET
dpc-5845	38	10	dose	dose	NOUN
dpc-5845	38	11	-	-	PUNCT
dpc-5845	38	12	reduction	reduction	NOUN
dpc-5845	38	13	survival	survival	NOUN
dpc-5845	38	14	was	be	AUX
dpc-5845	38	15	0.83	0.83	NUM
dpc-5845	38	16	(	(	PUNCT
dpc-5845	38	17	95	95	NUM
dpc-5845	38	18	%	%	NOUN
dpc-5845	38	19	ci	ci	NOUN
dpc-5845	38	20	:	:	PUNCT
dpc-5845	38	21	0.75–0.91	0.75–0.91	NUM
dpc-5845	38	22	)	)	PUNCT
dpc-5845	38	23	and	and	CCONJ
dpc-5845	38	24	0.66	0.66	NUM
dpc-5845	38	25	(	(	PUNCT
dpc-5845	38	26	95	95	NUM
dpc-5845	38	27	%	%	NOUN
dpc-5845	38	28	ci	ci	NOUN
dpc-5845	38	29	:	:	PUNCT
dpc-5845	38	30	0.55–0.78	0.55–0.78	NUM
dpc-5845	38	31	)	)	PUNCT
dpc-5845	38	32	,	,	PUNCT
dpc-5845	38	33	respectively	respectively	ADV
dpc-5845	38	34	.	.	PUNCT
dpc-5845	39	1	moreover	moreover	ADV
dpc-5845	39	2	,	,	PUNCT
dpc-5845	39	3	kaplan	kaplan	PROPN
dpc-5845	39	4	-	-	PUNCT
dpc-5845	39	5	meier	meier	PROPN
dpc-5845	39	6	curves	curve	NOUN
dpc-5845	39	7	suggested	suggest	VERB
dpc-5845	39	8	significant	significant	ADJ
dpc-5845	39	9	(	(	PUNCT
dpc-5845	39	10	p	p	ADJ
dpc-5845	39	11	-	-	PUNCT
dpc-5845	39	12	value	value	NOUN
dpc-5845	39	13	log	log	NOUN
dpc-5845	39	14	-	-	PUNCT
dpc-5845	39	15	rank	rank	NOUN
dpc-5845	39	16	test=0.018	test=0.018	NOUN
dpc-5845	39	17	)	)	PUNCT
dpc-5845	39	18	higher	high	ADJ
dpc-5845	39	19	dose	dose	NOUN
dpc-5845	39	20	reduction	reduction	NOUN
dpc-5845	39	21	survival	survival	NOUN
dpc-5845	39	22	for	for	ADP
dpc-5845	39	23	il-23	il-23	NOUN
dpc-5845	39	24	inhibitors	inhibitor	NOUN
dpc-5845	39	25	compared	compare	VERB
dpc-5845	39	26	to	to	ADP
dpc-5845	39	27	il-17	il-17	X
dpc-5845	39	28	.	.	PUNCT
dpc-5845	40	1	discussion	discussion	NOUN
dpc-5845	40	2	:	:	PUNCT
dpc-5845	40	3	our	our	PRON
dpc-5845	40	4	preliminary	preliminary	ADJ
dpc-5845	40	5	findings	finding	NOUN
dpc-5845	40	6	suggest	suggest	VERB
dpc-5845	40	7	that	that	SCONJ
dpc-5845	40	8	extended	extend	VERB
dpc-5845	40	9	dosing	dosing	NOUN
dpc-5845	40	10	intervals	interval	NOUN
dpc-5845	40	11	for	for	ADP
dpc-5845	40	12	il-17	il-17	ADV
dpc-5845	40	13	and	and	CCONJ
dpc-5845	40	14	il-23	il-23	NOUN
dpc-5845	40	15	inhibitors	inhibitor	NOUN
dpc-5845	40	16	can	can	AUX
dpc-5845	40	17	effectively	effectively	ADV
dpc-5845	40	18	maintain	maintain	VERB
dpc-5845	40	19	disease	disease	NOUN
dpc-5845	40	20	control	control	NOUN
dpc-5845	40	21	in	in	ADP
dpc-5845	40	22	stable	stable	ADJ
dpc-5845	40	23	plaque	plaque	NOUN
dpc-5845	40	24	psoriasis	psoriasis	NOUN
dpc-5845	40	25	.	.	PUNCT
dpc-5845	41	1	larger	large	ADJ
dpc-5845	41	2	randomized	randomized	ADJ
dpc-5845	41	3	trials	trial	NOUN
dpc-5845	41	4	are	be	AUX
dpc-5845	41	5	needed	need	VERB
dpc-5845	41	6	to	to	PART
dpc-5845	41	7	confirm	confirm	VERB
dpc-5845	41	8	these	these	DET
dpc-5845	41	9	results	result	NOUN
dpc-5845	41	10	,	,	PUNCT
dpc-5845	41	11	identify	identify	VERB
dpc-5845	41	12	predictive	predictive	ADJ
dpc-5845	41	13	markers	marker	NOUN
dpc-5845	41	14	of	of	ADP
dpc-5845	41	15	dr	dr	PROPN
dpc-5845	41	16	success	success	NOUN
dpc-5845	41	17	,	,	PUNCT
dpc-5845	41	18	and	and	CCONJ
dpc-5845	41	19	optimize	optimize	VERB
dpc-5845	41	20	patient	patient	ADJ
dpc-5845	41	21	selection	selection	NOUN
dpc-5845	41	22	for	for	ADP
dpc-5845	41	23	safe	safe	ADJ
dpc-5845	41	24	and	and	CCONJ
dpc-5845	41	25	cost	cost	NOUN
dpc-5845	41	26	-	-	PUNCT
dpc-5845	41	27	effective	effective	ADJ
dpc-5845	41	28	management	management	NOUN
dpc-5845	41	29	of	of	ADP
dpc-5845	41	30	psoriasis	psoriasis	NOUN
dpc-5845	41	31	.	.	PUNCT
dpc-5845	42	1	abstract	abstract	ADJ
dpc-5845	42	2	original	original	ADJ
dpc-5845	42	3	article	article	NOUN
dpc-5845	42	4	|	|	ADV
dpc-5845	42	5	dermatol	dermatol	ADJ
dpc-5845	42	6	pract	pract	NOUN
dpc-5845	42	7	concept	concept	NOUN
dpc-5845	42	8	.	.	PUNCT
dpc-5845	43	1	2025;15(3):5845	2025;15(3):5845	NUM
dpc-5845	43	2	3	3	NUM
dpc-5845	43	3	guselkumab	guselkumab	NOUN
dpc-5845	43	4	,	,	PUNCT
dpc-5845	43	5	and	and	CCONJ
dpc-5845	43	6	risankizumab	risankizumab	VERB
dpc-5845	43	7	in	in	ADP
dpc-5845	43	8	patients	patient	NOUN
dpc-5845	43	9	with	with	ADP
dpc-5845	43	10	plaque	plaque	NOUN
dpc-5845	43	11	psoriasis	psoriasis	NOUN
dpc-5845	44	1	;	;	PUNCT
dpc-5845	44	2	these	these	DET
dpc-5845	44	3	drugs	drug	NOUN
dpc-5845	44	4	were	be	AUX
dpc-5845	44	5	chosen	choose	VERB
dpc-5845	44	6	because	because	SCONJ
dpc-5845	44	7	of	of	ADP
dpc-5845	44	8	the	the	DET
dpc-5845	44	9	evidence	evidence	NOUN
dpc-5845	44	10	of	of	ADP
dpc-5845	44	11	their	their	PRON
dpc-5845	44	12	efficacy	efficacy	NOUN
dpc-5845	44	13	reported	report	VERB
dpc-5845	44	14	in	in	ADP
dpc-5845	44	15	previous	previous	ADJ
dpc-5845	44	16	studies	study	NOUN
dpc-5845	44	17	with	with	ADP
dpc-5845	44	18	rd	rd	NOUN
dpc-5845	45	1	[	[	X
dpc-5845	45	2	9	9	NUM
dpc-5845	45	3	-	-	SYM
dpc-5845	45	4	15	15	NUM
dpc-5845	45	5	]	]	PUNCT
dpc-5845	45	6	.	.	PUNCT
dpc-5845	46	1	adult	adult	NOUN
dpc-5845	46	2	patients	patient	NOUN
dpc-5845	46	3	with	with	ADP
dpc-5845	46	4	plaque	plaque	NOUN
dpc-5845	46	5	psoriasis	psoriasis	NOUN
dpc-5845	46	6	treated	treat	VERB
dpc-5845	46	7	with	with	ADP
dpc-5845	46	8	these	these	DET
dpc-5845	46	9	biologics	biologic	NOUN
dpc-5845	46	10	were	be	AUX
dpc-5845	46	11	eligible	eligible	ADJ
dpc-5845	46	12	for	for	ADP
dpc-5845	46	13	inclusion	inclusion	NOUN
dpc-5845	46	14	in	in	ADP
dpc-5845	46	15	the	the	DET
dpc-5845	46	16	study	study	NOUN
dpc-5845	46	17	when	when	SCONJ
dpc-5845	46	18	they	they	PRON
dpc-5845	46	19	had	have	VERB
dpc-5845	46	20	stable	stable	ADJ
dpc-5845	46	21	,	,	PUNCT
dpc-5845	46	22	low	low	ADJ
dpc-5845	46	23	disease	disease	NOUN
dpc-5845	46	24	activity	activity	NOUN
dpc-5845	46	25	on	on	ADP
dpc-5845	46	26	the	the	DET
dpc-5845	46	27	authorized	authorized	ADJ
dpc-5845	46	28	std	std	NOUN
dpc-5845	46	29	;	;	PUNCT
dpc-5845	46	30	an	an	DET
dpc-5845	46	31	absolute	absolute	ADJ
dpc-5845	46	32	pasi	pasi	NOUN
dpc-5845	46	33	≤	≤	NUM
dpc-5845	46	34	3	3	NUM
dpc-5845	46	35	and	and	CCONJ
dpc-5845	46	36	absolute	absolute	ADJ
dpc-5845	46	37	dlqi	dlqi	ADJ
dpc-5845	46	38	≤	≤	NOUN
dpc-5845	46	39	3	3	NUM
dpc-5845	46	40	for	for	ADP
dpc-5845	46	41	at	at	ADV
dpc-5845	46	42	least	least	ADV
dpc-5845	46	43	nine	nine	NUM
dpc-5845	46	44	months	month	NOUN
dpc-5845	46	45	was	be	AUX
dpc-5845	46	46	considered	consider	VERB
dpc-5845	46	47	as	as	ADP
dpc-5845	46	48	a	a	DET
dpc-5845	46	49	criterion	criterion	NOUN
dpc-5845	46	50	of	of	ADP
dpc-5845	46	51	treatment	treatment	NOUN
dpc-5845	46	52	success	success	NOUN
dpc-5845	46	53	and	and	CCONJ
dpc-5845	46	54	stability	stability	NOUN
dpc-5845	46	55	of	of	ADP
dpc-5845	46	56	response	response	NOUN
dpc-5845	46	57	.	.	PUNCT
dpc-5845	47	1	dr	dr	PROPN
dpc-5845	47	2	was	be	AUX
dpc-5845	47	3	achieved	achieve	VERB
dpc-5845	47	4	by	by	ADP
dpc-5845	47	5	dose	dose	NOUN
dpc-5845	47	6	spacing	spacing	NOUN
dpc-5845	47	7	(	(	PUNCT
dpc-5845	47	8	ds	ds	ADJ
dpc-5845	47	9	)	)	PUNCT
dpc-5845	47	10	,	,	PUNCT
dpc-5845	47	11	i.e.	i.e.	X
dpc-5845	47	12	,	,	PUNCT
dpc-5845	47	13	increasing	increase	VERB
dpc-5845	47	14	the	the	DET
dpc-5845	47	15	interval	interval	NOUN
dpc-5845	47	16	of	of	ADP
dpc-5845	47	17	drug	drug	NOUN
dpc-5845	47	18	administration	administration	NOUN
dpc-5845	47	19	;	;	PUNCT
dpc-5845	47	20	the	the	DET
dpc-5845	47	21	time	time	NOUN
dpc-5845	47	22	interval	interval	NOUN
dpc-5845	47	23	between	between	ADP
dpc-5845	47	24	the	the	DET
dpc-5845	47	25	maintenance	maintenance	NOUN
dpc-5845	47	26	dose	dose	NOUN
dpc-5845	47	27	injections	injection	NOUN
dpc-5845	47	28	was	be	AUX
dpc-5845	47	29	prolonged	prolong	VERB
dpc-5845	47	30	by	by	ADP
dpc-5845	47	31	1.5	1.5	NUM
dpc-5845	47	32	times	time	NOUN
dpc-5845	47	33	,	,	PUNCT
dpc-5845	47	34	resulting	result	VERB
dpc-5845	47	35	in	in	ADP
dpc-5845	47	36	administration	administration	NOUN
dpc-5845	47	37	of	of	ADP
dpc-5845	47	38	67	67	NUM
dpc-5845	47	39	%	%	NOUN
dpc-5845	47	40	of	of	ADP
dpc-5845	47	41	the	the	DET
dpc-5845	47	42	full	full	ADJ
dpc-5845	47	43	authorized	authorized	ADJ
dpc-5845	47	44	dose	dose	NOUN
dpc-5845	47	45	(	(	PUNCT
dpc-5845	47	46	table	table	NOUN
dpc-5845	47	47	1	1	NUM
dpc-5845	47	48	)	)	PUNCT
dpc-5845	47	49	.	.	PUNCT
dpc-5845	48	1	exclusion	exclusion	NOUN
dpc-5845	48	2	criteria	criterion	NOUN
dpc-5845	48	3	included	include	VERB
dpc-5845	48	4	individuals	individual	NOUN
dpc-5845	48	5	under	under	ADP
dpc-5845	48	6	age	age	NOUN
dpc-5845	48	7	18	18	NUM
dpc-5845	48	8	years	year	NOUN
dpc-5845	48	9	,	,	PUNCT
dpc-5845	48	10	patients	patient	NOUN
dpc-5845	48	11	with	with	ADP
dpc-5845	48	12	psoriatic	psoriatic	ADJ
dpc-5845	48	13	arthritis	arthritis	NOUN
dpc-5845	48	14	not	not	PART
dpc-5845	48	15	adequately	adequately	ADV
dpc-5845	48	16	controlled	control	VERB
dpc-5845	48	17	by	by	ADP
dpc-5845	48	18	therapy	therapy	NOUN
dpc-5845	48	19	,	,	PUNCT
dpc-5845	48	20	and	and	CCONJ
dpc-5845	48	21	those	those	PRON
dpc-5845	48	22	requiring	require	VERB
dpc-5845	48	23	multiple	multiple	ADJ
dpc-5845	48	24	immunomodulatory	immunomodulatory	ADJ
dpc-5845	48	25	therapies	therapy	NOUN
dpc-5845	48	26	to	to	PART
dpc-5845	48	27	manage	manage	VERB
dpc-5845	48	28	their	their	PRON
dpc-5845	48	29	disease	disease	NOUN
dpc-5845	48	30	.	.	PUNCT
dpc-5845	49	1	at	at	ADP
dpc-5845	49	2	baseline	baseline	NOUN
dpc-5845	49	3	,	,	PUNCT
dpc-5845	49	4	patient	patient	ADJ
dpc-5845	49	5	and	and	CCONJ
dpc-5845	49	6	treatment	treatment	NOUN
dpc-5845	49	7	characteristics	characteristic	NOUN
dpc-5845	49	8	were	be	AUX
dpc-5845	49	9	recorded	record	VERB
dpc-5845	49	10	,	,	PUNCT
dpc-5845	49	11	including	include	VERB
dpc-5845	49	12	age	age	NOUN
dpc-5845	49	13	,	,	PUNCT
dpc-5845	49	14	sex	sex	NOUN
dpc-5845	49	15	,	,	PUNCT
dpc-5845	49	16	weight	weight	NOUN
dpc-5845	49	17	,	,	PUNCT
dpc-5845	49	18	height	height	NOUN
dpc-5845	49	19	,	,	PUNCT
dpc-5845	49	20	body	body	NOUN
dpc-5845	49	21	mass	mass	NOUN
dpc-5845	49	22	index	index	NOUN
dpc-5845	49	23	(	(	PUNCT
dpc-5845	49	24	bmi	bmi	PROPN
dpc-5845	49	25	)	)	PUNCT
dpc-5845	49	26	,	,	PUNCT
dpc-5845	49	27	psoriasis	psoriasis	NOUN
dpc-5845	49	28	area	area	NOUN
dpc-5845	49	29	severity	severity	NOUN
dpc-5845	49	30	index	index	NOUN
dpc-5845	49	31	(	(	PUNCT
dpc-5845	49	32	pasi	pasi	NOUN
dpc-5845	49	33	)	)	PUNCT
dpc-5845	49	34	,	,	PUNCT
dpc-5845	49	35	concomitant	concomitant	ADJ
dpc-5845	49	36	psoriatic	psoriatic	ADJ
dpc-5845	49	37	arthritis	arthritis	NOUN
dpc-5845	49	38	(	(	PUNCT
dpc-5845	49	39	psa	psa	NOUN
dpc-5845	49	40	)	)	PUNCT
dpc-5845	49	41	,	,	PUNCT
dpc-5845	49	42	dermatology	dermatology	NOUN
dpc-5845	49	43	life	life	NOUN
dpc-5845	49	44	quality	quality	NOUN
dpc-5845	49	45	index	index	NOUN
dpc-5845	49	46	(	(	PUNCT
dpc-5845	49	47	dlqi	dlqi	PROPN
dpc-5845	49	48	)	)	PUNCT
dpc-5845	49	49	,	,	PUNCT
dpc-5845	49	50	treatment	treatment	NOUN
dpc-5845	49	51	history	history	NOUN
dpc-5845	49	52	,	,	PUNCT
dpc-5845	49	53	comorbidities	comorbiditie	NOUN
dpc-5845	49	54	,	,	PUNCT
dpc-5845	49	55	and	and	CCONJ
dpc-5845	49	56	disease	disease	NOUN
dpc-5845	49	57	duration	duration	NOUN
dpc-5845	49	58	.	.	PUNCT
dpc-5845	50	1	follow	follow	VERB
dpc-5845	50	2	-	-	PUNCT
dpc-5845	50	3	up	up	ADP
dpc-5845	50	4	assessments	assessment	NOUN
dpc-5845	50	5	were	be	AUX
dpc-5845	50	6	conducted	conduct	VERB
dpc-5845	50	7	at	at	ADP
dpc-5845	50	8	26	26	NUM
dpc-5845	50	9	weeks	week	NOUN
dpc-5845	50	10	±	±	NUM
dpc-5845	50	11	2	2	NUM
dpc-5845	50	12	,	,	PUNCT
dpc-5845	50	13	at	at	ADP
dpc-5845	50	14	52	52	NUM
dpc-5845	50	15	weeks	week	NOUN
dpc-5845	50	16	±	±	NUM
dpc-5845	50	17	2	2	NUM
dpc-5845	50	18	,	,	PUNCT
dpc-5845	50	19	at	at	ADP
dpc-5845	50	20	78	78	NUM
dpc-5845	50	21	weeks	week	NOUN
dpc-5845	50	22	±	±	NUM
dpc-5845	50	23	2	2	NUM
dpc-5845	50	24	,	,	PUNCT
dpc-5845	50	25	and	and	CCONJ
dpc-5845	50	26	then	then	ADV
dpc-5845	50	27	at	at	ADP
dpc-5845	50	28	104	104	NUM
dpc-5845	50	29	weeks	week	NOUN
dpc-5845	50	30	±	±	PROPN
dpc-5845	50	31	2	2	NUM
dpc-5845	50	32	;	;	PUNCT
dpc-5845	50	33	pasi	pasi	NOUN
dpc-5845	50	34	and	and	CCONJ
dpc-5845	50	35	dlqi	dlqi	PROPN
dpc-5845	50	36	were	be	AUX
dpc-5845	50	37	calculated	calculate	VERB
dpc-5845	50	38	and	and	CCONJ
dpc-5845	50	39	registered	register	VERB
dpc-5845	50	40	at	at	ADP
dpc-5845	50	41	each	each	DET
dpc-5845	50	42	visit	visit	NOUN
dpc-5845	50	43	.	.	PUNCT
dpc-5845	51	1	in	in	ADP
dpc-5845	51	2	cases	case	NOUN
dpc-5845	51	3	of	of	ADP
dpc-5845	51	4	disease	disease	NOUN
dpc-5845	51	5	flare	flare	NOUN
dpc-5845	51	6	(	(	PUNCT
dpc-5845	51	7	i.e.	i.e.	X
dpc-5845	51	8	,	,	PUNCT
dpc-5845	51	9	pasi	pasi	NOUN
dpc-5845	51	10	and/or	and/or	CCONJ
dpc-5845	51	11	dlqi	dlqi	VERB
dpc-5845	51	12	score	score	NOUN
dpc-5845	51	13	>	>	PROPN
dpc-5845	51	14	5	5	NUM
dpc-5845	51	15	)	)	PUNCT
dpc-5845	51	16	,	,	PUNCT
dpc-5845	51	17	patients	patient	NOUN
dpc-5845	51	18	were	be	AUX
dpc-5845	51	19	advised	advise	VERB
dpc-5845	51	20	to	to	PART
dpc-5845	51	21	return	return	VERB
dpc-5845	51	22	to	to	ADP
dpc-5845	51	23	their	their	PRON
dpc-5845	51	24	previous	previous	ADJ
dpc-5845	51	25	effective	effective	ADJ
dpc-5845	51	26	original	original	ADJ
dpc-5845	51	27	dose	dose	NOUN
dpc-5845	51	28	.	.	PUNCT
dpc-5845	52	1	supplementary	supplementary	PROPN
dpc-5845	52	2	study	study	NOUN
dpc-5845	52	3	visits	visit	NOUN
dpc-5845	52	4	were	be	AUX
dpc-5845	52	5	implemented	implement	VERB
dpc-5845	52	6	in	in	ADP
dpc-5845	52	7	cases	case	NOUN
dpc-5845	52	8	of	of	ADP
dpc-5845	52	9	worsening	worsen	VERB
dpc-5845	52	10	of	of	ADP
dpc-5845	52	11	the	the	DET
dpc-5845	52	12	disease	disease	NOUN
dpc-5845	52	13	;	;	PUNCT
dpc-5845	52	14	pasi	pasi	NOUN
dpc-5845	52	15	and	and	CCONJ
dpc-5845	52	16	dlqi	dlqi	ADJ
dpc-5845	52	17	score	score	NOUN
dpc-5845	52	18	were	be	AUX
dpc-5845	52	19	recorded	record	VERB
dpc-5845	52	20	in	in	ADP
dpc-5845	52	21	these	these	DET
dpc-5845	52	22	additional	additional	ADJ
dpc-5845	52	23	visits	visit	NOUN
dpc-5845	52	24	.	.	PUNCT
dpc-5845	53	1	the	the	DET
dpc-5845	53	2	study	study	NOUN
dpc-5845	53	3	was	be	AUX
dpc-5845	53	4	approved	approve	VERB
dpc-5845	53	5	by	by	ADP
dpc-5845	53	6	the	the	DET
dpc-5845	53	7	institutional	institutional	ADJ
dpc-5845	53	8	ethics	ethic	NOUN
dpc-5845	53	9	committee	committee	PROPN
dpc-5845	53	10	(	(	PUNCT
dpc-5845	53	11	comitato	comitato	PROPN
dpc-5845	53	12	etico	etico	PROPN
dpc-5845	53	13	interaziendale	interaziendale	PROPN
dpc-5845	53	14	aou	aou	PROPN
dpc-5845	53	15	maggiore	maggiore	PROPN
dpc-5845	53	16	della	della	PROPN
dpc-5845	53	17	carità	carità	PROPN
dpc-5845	53	18	,	,	PUNCT
dpc-5845	53	19	asl	asl	PROPN
dpc-5845	53	20	bi	bi	PROPN
dpc-5845	53	21	,	,	PUNCT
dpc-5845	53	22	asl	asl	PROPN
dpc-5845	53	23	no	no	PROPN
dpc-5845	53	24	,	,	PUNCT
dpc-5845	53	25	asl	asl	PROPN
dpc-5845	53	26	vco	vco	PROPN
dpc-5845	53	27	)	)	PUNCT
dpc-5845	53	28	and	and	CCONJ
dpc-5845	53	29	conducted	conduct	VERB
dpc-5845	53	30	according	accord	VERB
dpc-5845	53	31	to	to	ADP
dpc-5845	53	32	the	the	DET
dpc-5845	53	33	declaration	declaration	NOUN
dpc-5845	53	34	of	of	ADP
dpc-5845	53	35	helsinki	helsinki	PROPN
dpc-5845	53	36	principles	principle	NOUN
dpc-5845	53	37	,	,	PUNCT
dpc-5845	53	38	with	with	ADP
dpc-5845	53	39	all	all	DET
dpc-5845	53	40	patients	patient	NOUN
dpc-5845	53	41	providing	provide	VERB
dpc-5845	53	42	informed	informed	ADJ
dpc-5845	53	43	consent	consent	NOUN
dpc-5845	53	44	.	.	PUNCT
dpc-5845	54	1	study	study	NOUN
dpc-5845	54	2	population	population	NOUN
dpc-5845	54	3	the	the	DET
dpc-5845	54	4	psored	psore	VERB
dpc-5845	54	5	study	study	NOUN
dpc-5845	54	6	recruited	recruit	VERB
dpc-5845	54	7	patients	patient	NOUN
dpc-5845	54	8	through	through	ADP
dpc-5845	54	9	cooperation	cooperation	NOUN
dpc-5845	54	10	with	with	ADP
dpc-5845	54	11	dermatologists	dermatologist	NOUN
dpc-5845	54	12	specialized	specialize	VERB
dpc-5845	54	13	in	in	ADP
dpc-5845	54	14	the	the	DET
dpc-5845	54	15	treatment	treatment	NOUN
dpc-5845	54	16	of	of	ADP
dpc-5845	54	17	psoriasis	psoriasis	NOUN
dpc-5845	54	18	using	use	VERB
dpc-5845	54	19	biologics	biologic	NOUN
dpc-5845	54	20	.	.	PUNCT
dpc-5845	55	1	each	each	DET
dpc-5845	55	2	participant	participant	NOUN
dpc-5845	55	3	received	receive	VERB
dpc-5845	55	4	detailed	detailed	ADJ
dpc-5845	55	5	oral	oral	ADJ
dpc-5845	55	6	and	and	CCONJ
dpc-5845	55	7	written	write	VERB
dpc-5845	55	8	information	information	NOUN
dpc-5845	55	9	from	from	ADP
dpc-5845	55	10	the	the	DET
dpc-5845	55	11	local	local	ADJ
dpc-5845	55	12	investigator	investigator	NOUN
dpc-5845	55	13	,	,	PUNCT
dpc-5845	55	14	who	who	PRON
dpc-5845	55	15	also	also	ADV
dpc-5845	55	16	obtained	obtain	VERB
dpc-5845	55	17	written	write	VERB
dpc-5845	55	18	informed	inform	VERB
dpc-5845	55	19	consent	consent	NOUN
dpc-5845	55	20	.	.	PUNCT
dpc-5845	56	1	the	the	DET
dpc-5845	56	2	dosing	dose	VERB
dpc-5845	56	3	schedule	schedule	NOUN
dpc-5845	56	4	was	be	AUX
dpc-5845	56	5	tailored	tailor	VERB
dpc-5845	56	6	to	to	ADP
dpc-5845	56	7	the	the	DET
dpc-5845	56	8	specific	specific	ADJ
dpc-5845	56	9	biologic	biologic	NOUN
dpc-5845	56	10	therapy	therapy	NOUN
dpc-5845	56	11	used	use	VERB
dpc-5845	56	12	by	by	ADP
dpc-5845	56	13	each	each	DET
dpc-5845	56	14	patient	patient	NOUN
dpc-5845	56	15	.	.	PUNCT
dpc-5845	57	1	patients	patient	NOUN
dpc-5845	57	2	were	be	AUX
dpc-5845	57	3	free	free	ADJ
dpc-5845	57	4	to	to	PART
dpc-5845	57	5	withdraw	withdraw	VERB
dpc-5845	57	6	from	from	ADP
dpc-5845	57	7	the	the	DET
dpc-5845	57	8	study	study	NOUN
dpc-5845	57	9	at	at	ADP
dpc-5845	57	10	any	any	DET
dpc-5845	57	11	time	time	NOUN
dpc-5845	57	12	without	without	ADP
dpc-5845	57	13	repercussions	repercussion	NOUN
dpc-5845	57	14	,	,	PUNCT
dpc-5845	57	15	while	while	SCONJ
dpc-5845	57	16	investigators	investigator	NOUN
dpc-5845	57	17	retained	retain	VERB
dpc-5845	57	18	the	the	DET
dpc-5845	57	19	authority	authority	NOUN
dpc-5845	57	20	to	to	PART
dpc-5845	57	21	withdraw	withdraw	VERB
dpc-5845	57	22	patients	patient	NOUN
dpc-5845	57	23	for	for	ADP
dpc-5845	57	24	urgent	urgent	ADJ
dpc-5845	57	25	medical	medical	ADJ
dpc-5845	57	26	reasons	reason	NOUN
dpc-5845	57	27	.	.	PUNCT
dpc-5845	58	1	preliminary	preliminary	ADJ
dpc-5845	58	2	data	datum	NOUN
dpc-5845	58	3	from	from	ADP
dpc-5845	58	4	the	the	DET
dpc-5845	58	5	first	first	ADJ
dpc-5845	58	6	52	52	NUM
dpc-5845	58	7	weeks	week	NOUN
dpc-5845	58	8	of	of	ADP
dpc-5845	58	9	the	the	DET
dpc-5845	58	10	study	study	NOUN
dpc-5845	58	11	were	be	AUX
dpc-5845	58	12	analyzed	analyze	VERB
dpc-5845	58	13	for	for	ADP
dpc-5845	58	14	this	this	DET
dpc-5845	58	15	paper	paper	NOUN
dpc-5845	58	16	.	.	PUNCT
dpc-5845	59	1	additional	additional	ADJ
dpc-5845	59	2	study	study	NOUN
dpc-5845	59	3	visits	visit	NOUN
dpc-5845	59	4	were	be	AUX
dpc-5845	59	5	scheduled	schedule	VERB
dpc-5845	59	6	as	as	SCONJ
dpc-5845	59	7	needed	need	VERB
dpc-5845	59	8	in	in	ADP
dpc-5845	59	9	response	response	NOUN
dpc-5845	59	10	to	to	ADP
dpc-5845	59	11	disease	disease	NOUN
dpc-5845	59	12	flares	flare	NOUN
dpc-5845	59	13	occurring	occur	VERB
dpc-5845	59	14	outside	outside	ADP
dpc-5845	59	15	the	the	DET
dpc-5845	59	16	planned	plan	VERB
dpc-5845	59	17	follow	follow	NOUN
dpc-5845	59	18	-	-	PUNCT
dpc-5845	59	19	up	up	ADP
dpc-5845	59	20	appointments	appointment	NOUN
dpc-5845	59	21	.	.	PUNCT
dpc-5845	60	1	statistical	statistical	ADJ
dpc-5845	60	2	analysis	analysis	NOUN
dpc-5845	60	3	descriptive	descriptive	ADJ
dpc-5845	60	4	statistics	statistic	NOUN
dpc-5845	60	5	of	of	ADP
dpc-5845	60	6	the	the	DET
dpc-5845	60	7	subjects	subject	NOUN
dpc-5845	60	8	included	include	VERB
dpc-5845	60	9	are	be	AUX
dpc-5845	60	10	reported	report	VERB
dpc-5845	60	11	overall	overall	ADV
dpc-5845	60	12	and	and	CCONJ
dpc-5845	60	13	separately	separately	ADV
dpc-5845	60	14	for	for	ADP
dpc-5845	60	15	treatment	treatment	NOUN
dpc-5845	60	16	type	type	NOUN
dpc-5845	60	17	(	(	PUNCT
dpc-5845	60	18	il-17i	il-17i	PROPN
dpc-5845	60	19	and	and	CCONJ
dpc-5845	60	20	il-23i	il-23i	NOUN
dpc-5845	60	21	)	)	PUNCT
dpc-5845	60	22	.	.	PUNCT
dpc-5845	61	1	categorical	categorical	ADJ
dpc-5845	61	2	variables	variable	NOUN
dpc-5845	61	3	are	be	AUX
dpc-5845	61	4	summarized	summarize	VERB
dpc-5845	61	5	using	use	VERB
dpc-5845	61	6	absolute	absolute	ADJ
dpc-5845	61	7	and	and	CCONJ
dpc-5845	61	8	relative	relative	ADJ
dpc-5845	61	9	frequencies	frequency	NOUN
dpc-5845	61	10	,	,	PUNCT
dpc-5845	61	11	while	while	SCONJ
dpc-5845	61	12	for	for	ADP
dpc-5845	61	13	numerical	numerical	ADJ
dpc-5845	61	14	ones	one	NOUN
dpc-5845	61	15	,	,	PUNCT
dpc-5845	61	16	mean	mean	ADJ
dpc-5845	61	17	and	and	CCONJ
dpc-5845	61	18	standard	standard	ADJ
dpc-5845	61	19	deviation	deviation	NOUN
dpc-5845	61	20	(	(	PUNCT
dpc-5845	61	21	sd	sd	NOUN
dpc-5845	61	22	)	)	PUNCT
dpc-5845	61	23	or	or	CCONJ
dpc-5845	61	24	median	median	NOUN
dpc-5845	61	25	and	and	CCONJ
dpc-5845	61	26	interquartile	interquartile	ADJ
dpc-5845	61	27	range	range	NOUN
dpc-5845	61	28	are	be	AUX
dpc-5845	61	29	reported	report	VERB
dpc-5845	61	30	,	,	PUNCT
dpc-5845	61	31	as	as	ADP
dpc-5845	61	32	appropriate	appropriate	ADJ
dpc-5845	61	33	.	.	PUNCT
dpc-5845	62	1	differences	difference	NOUN
dpc-5845	62	2	at	at	ADP
dpc-5845	62	3	baseline	baseline	NOUN
dpc-5845	62	4	between	between	ADP
dpc-5845	62	5	groups	group	NOUN
dpc-5845	62	6	were	be	AUX
dpc-5845	62	7	evaluated	evaluate	VERB
dpc-5845	62	8	using	use	VERB
dpc-5845	62	9	chi	chi	NOUN
dpc-5845	62	10	-	-	PUNCT
dpc-5845	62	11	squared	square	VERB
dpc-5845	62	12	/	/	SYM
dpc-5845	62	13	fisher	fisher	PROPN
dpc-5845	62	14	test	test	NOUN
dpc-5845	62	15	or	or	CCONJ
dpc-5845	62	16	t	t	PROPN
dpc-5845	62	17	-	-	PUNCT
dpc-5845	62	18	test/	test/	NUM
dpc-5845	62	19	alternative	alternative	ADJ
dpc-5845	62	20	non	non	ADJ
dpc-5845	62	21	-	-	ADJ
dpc-5845	62	22	parametric	parametric	ADJ
dpc-5845	62	23	tests	test	NOUN
dpc-5845	62	24	,	,	PUNCT
dpc-5845	62	25	as	as	ADP
dpc-5845	62	26	appropriate	appropriate	ADJ
dpc-5845	62	27	.	.	PUNCT
dpc-5845	63	1	dr	dr	PROPN
dpc-5845	63	2	survival	survival	PROPN
dpc-5845	63	3	was	be	AUX
dpc-5845	63	4	defined	define	VERB
dpc-5845	63	5	as	as	ADP
dpc-5845	63	6	the	the	DET
dpc-5845	63	7	time	time	NOUN
dpc-5845	63	8	from	from	ADP
dpc-5845	63	9	the	the	DET
dpc-5845	63	10	dose	dose	NOUN
dpc-5845	63	11	reduction	reduction	NOUN
dpc-5845	63	12	start	start	VERB
dpc-5845	63	13	to	to	ADP
dpc-5845	63	14	failure	failure	NOUN
dpc-5845	63	15	of	of	ADP
dpc-5845	63	16	dr	dr	PROPN
dpc-5845	63	17	for	for	ADP
dpc-5845	63	18	any	any	DET
dpc-5845	63	19	patient	patient	NOUN
dpc-5845	63	20	;	;	PUNCT
dpc-5845	63	21	time	time	NOUN
dpc-5845	63	22	was	be	AUX
dpc-5845	63	23	censored	censor	VERB
dpc-5845	63	24	to	to	ADP
dpc-5845	63	25	52	52	NUM
dpc-5845	63	26	weeks	week	NOUN
dpc-5845	63	27	.	.	PUNCT
dpc-5845	64	1	median	median	PROPN
dpc-5845	64	2	dr	dr	PROPN
dpc-5845	64	3	survival	survival	PROPN
dpc-5845	64	4	time	time	NOUN
dpc-5845	64	5	and	and	CCONJ
dpc-5845	64	6	median	median	NOUN
dpc-5845	64	7	follow	follow	VERB
dpc-5845	64	8	up	up	ADP
dpc-5845	64	9	were	be	AUX
dpc-5845	64	10	estimated	estimate	VERB
dpc-5845	64	11	using	use	VERB
dpc-5845	64	12	the	the	DET
dpc-5845	64	13	kaplan	kaplan	PROPN
dpc-5845	64	14	-	-	PUNCT
dpc-5845	64	15	meier	meier	PROPN
dpc-5845	64	16	(	(	PUNCT
dpc-5845	64	17	km	km	NOUN
dpc-5845	64	18	)	)	PUNCT
dpc-5845	64	19	methods	method	NOUN
dpc-5845	64	20	.	.	PUNCT
dpc-5845	65	1	km	km	NOUN
dpc-5845	65	2	curves	curve	NOUN
dpc-5845	65	3	were	be	AUX
dpc-5845	65	4	estimated	estimate	VERB
dpc-5845	65	5	,	,	PUNCT
dpc-5845	65	6	and	and	CCONJ
dpc-5845	65	7	the	the	DET
dpc-5845	65	8	log	log	NOUN
dpc-5845	65	9	rank	rank	NOUN
dpc-5845	65	10	test	test	NOUN
dpc-5845	65	11	was	be	AUX
dpc-5845	65	12	calculated	calculate	VERB
dpc-5845	65	13	to	to	PART
dpc-5845	65	14	evaluate	evaluate	VERB
dpc-5845	65	15	differences	difference	NOUN
dpc-5845	65	16	between	between	ADP
dpc-5845	65	17	treatment	treatment	NOUN
dpc-5845	65	18	groups	group	NOUN
dpc-5845	65	19	.	.	PUNCT
dpc-5845	66	1	moreover	moreover	ADV
dpc-5845	66	2	,	,	PUNCT
dpc-5845	66	3	dose	dose	NOUN
dpc-5845	66	4	reduction	reduction	NOUN
dpc-5845	66	5	survival	survival	NOUN
dpc-5845	66	6	at	at	ADP
dpc-5845	66	7	52	52	NUM
dpc-5845	66	8	weeks	week	NOUN
dpc-5845	66	9	was	be	AUX
dpc-5845	66	10	reported	report	VERB
dpc-5845	66	11	with	with	ADP
dpc-5845	66	12	95	95	NUM
dpc-5845	66	13	%	%	NOUN
dpc-5845	66	14	confidence	confidence	NOUN
dpc-5845	66	15	intervals	interval	NOUN
dpc-5845	66	16	(	(	PUNCT
dpc-5845	66	17	95	95	NUM
dpc-5845	66	18	%	%	NOUN
dpc-5845	66	19	ci	ci	NOUN
dpc-5845	66	20	)	)	PUNCT
dpc-5845	66	21	.	.	PUNCT
dpc-5845	67	1	then	then	ADV
dpc-5845	67	2	,	,	PUNCT
dpc-5845	67	3	the	the	DET
dpc-5845	67	4	relationship	relationship	NOUN
dpc-5845	67	5	between	between	ADP
dpc-5845	67	6	dr	dr	PROPN
dpc-5845	67	7	survival	survival	PROPN
dpc-5845	67	8	and	and	CCONJ
dpc-5845	67	9	treatment	treatment	NOUN
dpc-5845	67	10	type	type	NOUN
dpc-5845	67	11	was	be	AUX
dpc-5845	67	12	considered	consider	VERB
dpc-5845	67	13	in	in	ADP
dpc-5845	67	14	unadjusted	unadjusted	ADJ
dpc-5845	67	15	and	and	CCONJ
dpc-5845	67	16	adjusted	adjust	VERB
dpc-5845	67	17	cox	cox	PROPN
dpc-5845	67	18	models	model	NOUN
dpc-5845	67	19	,	,	PUNCT
dpc-5845	67	20	and	and	CCONJ
dpc-5845	67	21	hazard	hazard	NOUN
dpc-5845	67	22	ratios	ratio	NOUN
dpc-5845	67	23	(	(	PUNCT
dpc-5845	67	24	hrs	hrs	NOUN
dpc-5845	67	25	)	)	PUNCT
dpc-5845	67	26	with	with	ADP
dpc-5845	67	27	95	95	NUM
dpc-5845	67	28	%	%	NOUN
dpc-5845	67	29	ci	ci	NOUN
dpc-5845	67	30	were	be	AUX
dpc-5845	67	31	estimated	estimate	VERB
dpc-5845	67	32	.	.	PUNCT
dpc-5845	68	1	particularly	particularly	ADV
dpc-5845	68	2	,	,	PUNCT
dpc-5845	68	3	the	the	DET
dpc-5845	68	4	adjustment	adjustment	NOUN
dpc-5845	68	5	for	for	ADP
dpc-5845	68	6	clinical	clinical	ADJ
dpc-5845	68	7	covariates	covariate	NOUN
dpc-5845	68	8	(	(	PUNCT
dpc-5845	68	9	age	age	NOUN
dpc-5845	68	10	,	,	PUNCT
dpc-5845	68	11	sex	sex	NOUN
dpc-5845	68	12	,	,	PUNCT
dpc-5845	68	13	baseline	baseline	NOUN
dpc-5845	68	14	bmi	bmi	NOUN
dpc-5845	68	15	,	,	PUNCT
dpc-5845	68	16	psoriasis	psoriasis	NOUN
dpc-5845	68	17	type	type	NOUN
dpc-5845	68	18	,	,	PUNCT
dpc-5845	68	19	comorbidity	comorbidity	NOUN
dpc-5845	68	20	,	,	PUNCT
dpc-5845	68	21	previous	previous	ADJ
dpc-5845	68	22	biological	biological	ADJ
dpc-5845	68	23	treatment	treatment	NOUN
dpc-5845	68	24	,	,	PUNCT
dpc-5845	68	25	therapy	therapy	NOUN
dpc-5845	68	26	time	time	NOUN
dpc-5845	68	27	before	before	ADP
dpc-5845	68	28	dr	dr	PROPN
dpc-5845	68	29	)	)	PUNCT
dpc-5845	68	30	was	be	AUX
dpc-5845	68	31	performed	perform	VERB
dpc-5845	68	32	calculating	calculate	VERB
dpc-5845	68	33	the	the	DET
dpc-5845	68	34	linear	linear	ADJ
dpc-5845	68	35	predictors	predictor	NOUN
dpc-5845	68	36	for	for	ADP
dpc-5845	68	37	each	each	DET
dpc-5845	68	38	subject	subject	NOUN
dpc-5845	68	39	obtained	obtain	VERB
dpc-5845	68	40	by	by	ADP
dpc-5845	68	41	logistic	logistic	ADJ
dpc-5845	68	42	model	model	NOUN
dpc-5845	68	43	with	with	ADP
dpc-5845	68	44	all	all	DET
dpc-5845	68	45	the	the	DET
dpc-5845	68	46	covariates	covariate	NOUN
dpc-5845	68	47	included	include	VERB
dpc-5845	68	48	.	.	PUNCT
dpc-5845	69	1	missing	miss	VERB
dpc-5845	69	2	values	value	NOUN
dpc-5845	69	3	in	in	ADP
dpc-5845	69	4	the	the	DET
dpc-5845	69	5	covariates	covariate	NOUN
dpc-5845	69	6	were	be	AUX
dpc-5845	69	7	imputed	impute	VERB
dpc-5845	69	8	using	use	VERB
dpc-5845	69	9	a	a	DET
dpc-5845	69	10	simple	simple	ADJ
dpc-5845	69	11	approach	approach	NOUN
dpc-5845	69	12	:	:	PUNCT
dpc-5845	69	13	the	the	DET
dpc-5845	69	14	mean	mean	NOUN
dpc-5845	69	15	or	or	CCONJ
dpc-5845	69	16	median	median	NOUN
dpc-5845	69	17	was	be	AUX
dpc-5845	69	18	used	use	VERB
dpc-5845	69	19	for	for	ADP
dpc-5845	69	20	continuous	continuous	ADJ
dpc-5845	69	21	variables	variable	NOUN
dpc-5845	69	22	,	,	PUNCT
dpc-5845	69	23	and	and	CCONJ
dpc-5845	69	24	the	the	DET
dpc-5845	69	25	mode	mode	NOUN
dpc-5845	69	26	was	be	AUX
dpc-5845	69	27	used	use	VERB
dpc-5845	69	28	for	for	ADP
dpc-5845	69	29	categorical	categorical	ADJ
dpc-5845	69	30	variables	variable	NOUN
dpc-5845	69	31	.	.	PUNCT
dpc-5845	70	1	all	all	DET
dpc-5845	70	2	the	the	DET
dpc-5845	70	3	analyses	analysis	NOUN
dpc-5845	70	4	were	be	AUX
dpc-5845	70	5	performed	perform	VERB
dpc-5845	70	6	using	use	VERB
dpc-5845	70	7	sas	sas	PROPN
dpc-5845	70	8	9.4	9.4	NUM
dpc-5845	70	9	and	and	CCONJ
dpc-5845	70	10	r	r	NOUN
dpc-5845	70	11	,	,	PUNCT
dpc-5845	70	12	and	and	CCONJ
dpc-5845	70	13	the	the	DET
dpc-5845	70	14	significance	significance	NOUN
dpc-5845	70	15	threshold	threshold	NOUN
dpc-5845	70	16	was	be	AUX
dpc-5845	70	17	set	set	VERB
dpc-5845	70	18	to	to	ADP
dpc-5845	70	19	0.05	0.05	NUM
dpc-5845	70	20	(	(	PUNCT
dpc-5845	70	21	two	two	NUM
dpc-5845	70	22	-	-	PUNCT
dpc-5845	70	23	tailed	tail	VERB
dpc-5845	70	24	)	)	PUNCT
dpc-5845	70	25	.	.	PUNCT
dpc-5845	71	1	results	result	VERB
dpc-5845	71	2	patient	patient	ADJ
dpc-5845	71	3	characteristics	characteristic	NOUN
dpc-5845	71	4	a	a	DET
dpc-5845	71	5	total	total	NOUN
dpc-5845	71	6	of	of	ADP
dpc-5845	71	7	361	361	NUM
dpc-5845	71	8	patients	patient	NOUN
dpc-5845	71	9	,	,	PUNCT
dpc-5845	71	10	from	from	ADP
dpc-5845	71	11	10	10	NUM
dpc-5845	71	12	participating	participate	VERB
dpc-5845	71	13	hospitals	hospital	NOUN
dpc-5845	71	14	in	in	ADP
dpc-5845	71	15	the	the	DET
dpc-5845	71	16	piedmont	piedmont	PROPN
dpc-5845	71	17	region	region	NOUN
dpc-5845	71	18	,	,	PUNCT
dpc-5845	71	19	provided	provide	VERB
dpc-5845	71	20	informed	informed	ADJ
dpc-5845	71	21	consent	consent	NOUN
dpc-5845	71	22	and	and	CCONJ
dpc-5845	71	23	were	be	AUX
dpc-5845	71	24	table	table	NOUN
dpc-5845	71	25	1	1	NUM
dpc-5845	71	26	.	.	X
dpc-5845	71	27	secukinumab	secukinumab	NOUN
dpc-5845	71	28	,	,	PUNCT
dpc-5845	71	29	brodalumab	brodalumab	NOUN
dpc-5845	71	30	,	,	PUNCT
dpc-5845	71	31	risankizumab	risankizumab	NOUN
dpc-5845	71	32	,	,	PUNCT
dpc-5845	71	33	and	and	CCONJ
dpc-5845	71	34	guselkumab	guselkumab	NOUN
dpc-5845	71	35	authorized	authorize	VERB
dpc-5845	71	36	interval	interval	NOUN
dpc-5845	71	37	of	of	ADP
dpc-5845	71	38	drug	drug	NOUN
dpc-5845	71	39	administration	administration	NOUN
dpc-5845	71	40	at	at	ADP
dpc-5845	71	41	maintenance	maintenance	NOUN
dpc-5845	71	42	compared	compare	VERB
dpc-5845	71	43	with	with	ADP
dpc-5845	71	44	dose	dose	NOUN
dpc-5845	71	45	spacing	spacing	NOUN
dpc-5845	71	46	for	for	ADP
dpc-5845	71	47	the	the	DET
dpc-5845	71	48	same	same	ADJ
dpc-5845	71	49	drugs	drug	NOUN
dpc-5845	71	50	.	.	PUNCT
dpc-5845	72	1	biologic	biologic	NOUN
dpc-5845	72	2	therapy	therapy	NOUN
dpc-5845	72	3	authorized	authorize	VERB
dpc-5845	72	4	interval	interval	NOUN
dpc-5845	72	5	of	of	ADP
dpc-5845	72	6	drug	drug	NOUN
dpc-5845	72	7	administration	administration	NOUN
dpc-5845	72	8	at	at	ADP
dpc-5845	72	9	maintenance	maintenance	NOUN
dpc-5845	72	10	dose	dose	NOUN
dpc-5845	72	11	spacing	space	VERB
dpc-5845	72	12	secukinumab	secukinumab	NOUN
dpc-5845	72	13	300	300	NUM
dpc-5845	72	14	mg	mg	NOUN
dpc-5845	72	15	q4w	q4w	ADV
dpc-5845	72	16	300	300	NUM
dpc-5845	72	17	mg	mg	NUM
dpc-5845	72	18	q6w	q6w	PROPN
dpc-5845	72	19	brodalumab	brodalumab	NOUN
dpc-5845	72	20	210	210	NUM
dpc-5845	72	21	mg	mg	NOUN
dpc-5845	72	22	q2w	q2w	NOUN
dpc-5845	72	23	210	210	NUM
dpc-5845	72	24	mg	mg	PROPN
dpc-5845	72	25	q3w	q3w	NOUN
dpc-5845	72	26	risankizumab	risankizumab	NOUN
dpc-5845	72	27	150	150	NUM
dpc-5845	72	28	mg	mg	NOUN
dpc-5845	72	29	q12w	q12w	NOUN
dpc-5845	72	30	150	150	NUM
dpc-5845	72	31	mg	mg	PROPN
dpc-5845	72	32	q18w	q18w	NUM
dpc-5845	72	33	guselkumab	guselkumab	NOUN
dpc-5845	72	34	100	100	NUM
dpc-5845	72	35	mg	mg	NOUN
dpc-5845	73	1	q8w	q8w	ADV
dpc-5845	73	2	100	100	NUM
dpc-5845	73	3	mg	mg	ADJ
dpc-5845	73	4	q12w	q12w	NOUN
dpc-5845	73	5	4	4	NUM
dpc-5845	73	6	original	original	ADJ
dpc-5845	73	7	article	article	NOUN
dpc-5845	73	8	|	|	ADV
dpc-5845	73	9	dermatol	dermatol	ADJ
dpc-5845	73	10	pract	pract	NOUN
dpc-5845	73	11	concept	concept	NOUN
dpc-5845	73	12	.	.	PUNCT
dpc-5845	74	1	2025;15(3):5845	2025;15(3):5845	NOUN
dpc-5845	74	2	at	at	ADP
dpc-5845	74	3	baseline	baseline	NOUN
dpc-5845	74	4	,	,	PUNCT
dpc-5845	74	5	the	the	DET
dpc-5845	74	6	 	 	SPACE
dpc-5845	74	7	mean	mean	NOUN
dpc-5845	74	8	(	(	PUNCT
dpc-5845	74	9	sd	sd	NOUN
dpc-5845	74	10	)	)	PUNCT
dpc-5845	74	11	pasi	pasi	NOUN
dpc-5845	74	12	was	be	AUX
dpc-5845	74	13	 	 	SPACE
dpc-5845	74	14	15.12	15.12	NUM
dpc-5845	74	15	(	(	PUNCT
dpc-5845	74	16	7.14	7.14	NUM
dpc-5845	74	17	)	)	PUNCT
dpc-5845	74	18	,	,	PUNCT
dpc-5845	74	19	without	without	ADP
dpc-5845	74	20	significant	significant	ADJ
dpc-5845	74	21	differences	difference	NOUN
dpc-5845	74	22	between	between	ADP
dpc-5845	74	23	the	the	DET
dpc-5845	74	24	two	two	NUM
dpc-5845	74	25	groups	group	NOUN
dpc-5845	74	26	(	(	PUNCT
dpc-5845	74	27	p=0.7619	p=0.7619	NUM
dpc-5845	74	28	)	)	PUNCT
dpc-5845	74	29	;	;	PUNCT
dpc-5845	74	30	conversely	conversely	ADV
dpc-5845	74	31	,	,	PUNCT
dpc-5845	74	32	the	the	DET
dpc-5845	74	33	mean	mean	ADJ
dpc-5845	74	34	(	(	PUNCT
dpc-5845	74	35	sd	sd	NOUN
dpc-5845	74	36	)	)	PUNCT
dpc-5845	74	37	dlqi	dlqi	PROPN
dpc-5845	74	38	was	be	AUX
dpc-5845	74	39	 	 	SPACE
dpc-5845	74	40	12.84	12.84	NUM
dpc-5845	74	41	(	(	PUNCT
dpc-5845	74	42	6.08	6.08	NUM
dpc-5845	74	43	)	)	PUNCT
dpc-5845	74	44	,	,	PUNCT
dpc-5845	74	45	with	with	ADP
dpc-5845	74	46	a	a	DET
dpc-5845	74	47	significant	significant	ADJ
dpc-5845	74	48	difference	difference	NOUN
dpc-5845	74	49	between	between	ADP
dpc-5845	74	50	il-17i	il-17i	PROPN
dpc-5845	74	51	and	and	CCONJ
dpc-5845	74	52	il-23i	il-23i	NOUN
dpc-5845	74	53	groups	group	NOUN
dpc-5845	74	54	(	(	PUNCT
dpc-5845	74	55	p=0.0009	p=0.0009	X
dpc-5845	74	56	)	)	PUNCT
dpc-5845	74	57	.	.	PUNCT
dpc-5845	75	1	the	the	DET
dpc-5845	75	2	majority	majority	NOUN
dpc-5845	75	3	of	of	ADP
dpc-5845	75	4	patients	patient	NOUN
dpc-5845	75	5	achieved	achieve	VERB
dpc-5845	75	6	and	and	CCONJ
dpc-5845	75	7	maintained	maintain	VERB
dpc-5845	75	8	good	good	ADJ
dpc-5845	75	9	disease	disease	NOUN
dpc-5845	75	10	management	management	NOUN
dpc-5845	75	11	,	,	PUNCT
dpc-5845	75	12	both	both	PRON
dpc-5845	75	13	for	for	ADP
dpc-5845	75	14	pasi	pasi	NOUN
dpc-5845	75	15	and	and	CCONJ
dpc-5845	75	16	dlqi	dlqi	NOUN
dpc-5845	75	17	,	,	PUNCT
dpc-5845	75	18	during	during	ADP
dpc-5845	75	19	the	the	DET
dpc-5845	75	20	52	52	NUM
dpc-5845	75	21	weeks	week	NOUN
dpc-5845	75	22	of	of	ADP
dpc-5845	75	23	follow	follow	NOUN
dpc-5845	75	24	-	-	PUNCT
dpc-5845	75	25	up	up	NOUN
dpc-5845	75	26	;	;	PUNCT
dpc-5845	75	27	these	these	DET
dpc-5845	75	28	results	result	NOUN
dpc-5845	75	29	are	be	AUX
dpc-5845	75	30	summarized	summarize	VERB
dpc-5845	75	31	in	in	ADP
dpc-5845	75	32	table	table	NOUN
dpc-5845	75	33	3	3	NUM
dpc-5845	75	34	.	.	PUNCT
dpc-5845	75	35	flare	flare	NOUN
dpc-5845	75	36	-	-	PUNCT
dpc-5845	75	37	ups	up	NOUN
dpc-5845	75	38	,	,	PUNCT
dpc-5845	75	39	treatment	treatment	NOUN
dpc-5845	75	40	adjustments	adjustment	NOUN
dpc-5845	75	41	,	,	PUNCT
dpc-5845	75	42	and	and	CCONJ
dpc-5845	75	43	dose	dose	NOUN
dpc-5845	75	44	reduction	reduction	NOUN
dpc-5845	75	45	survival	survival	NOUN
dpc-5845	75	46	thirty	thirty	NUM
dpc-5845	75	47	-	-	PUNCT
dpc-5845	75	48	nine	nine	NUM
dpc-5845	75	49	patients	patient	NOUN
dpc-5845	75	50	interrupted	interrupt	VERB
dpc-5845	75	51	the	the	DET
dpc-5845	75	52	dr	dr	PROPN
dpc-5845	75	53	:	:	PUNCT
dpc-5845	75	54	four	four	NUM
dpc-5845	75	55	before	before	ADP
dpc-5845	75	56	first	first	ADJ
dpc-5845	75	57	follow	follow	VERB
dpc-5845	75	58	-	-	PUNCT
dpc-5845	75	59	up	up	ADP
dpc-5845	75	60	visit	visit	NOUN
dpc-5845	75	61	,	,	PUNCT
dpc-5845	75	62	27	27	NUM
dpc-5845	75	63	during	during	ADP
dpc-5845	75	64	the	the	DET
dpc-5845	75	65	first	first	ADJ
dpc-5845	75	66	visit	visit	NOUN
dpc-5845	75	67	,	,	PUNCT
dpc-5845	75	68	one	one	NUM
dpc-5845	75	69	between	between	ADP
dpc-5845	75	70	the	the	DET
dpc-5845	75	71	first	first	ADJ
dpc-5845	75	72	and	and	CCONJ
dpc-5845	75	73	second	second	ADJ
dpc-5845	75	74	follow	follow	NOUN
dpc-5845	75	75	-	-	PUNCT
dpc-5845	75	76	up	up	ADP
dpc-5845	75	77	visit	visit	NOUN
dpc-5845	75	78	,	,	PUNCT
dpc-5845	75	79	and	and	CCONJ
dpc-5845	75	80	seven	seven	NUM
dpc-5845	75	81	during	during	ADP
dpc-5845	75	82	the	the	DET
dpc-5845	75	83	second	second	ADJ
dpc-5845	75	84	follow	follow	NOUN
dpc-5845	75	85	-	-	PUNCT
dpc-5845	75	86	up	up	ADP
dpc-5845	75	87	visit	visit	NOUN
dpc-5845	75	88	.	.	PUNCT
dpc-5845	76	1	disease	disease	NOUN
dpc-5845	76	2	flare	flare	NOUN
dpc-5845	76	3	-	-	PUNCT
dpc-5845	76	4	ups	up	NOUN
dpc-5845	76	5	,	,	PUNCT
dpc-5845	76	6	and	and	CCONJ
dpc-5845	76	7	subsequent	subsequent	ADJ
dpc-5845	76	8	reversion	reversion	NOUN
dpc-5845	76	9	to	to	ADP
dpc-5845	76	10	the	the	DET
dpc-5845	76	11	std	std	NOUN
dpc-5845	76	12	,	,	PUNCT
dpc-5845	76	13	were	be	AUX
dpc-5845	76	14	observed	observe	VERB
dpc-5845	76	15	in	in	ADP
dpc-5845	76	16	24	24	NUM
dpc-5845	76	17	patients	patient	NOUN
dpc-5845	76	18	with	with	ADP
dpc-5845	76	19	il-17	il-17	NUM
dpc-5845	76	20	and	and	CCONJ
dpc-5845	76	21	15	15	NUM
dpc-5845	76	22	with	with	ADP
dpc-5845	76	23	il-23	il-23	NOUN
dpc-5845	76	24	.	.	PUNCT
dpc-5845	77	1	kaplan	kaplan	PROPN
dpc-5845	77	2	-	-	PROPN
dpc-5845	77	3	meier	meier	PROPN
dpc-5845	77	4	dr	dr	PROPN
dpc-5845	77	5	survival	survival	PROPN
dpc-5845	77	6	curves	curve	NOUN
dpc-5845	77	7	–	–	PUNCT
dpc-5845	77	8	overall	overall	ADJ
dpc-5845	77	9	and	and	CCONJ
dpc-5845	77	10	d	d	ADP
dpc-5845	77	11	ifferentiated	ifferentiate	VERB
dpc-5845	77	12	–	–	PUNCT
dpc-5845	77	13	are	be	AUX
dpc-5845	77	14	reported	report	VERB
dpc-5845	77	15	in	in	ADP
dpc-5845	77	16	figure	figure	NOUN
dpc-5845	77	17	1	1	NUM
dpc-5845	77	18	.	.	PUNCT
dpc-5845	78	1	overall	overall	ADJ
dpc-5845	78	2	dr	dr	PROPN
dpc-5845	78	3	survival	survival	NOUN
dpc-5845	78	4	at	at	ADP
dpc-5845	78	5	52	52	NUM
dpc-5845	78	6	weeks	week	NOUN
dpc-5845	78	7	was	be	AUX
dpc-5845	78	8	0.75	0.75	NUM
dpc-5845	78	9	(	(	PUNCT
dpc-5845	78	10	95	95	NUM
dpc-5845	78	11	%	%	NOUN
dpc-5845	78	12	ci	ci	NOUN
dpc-5845	78	13	:	:	PUNCT
dpc-5845	78	14	0.69–0.82	0.69–0.82	NUM
dpc-5845	78	15	)	)	PUNCT
dpc-5845	78	16	.	.	PUNCT
dpc-5845	79	1	moreover	moreover	ADV
dpc-5845	79	2	,	,	PUNCT
dpc-5845	79	3	enrolled	enrol	VERB
dpc-5845	79	4	in	in	ADP
dpc-5845	79	5	the	the	DET
dpc-5845	79	6	study	study	NOUN
dpc-5845	79	7	between	between	ADP
dpc-5845	79	8	march	march	PROPN
dpc-5845	79	9	2023	2023	NUM
dpc-5845	79	10	and	and	CCONJ
dpc-5845	79	11	january	january	PROPN
dpc-5845	79	12	2025	2025	NUM
dpc-5845	79	13	.	.	PUNCT
dpc-5845	80	1	in	in	ADP
dpc-5845	80	2	this	this	DET
dpc-5845	80	3	preliminary	preliminary	ADJ
dpc-5845	80	4	analysis	analysis	NOUN
dpc-5845	80	5	,	,	PUNCT
dpc-5845	80	6	only	only	ADV
dpc-5845	80	7	patients	patient	NOUN
dpc-5845	80	8	with	with	ADP
dpc-5845	80	9	at	at	ADV
dpc-5845	80	10	least	least	ADV
dpc-5845	80	11	52	52	NUM
dpc-5845	80	12	weeks	week	NOUN
dpc-5845	80	13	of	of	ADP
dpc-5845	80	14	follow	follow	VERB
dpc-5845	80	15	-	-	PUNCT
dpc-5845	80	16	up	up	NOUN
dpc-5845	80	17	or	or	CCONJ
dpc-5845	80	18	patients	patient	NOUN
dpc-5845	80	19	who	who	PRON
dpc-5845	80	20	exited	exit	VERB
dpc-5845	80	21	the	the	DET
dpc-5845	80	22	study	study	NOUN
dpc-5845	80	23	for	for	ADP
dpc-5845	80	24	dr	dr	PROPN
dpc-5845	80	25	failure	failure	NOUN
dpc-5845	80	26	were	be	AUX
dpc-5845	80	27	considered	consider	VERB
dpc-5845	80	28	.	.	PUNCT
dpc-5845	81	1	particularly	particularly	ADV
dpc-5845	81	2	,	,	PUNCT
dpc-5845	81	3	we	we	PRON
dpc-5845	81	4	excluded	exclude	VERB
dpc-5845	81	5	109	109	NUM
dpc-5845	81	6	patients	patient	NOUN
dpc-5845	81	7	with	with	ADP
dpc-5845	81	8	only	only	ADJ
dpc-5845	81	9	baseline	baseline	ADJ
dpc-5845	81	10	information	information	NOUN
dpc-5845	81	11	and	and	CCONJ
dpc-5845	81	12	96	96	NUM
dpc-5845	81	13	with	with	ADP
dpc-5845	81	14	26	26	NUM
dpc-5845	81	15	weeks	week	NOUN
dpc-5845	81	16	of	of	ADP
dpc-5845	81	17	follow	follow	NOUN
dpc-5845	81	18	-	-	PUNCT
dpc-5845	81	19	up	up	NOUN
dpc-5845	81	20	.	.	PUNCT
dpc-5845	82	1	among	among	ADP
dpc-5845	82	2	the	the	DET
dpc-5845	82	3	156	156	NUM
dpc-5845	82	4	patients	patient	NOUN
dpc-5845	82	5	included	include	VERB
dpc-5845	82	6	,	,	PUNCT
dpc-5845	82	7	70	70	NUM
dpc-5845	82	8	(	(	PUNCT
dpc-5845	82	9	44.87	44.87	NUM
dpc-5845	82	10	%	%	NOUN
dpc-5845	82	11	)	)	PUNCT
dpc-5845	82	12	received	receive	VERB
dpc-5845	82	13	il-17i	il-17i	PROPN
dpc-5845	82	14	and	and	CCONJ
dpc-5845	82	15	86	86	NUM
dpc-5845	82	16	(	(	PUNCT
dpc-5845	82	17	55.13	55.13	NUM
dpc-5845	82	18	%	%	NOUN
dpc-5845	82	19	)	)	PUNCT
dpc-5845	82	20	il-23i	il-23i	PROPN
dpc-5845	82	21	.	.	PUNCT
dpc-5845	83	1	regarding	regard	VERB
dpc-5845	83	2	treatment	treatment	NOUN
dpc-5845	83	3	distribution	distribution	NOUN
dpc-5845	83	4	,	,	PUNCT
dpc-5845	83	5	the	the	DET
dpc-5845	83	6	most	most	ADV
dpc-5845	83	7	prescribed	prescribed	ADJ
dpc-5845	83	8	dose	dose	NOUN
dpc-5845	83	9	spacing	space	VERB
dpc-5845	83	10	regimen	regiman	NOUN
dpc-5845	83	11	was	be	AUX
dpc-5845	83	12	secukinumab	secukinumab	NOUN
dpc-5845	83	13	(	(	PUNCT
dpc-5845	83	14	50	50	NUM
dpc-5845	83	15	,	,	PUNCT
dpc-5845	83	16	32.05	32.05	NUM
dpc-5845	83	17	%	%	NOUN
dpc-5845	83	18	)	)	PUNCT
dpc-5845	83	19	,	,	PUNCT
dpc-5845	83	20	followed	follow	VERB
dpc-5845	83	21	by	by	ADP
dpc-5845	83	22	guselkumab	guselkumab	NOUN
dpc-5845	83	23	(	(	PUNCT
dpc-5845	83	24	49	49	NUM
dpc-5845	83	25	,	,	PUNCT
dpc-5845	83	26	31.41	31.41	NUM
dpc-5845	83	27	%	%	NOUN
dpc-5845	83	28	)	)	PUNCT
dpc-5845	83	29	,	,	PUNCT
dpc-5845	83	30	risankizumab	risankizumab	NOUN
dpc-5845	83	31	(	(	PUNCT
dpc-5845	83	32	37	37	NUM
dpc-5845	83	33	,	,	PUNCT
dpc-5845	83	34	23.72	23.72	NUM
dpc-5845	83	35	%	%	NOUN
dpc-5845	83	36	)	)	PUNCT
dpc-5845	83	37	,	,	PUNCT
dpc-5845	83	38	and	and	CCONJ
dpc-5845	83	39	brodalumab	brodalumab	NOUN
dpc-5845	83	40	(	(	PUNCT
dpc-5845	83	41	20	20	NUM
dpc-5845	83	42	,	,	PUNCT
dpc-5845	83	43	12.82	12.82	NUM
dpc-5845	83	44	%	%	NOUN
dpc-5845	83	45	)	)	PUNCT
dpc-5845	83	46	.	.	PUNCT
dpc-5845	84	1	the	the	DET
dpc-5845	84	2	mean	mean	ADJ
dpc-5845	84	3	age	age	NOUN
dpc-5845	84	4	(	(	PUNCT
dpc-5845	84	5	sd	sd	NOUN
dpc-5845	84	6	)	)	PUNCT
dpc-5845	84	7	at	at	ADP
dpc-5845	84	8	diagnosis	diagnosis	NOUN
dpc-5845	84	9	was	be	AUX
dpc-5845	84	10	53.68	53.68	NUM
dpc-5845	84	11	(	(	PUNCT
dpc-5845	84	12	15.83	15.83	NUM
dpc-5845	84	13	)	)	PUNCT
dpc-5845	84	14	years	year	NOUN
dpc-5845	84	15	(	(	PUNCT
dpc-5845	84	16	range	range	NOUN
dpc-5845	84	17	:	:	PUNCT
dpc-5845	84	18	18–85	18–85	NUM
dpc-5845	84	19	)	)	PUNCT
dpc-5845	84	20	,	,	PUNCT
dpc-5845	84	21	with	with	ADP
dpc-5845	84	22	a	a	DET
dpc-5845	84	23	predominance	predominance	NOUN
dpc-5845	84	24	of	of	ADP
dpc-5845	84	25	males	male	NOUN
dpc-5845	84	26	(	(	PUNCT
dpc-5845	84	27	n=101	n=101	PROPN
dpc-5845	84	28	,	,	PUNCT
dpc-5845	84	29	68.24	68.24	NUM
dpc-5845	84	30	%	%	NOUN
dpc-5845	84	31	)	)	PUNCT
dpc-5845	84	32	.	.	PUNCT
dpc-5845	85	1	the	the	DET
dpc-5845	85	2	mean	mean	ADJ
dpc-5845	85	3	bmi	bmi	NOUN
dpc-5845	85	4	score	score	NOUN
dpc-5845	85	5	was	be	AUX
dpc-5845	85	6	25.92	25.92	NUM
dpc-5845	85	7	(	(	PUNCT
dpc-5845	85	8	sd	sd	ADP
dpc-5845	85	9	6.38	6.38	NUM
dpc-5845	85	10	)	)	PUNCT
dpc-5845	85	11	.	.	PUNCT
dpc-5845	86	1	patient	patient	ADJ
dpc-5845	86	2	and	and	CCONJ
dpc-5845	86	3	treatment	treatment	NOUN
dpc-5845	86	4	characteristics	characteristic	NOUN
dpc-5845	86	5	were	be	AUX
dpc-5845	86	6	summarized	summarize	VERB
dpc-5845	86	7	in	in	ADP
dpc-5845	86	8	table	table	NOUN
dpc-5845	86	9	2	2	NUM
dpc-5845	86	10	.	.	PUNCT
dpc-5845	86	11	baseline	baseline	PROPN
dpc-5845	86	12	characteristics	characteristic	NOUN
dpc-5845	86	13	and	and	CCONJ
dpc-5845	86	14	preliminary	preliminary	ADJ
dpc-5845	86	15	dose	dose	NOUN
dpc-5845	86	16	spacing	space	VERB
dpc-5845	86	17	results	result	NOUN
dpc-5845	86	18	,	,	PUNCT
dpc-5845	86	19	grouped	group	VERB
dpc-5845	86	20	and	and	CCONJ
dpc-5845	86	21	subcohort	subcohort	NOUN
dpc-5845	86	22	analysis	analysis	NOUN
dpc-5845	86	23	.	.	PUNCT
dpc-5845	87	1	patient	patient	NOUN
dpc-5845	87	2	’	'	PUNCT
dpc-5845	87	3	pasi	pasi	NOUN
dpc-5845	87	4	and	and	CCONJ
dpc-5845	87	5	dlqi	dlqi	ADJ
dpc-5845	87	6	records	record	NOUN
dpc-5845	87	7	were	be	AUX
dpc-5845	87	8	analyzed	analyze	VERB
dpc-5845	87	9	at	at	ADP
dpc-5845	87	10	baseline	baseline	NOUN
dpc-5845	87	11	,	,	PUNCT
dpc-5845	87	12	considered	consider	VERB
dpc-5845	87	13	as	as	ADP
dpc-5845	87	14	start	start	NOUN
dpc-5845	87	15	of	of	ADP
dpc-5845	87	16	treatment	treatment	NOUN
dpc-5845	87	17	,	,	PUNCT
dpc-5845	87	18	at	at	ADP
dpc-5845	87	19	the	the	DET
dpc-5845	87	20	initiation	initiation	NOUN
dpc-5845	87	21	of	of	ADP
dpc-5845	87	22	dr	dr	PROPN
dpc-5845	87	23	,	,	PUNCT
dpc-5845	87	24	and	and	CCONJ
dpc-5845	87	25	during	during	ADP
dpc-5845	87	26	the	the	DET
dpc-5845	87	27	follow	follow	NOUN
dpc-5845	87	28	-	-	PUNCT
dpc-5845	87	29	up	up	NOUN
dpc-5845	87	30	visits	visit	NOUN
dpc-5845	87	31	at	at	ADP
dpc-5845	87	32	26	26	NUM
dpc-5845	87	33	±	±	NUM
dpc-5845	87	34	2	2	NUM
dpc-5845	87	35	weeks	week	NOUN
dpc-5845	87	36	and	and	CCONJ
dpc-5845	87	37	52	52	NUM
dpc-5845	87	38	±	±	NUM
dpc-5845	87	39	2	2	NUM
dpc-5845	87	40	weeks	week	NOUN
dpc-5845	87	41	.	.	PUNCT
dpc-5845	88	1	table	table	NOUN
dpc-5845	88	2	2	2	NUM
dpc-5845	88	3	.	.	PUNCT
dpc-5845	88	4	patient	patient	ADJ
dpc-5845	88	5	and	and	CCONJ
dpc-5845	88	6	treatment	treatment	NOUN
dpc-5845	88	7	characteristics	characteristic	NOUN
dpc-5845	88	8	,	,	PUNCT
dpc-5845	88	9	overall	overall	ADJ
dpc-5845	88	10	and	and	CCONJ
dpc-5845	88	11	by	by	ADP
dpc-5845	88	12	treatment	treatment	NOUN
dpc-5845	88	13	drug	drug	NOUN
dpc-5845	88	14	.	.	PUNCT
dpc-5845	89	1	absolute	absolute	ADJ
dpc-5845	89	2	and	and	CCONJ
dpc-5845	89	3	relative	relative	ADJ
dpc-5845	89	4	frequencies	frequency	NOUN
dpc-5845	89	5	are	be	AUX
dpc-5845	89	6	reported	report	VERB
dpc-5845	89	7	for	for	ADP
dpc-5845	89	8	categorical	categorical	ADJ
dpc-5845	89	9	variables	variable	NOUN
dpc-5845	89	10	and	and	CCONJ
dpc-5845	89	11	means	mean	VERB
dpc-5845	89	12	(	(	PUNCT
dpc-5845	89	13	standard	standard	ADJ
dpc-5845	89	14	deviation	deviation	NOUN
dpc-5845	89	15	)	)	PUNCT
dpc-5845	89	16	or	or	CCONJ
dpc-5845	89	17	median	median	NOUN
dpc-5845	89	18	[	[	X
dpc-5845	89	19	q1	q1	PROPN
dpc-5845	89	20	;	;	PUNCT
dpc-5845	89	21	q3	q3	PROPN
dpc-5845	89	22	]	]	PUNCT
dpc-5845	89	23	for	for	ADP
dpc-5845	89	24	numerical	numerical	ADJ
dpc-5845	89	25	ones	one	NOUN
dpc-5845	89	26	.	.	PUNCT
dpc-5845	90	1	p	p	X
dpc-5845	90	2	-	-	PUNCT
dpc-5845	90	3	values	value	NOUN
dpc-5845	90	4	are	be	AUX
dpc-5845	90	5	also	also	ADV
dpc-5845	90	6	reported	report	VERB
dpc-5845	90	7	.	.	PUNCT
dpc-5845	91	1	patients	patient	NOUN
dpc-5845	91	2	(	(	PUNCT
dpc-5845	91	3	overall	overall	ADV
dpc-5845	91	4	)	)	PUNCT
dpc-5845	91	5	all	all	PRON
dpc-5845	91	6	(	(	PUNCT
dpc-5845	91	7	n=156	n=156	PROPN
dpc-5845	91	8	)	)	PUNCT
dpc-5845	91	9	il-17	il-17	ADV
dpc-5845	91	10	(	(	PUNCT
dpc-5845	91	11	n=70	n=70	ADJ
dpc-5845	91	12	)	)	PUNCT
dpc-5845	91	13	il-23	il-23	NOUN
dpc-5845	91	14	(	(	PUNCT
dpc-5845	91	15	n=86	n=86	PROPN
dpc-5845	91	16	)	)	PUNCT
dpc-5845	91	17	p	p	ADJ
dpc-5845	91	18	-	-	PUNCT
dpc-5845	91	19	value	value	NOUN
dpc-5845	91	20	age	age	NOUN
dpc-5845	91	21	,	,	PUNCT
dpc-5845	91	22	years	year	NOUN
dpc-5845	91	23	mean	mean	VERB
dpc-5845	91	24	(	(	PUNCT
dpc-5845	91	25	sd	sd	NOUN
dpc-5845	91	26	)	)	PUNCT
dpc-5845	91	27	53.68	53.68	NUM
dpc-5845	91	28	(	(	PUNCT
dpc-5845	91	29	15.83	15.83	NUM
dpc-5845	91	30	)	)	PUNCT
dpc-5845	91	31	55.67	55.67	NUM
dpc-5845	91	32	(	(	PUNCT
dpc-5845	91	33	14.41	14.41	NUM
dpc-5845	91	34	)	)	PUNCT
dpc-5845	91	35	52.13	52.13	NUM
dpc-5845	91	36	(	(	PUNCT
dpc-5845	91	37	16.77	16.77	NUM
dpc-5845	91	38	)	)	PUNCT
dpc-5845	91	39	0.1702	0.1702	NUM
dpc-5845	91	40	sex	sex	NOUN
dpc-5845	91	41	male	male	NOUN
dpc-5845	91	42	101	101	NUM
dpc-5845	91	43	(	(	PUNCT
dpc-5845	91	44	68.24	68.24	NUM
dpc-5845	91	45	%	%	NOUN
dpc-5845	91	46	)	)	PUNCT
dpc-5845	91	47	49	49	NUM
dpc-5845	91	48	(	(	PUNCT
dpc-5845	91	49	74.24	74.24	NUM
dpc-5845	91	50	)	)	PUNCT
dpc-5845	91	51	52	52	NUM
dpc-5845	91	52	(	(	PUNCT
dpc-5845	91	53	63.41	63.41	NUM
dpc-5845	91	54	)	)	PUNCT
dpc-5845	91	55	0.1596	0.1596	NUM
dpc-5845	91	56	physical	physical	ADJ
dpc-5845	91	57	characteristics	characteristic	NOUN
dpc-5845	91	58	height	height	NOUN
dpc-5845	91	59	,	,	PUNCT
dpc-5845	91	60	m	m	VERB
dpc-5845	91	61	mean	mean	VERB
dpc-5845	91	62	(	(	PUNCT
dpc-5845	91	63	sd	sd	NOUN
dpc-5845	91	64	)	)	PUNCT
dpc-5845	91	65	weight	weight	NOUN
dpc-5845	91	66	,	,	PUNCT
dpc-5845	91	67	kg	kg	PRON
dpc-5845	91	68	mean	mean	VERB
dpc-5845	91	69	(	(	PUNCT
dpc-5845	91	70	sd	sd	NOUN
dpc-5845	91	71	)	)	PUNCT
dpc-5845	91	72	bmi	bmi	NOUN
dpc-5845	91	73	,	,	PUNCT
dpc-5845	91	74	kg	kg	PROPN
dpc-5845	91	75	/	/	SYM
dpc-5845	91	76	m2	m2	PROPN
dpc-5845	91	77	mean	mean	NOUN
dpc-5845	91	78	(	(	PUNCT
dpc-5845	91	79	sd	sd	NOUN
dpc-5845	91	80	)	)	PUNCT
dpc-5845	91	81	1.71	1.71	NUM
dpc-5845	91	82	(	(	PUNCT
dpc-5845	91	83	0.09	0.09	NUM
dpc-5845	91	84	)	)	PUNCT
dpc-5845	91	85	76.48	76.48	NUM
dpc-5845	91	86	(	(	PUNCT
dpc-5845	91	87	16.86	16.86	NUM
dpc-5845	91	88	)	)	PUNCT
dpc-5845	91	89	25.92	25.92	NUM
dpc-5845	91	90	(	(	PUNCT
dpc-5845	91	91	6.38	6.38	NUM
dpc-5845	91	92	)	)	PUNCT
dpc-5845	91	93	1.71	1.71	NUM
dpc-5845	91	94	(	(	PUNCT
dpc-5845	91	95	0.09	0.09	NUM
dpc-5845	91	96	)	)	PUNCT
dpc-5845	91	97	74.90	74.90	NUM
dpc-5845	91	98	(	(	PUNCT
dpc-5845	91	99	13.53	13.53	NUM
dpc-5845	91	100	)	)	PUNCT
dpc-5845	91	101	25.02	25.02	NUM
dpc-5845	91	102	(	(	PUNCT
dpc-5845	91	103	4.76	4.76	NUM
dpc-5845	91	104	)	)	PUNCT
dpc-5845	91	105	1.71	1.71	NUM
dpc-5845	91	106	(	(	PUNCT
dpc-5845	91	107	0.09	0.09	NUM
dpc-5845	91	108	)	)	PUNCT
dpc-5845	91	109	77.76	77.76	NUM
dpc-5845	91	110	(	(	PUNCT
dpc-5845	91	111	19.14	19.14	NUM
dpc-5845	91	112	)	)	PUNCT
dpc-5845	91	113	26.66	26.66	NUM
dpc-5845	91	114	(	(	PUNCT
dpc-5845	91	115	7.39	7.39	NUM
dpc-5845	91	116	)	)	PUNCT
dpc-5845	91	117	0.8385	0.8385	PROPN
dpc-5845	91	118	0.3069	0.3069	NUM
dpc-5845	91	119	0.1195	0.1195	NUM
dpc-5845	91	120	smoking	smoking	NOUN
dpc-5845	91	121	history	history	NOUN
dpc-5845	91	122	never	never	ADV
dpc-5845	91	123	ex	ex	ADJ
dpc-5845	91	124	(	(	PUNCT
dpc-5845	91	125	>	>	SYM
dpc-5845	91	126	1	1	NUM
dpc-5845	91	127	year	year	NOUN
dpc-5845	91	128	)	)	PUNCT
dpc-5845	91	129	current	current	ADJ
dpc-5845	91	130	62	62	NUM
dpc-5845	91	131	(	(	PUNCT
dpc-5845	91	132	44.29	44.29	NUM
dpc-5845	91	133	)	)	PUNCT
dpc-5845	91	134	39	39	NUM
dpc-5845	91	135	(	(	PUNCT
dpc-5845	91	136	27.86	27.86	NUM
dpc-5845	91	137	)	)	PUNCT
dpc-5845	91	138	39	39	NUM
dpc-5845	91	139	(	(	PUNCT
dpc-5845	91	140	27.86	27.86	NUM
dpc-5845	91	141	)	)	PUNCT
dpc-5845	91	142	23	23	NUM
dpc-5845	91	143	(	(	PUNCT
dpc-5845	91	144	37.70	37.70	NUM
dpc-5845	91	145	)	)	PUNCT
dpc-5845	91	146	14	14	NUM
dpc-5845	91	147	(	(	PUNCT
dpc-5845	91	148	22.95	22.95	NUM
dpc-5845	91	149	)	)	PUNCT
dpc-5845	91	150	24	24	NUM
dpc-5845	91	151	(	(	PUNCT
dpc-5845	91	152	39.34	39.34	NUM
dpc-5845	91	153	)	)	PUNCT
dpc-5845	91	154	39	39	NUM
dpc-5845	91	155	(	(	PUNCT
dpc-5845	91	156	49.37	49.37	NUM
dpc-5845	91	157	)	)	PUNCT
dpc-5845	91	158	25	25	NUM
dpc-5845	91	159	(	(	PUNCT
dpc-5845	91	160	31.65	31.65	NUM
dpc-5845	91	161	)	)	PUNCT
dpc-5845	91	162	15	15	NUM
dpc-5845	91	163	(	(	PUNCT
dpc-5845	91	164	18.99	18.99	NUM
dpc-5845	91	165	)	)	PUNCT
dpc-5845	91	166	0.0286	0.0286	NUM
dpc-5845	91	167	level	level	NOUN
dpc-5845	91	168	of	of	ADP
dpc-5845	91	169	education	education	NOUN
dpc-5845	91	170	*	*	PUNCT
dpc-5845	91	171	low	low	ADJ
dpc-5845	91	172	medium	medium	ADJ
dpc-5845	91	173	high	high	ADJ
dpc-5845	91	174	68	68	NUM
dpc-5845	91	175	(	(	PUNCT
dpc-5845	91	176	48.92	48.92	NUM
dpc-5845	91	177	)	)	PUNCT
dpc-5845	91	178	60	60	NUM
dpc-5845	91	179	(	(	PUNCT
dpc-5845	91	180	43.17	43.17	NUM
dpc-5845	91	181	)	)	PUNCT
dpc-5845	91	182	11	11	NUM
dpc-5845	91	183	(	(	PUNCT
dpc-5845	91	184	7.91	7.91	NUM
dpc-5845	91	185	)	)	PUNCT
dpc-5845	91	186	34	34	NUM
dpc-5845	91	187	(	(	PUNCT
dpc-5845	91	188	54.84	54.84	NUM
dpc-5845	91	189	)	)	PUNCT
dpc-5845	91	190	25	25	NUM
dpc-5845	91	191	(	(	PUNCT
dpc-5845	91	192	40.32	40.32	NUM
dpc-5845	91	193	)	)	PUNCT
dpc-5845	91	194	3	3	NUM
dpc-5845	91	195	(	(	PUNCT
dpc-5845	91	196	4.84	4.84	NUM
dpc-5845	91	197	)	)	PUNCT
dpc-5845	91	198	34	34	NUM
dpc-5845	91	199	(	(	PUNCT
dpc-5845	91	200	44.16	44.16	NUM
dpc-5845	91	201	)	)	PUNCT
dpc-5845	91	202	35	35	NUM
dpc-5845	91	203	(	(	PUNCT
dpc-5845	91	204	45.45	45.45	NUM
dpc-5845	91	205	)	)	PUNCT
dpc-5845	91	206	8	8	NUM
dpc-5845	91	207	(	(	PUNCT
dpc-5845	91	208	10.39	10.39	NUM
dpc-5845	91	209	)	)	PUNCT
dpc-5845	91	210	0.3091	0.3091	NUM
dpc-5845	91	211	psoriasis	psoriasis	NOUN
dpc-5845	91	212	type	type	NOUN
dpc-5845	91	213	vulgaris	vulgaris	NOUN
dpc-5845	91	214	139	139	NUM
dpc-5845	91	215	(	(	PUNCT
dpc-5845	91	216	91.45	91.45	NUM
dpc-5845	91	217	)	)	PUNCT
dpc-5845	91	218	62	62	NUM
dpc-5845	91	219	(	(	PUNCT
dpc-5845	91	220	89.86	89.86	NUM
dpc-5845	91	221	)	)	PUNCT
dpc-5845	91	222	77	77	NUM
dpc-5845	91	223	(	(	PUNCT
dpc-5845	91	224	92.77	92.77	NUM
dpc-5845	91	225	)	)	PUNCT
dpc-5845	91	226	0.5222	0.5222	NUM
dpc-5845	91	227	arthropathy	arthropathy	ADJ
dpc-5845	91	228	yes	yes	INTJ
dpc-5845	91	229	20	20	NUM
dpc-5845	91	230	(	(	PUNCT
dpc-5845	91	231	14.08	14.08	NUM
dpc-5845	91	232	)	)	PUNCT
dpc-5845	91	233	15	15	NUM
dpc-5845	91	234	(	(	PUNCT
dpc-5845	91	235	22.73	22.73	NUM
dpc-5845	91	236	)	)	PUNCT
dpc-5845	91	237	5	5	NUM
dpc-5845	91	238	(	(	PUNCT
dpc-5845	91	239	6.58	6.58	NUM
dpc-5845	91	240	)	)	PUNCT
dpc-5845	91	241	0.0058	0.0058	NUM
dpc-5845	91	242	comorbidity	comorbidity	NOUN
dpc-5845	91	243	yes	yes	INTJ
dpc-5845	91	244	63	63	NUM
dpc-5845	91	245	(	(	PUNCT
dpc-5845	91	246	40.38	40.38	NUM
dpc-5845	91	247	)	)	PUNCT
dpc-5845	91	248	29	29	NUM
dpc-5845	91	249	(	(	PUNCT
dpc-5845	91	250	41.43	41.43	NUM
dpc-5845	91	251	)	)	PUNCT
dpc-5845	91	252	34	34	NUM
dpc-5845	91	253	(	(	PUNCT
dpc-5845	91	254	39.53	39.53	NUM
dpc-5845	91	255	)	)	PUNCT
dpc-5845	91	256	0.8105	0.8105	NUM
dpc-5845	91	257	previous	previous	ADJ
dpc-5845	91	258	biological	biological	ADJ
dpc-5845	91	259	treatment	treatment	NOUN
dpc-5845	91	260	yes	yes	INTJ
dpc-5845	91	261	27	27	NUM
dpc-5845	91	262	(	(	PUNCT
dpc-5845	91	263	18.12	18.12	NUM
dpc-5845	91	264	)	)	PUNCT
dpc-5845	91	265	13	13	NUM
dpc-5845	91	266	(	(	PUNCT
dpc-5845	91	267	19.40	19.40	NUM
dpc-5845	91	268	)	)	PUNCT
dpc-5845	91	269	14	14	NUM
dpc-5845	91	270	(	(	PUNCT
dpc-5845	91	271	17.07	17.07	NUM
dpc-5845	91	272	)	)	PUNCT
dpc-5845	91	273	0.7134	0.7134	NUM
dpc-5845	91	274	therapy	therapy	NOUN
dpc-5845	91	275	time	time	NOUN
dpc-5845	91	276	before	before	ADP
dpc-5845	91	277	dr	dr	PROPN
dpc-5845	91	278	median	median	PROPN
dpc-5845	91	279	[	[	X
dpc-5845	91	280	q1	q1	PROPN
dpc-5845	91	281	;	;	PUNCT
dpc-5845	91	282	q3	q3	PROPN
dpc-5845	91	283	]	]	X
dpc-5845	91	284	2.80	2.80	NUM
dpc-5845	92	1	[	[	X
dpc-5845	92	2	1.60	1.60	NUM
dpc-5845	92	3	;	;	PUNCT
dpc-5845	92	4	4.20	4.20	NUM
dpc-5845	92	5	]	]	PUNCT
dpc-5845	92	6	4.10	4.10	NUM
dpc-5845	92	7	[	[	X
dpc-5845	92	8	3.00	3.00	NUM
dpc-5845	92	9	;	;	PUNCT
dpc-5845	92	10	5.30	5.30	NUM
dpc-5845	92	11	]	]	PUNCT
dpc-5845	92	12	1.80	1.80	NUM
dpc-5845	93	1	[	[	X
dpc-5845	93	2	1.00	1.00	NUM
dpc-5845	93	3	;	;	PUNCT
dpc-5845	93	4	3.00	3.00	NUM
dpc-5845	93	5	]	]	PUNCT
dpc-5845	93	6	<	<	X
dpc-5845	93	7	.0001	.0001	X
dpc-5845	93	8	*	*	PUNCT
dpc-5845	93	9	low	low	ADJ
dpc-5845	93	10	=	=	ADJ
dpc-5845	93	11	middle	middle	ADJ
dpc-5845	93	12	school	school	NOUN
dpc-5845	93	13	or	or	CCONJ
dpc-5845	93	14	less	less	ADJ
dpc-5845	93	15	,	,	PUNCT
dpc-5845	93	16	medium	medium	ADJ
dpc-5845	93	17	=	=	ADJ
dpc-5845	93	18	high	high	ADJ
dpc-5845	93	19	school	school	NOUN
dpc-5845	93	20	,	,	PUNCT
dpc-5845	93	21	high=	high=	NUM
dpc-5845	93	22	college	college	NOUN
dpc-5845	93	23	degree	degree	NOUN
dpc-5845	93	24	or	or	CCONJ
dpc-5845	93	25	more	more	ADJ
dpc-5845	93	26	.	.	PUNCT
dpc-5845	94	1	original	original	ADJ
dpc-5845	94	2	article	article	NOUN
dpc-5845	94	3	|	|	ADV
dpc-5845	94	4	dermatol	dermatol	ADJ
dpc-5845	94	5	pract	pract	NOUN
dpc-5845	94	6	concept	concept	NOUN
dpc-5845	94	7	.	.	PUNCT
dpc-5845	95	1	2025;15(3):5845	2025;15(3):5845	NUM
dpc-5845	95	2	5	5	NUM
dpc-5845	95	3	survival	survival	NOUN
dpc-5845	95	4	observed	observe	VERB
dpc-5845	95	5	for	for	ADP
dpc-5845	95	6	il-17i	il-17i	PROPN
dpc-5845	95	7	was	be	AUX
dpc-5845	95	8	0.68	0.68	NUM
dpc-5845	95	9	(	(	PUNCT
dpc-5845	95	10	95	95	NUM
dpc-5845	95	11	%	%	NOUN
dpc-5845	95	12	ci	ci	NOUN
dpc-5845	95	13	:	:	PUNCT
dpc-5845	95	14	0.56–0.82	0.56–0.82	NUM
dpc-5845	95	15	]	]	PUNCT
dpc-5845	95	16	for	for	ADP
dpc-5845	95	17	secukinumab	secukinumab	NOUN
dpc-5845	95	18	and	and	CCONJ
dpc-5845	95	19	0.60	0.60	NUM
dpc-5845	95	20	(	(	PUNCT
dpc-5845	95	21	95	95	NUM
dpc-5845	95	22	%	%	NOUN
dpc-5845	95	23	ci	ci	NOUN
dpc-5845	95	24	:	:	PUNCT
dpc-5845	95	25	0.42–0.86	0.42–0.86	NUM
dpc-5845	95	26	]	]	PUNCT
dpc-5845	95	27	for	for	ADP
dpc-5845	95	28	brodalumab	brodalumab	NOUN
dpc-5845	95	29	.	.	PUNCT
dpc-5845	96	1	no	no	DET
dpc-5845	96	2	statistically	statistically	ADV
dpc-5845	96	3	significant	significant	ADJ
dpc-5845	96	4	difference	difference	NOUN
dpc-5845	96	5	between	between	ADP
dpc-5845	96	6	different	different	ADJ
dpc-5845	96	7	treatments	treatment	NOUN
dpc-5845	96	8	was	be	AUX
dpc-5845	96	9	observed	observe	VERB
dpc-5845	96	10	(	(	PUNCT
dpc-5845	96	11	p=0.0849	p=0.0849	NOUN
dpc-5845	96	12	)	)	PUNCT
dpc-5845	96	13	.	.	PUNCT
dpc-5845	97	1	among	among	ADP
dpc-5845	97	2	the	the	DET
dpc-5845	97	3	39	39	NUM
dpc-5845	97	4	patients	patient	NOUN
dpc-5845	97	5	who	who	PRON
dpc-5845	97	6	experienced	experience	VERB
dpc-5845	97	7	a	a	DET
dpc-5845	97	8	disease	disease	NOUN
dpc-5845	97	9	flare	flare	NOUN
dpc-5845	97	10	-	-	PUNCT
dpc-5845	97	11	up	up	NOUN
dpc-5845	97	12	and	and	CCONJ
dpc-5845	97	13	reverted	revert	VERB
dpc-5845	97	14	to	to	ADP
dpc-5845	97	15	the	the	DET
dpc-5845	97	16	std	std	NOUN
dpc-5845	97	17	;	;	PUNCT
dpc-5845	97	18	97.44	97.44	NUM
dpc-5845	97	19	%	%	NOUN
dpc-5845	97	20	of	of	ADP
dpc-5845	97	21	patients	patient	NOUN
dpc-5845	97	22	(	(	PUNCT
dpc-5845	97	23	n=38/39	n=38/39	PROPN
dpc-5845	97	24	)	)	PUNCT
dpc-5845	97	25	achieved	achieve	VERB
dpc-5845	97	26	an	an	DET
dpc-5845	97	27	adequate	adequate	ADJ
dpc-5845	97	28	disease	disease	NOUN
dpc-5845	97	29	response	response	NOUN
dpc-5845	97	30	resuming	resume	VERB
dpc-5845	97	31	the	the	DET
dpc-5845	97	32	std	std	NOUN
dpc-5845	97	33	;	;	PUNCT
dpc-5845	97	34	only	only	ADV
dpc-5845	97	35	one	one	NUM
dpc-5845	97	36	patient	patient	NOUN
dpc-5845	97	37	(	(	PUNCT
dpc-5845	97	38	2.56	2.56	NUM
dpc-5845	97	39	%	%	NOUN
dpc-5845	97	40	)	)	PUNCT
dpc-5845	97	41	required	require	VERB
dpc-5845	97	42	a	a	DET
dpc-5845	97	43	therapy	therapy	NOUN
dpc-5845	97	44	change	change	NOUN
dpc-5845	97	45	(	(	PUNCT
dpc-5845	97	46	secukinumab	secukinumab	NOUN
dpc-5845	97	47	switching	switch	VERB
dpc-5845	97	48	to	to	PART
dpc-5845	97	49	risankizumab	risankizumab	VERB
dpc-5845	97	50	)	)	PUNCT
dpc-5845	97	51	in	in	ADP
dpc-5845	97	52	order	order	NOUN
dpc-5845	97	53	to	to	PART
dpc-5845	97	54	regain	regain	VERB
dpc-5845	97	55	good	good	ADJ
dpc-5845	97	56	control	control	NOUN
dpc-5845	97	57	of	of	ADP
dpc-5845	97	58	the	the	DET
dpc-5845	97	59	disease	disease	NOUN
dpc-5845	97	60	.	.	PUNCT
dpc-5845	98	1	adverse	adverse	ADJ
dpc-5845	98	2	events	event	NOUN
dpc-5845	98	3	(	(	PUNCT
dpc-5845	98	4	aes	aes	NOUN
dpc-5845	98	5	)	)	PUNCT
dpc-5845	98	6	were	be	AUX
dpc-5845	98	7	experienced	experience	VERB
dpc-5845	98	8	by	by	ADP
dpc-5845	98	9	five	five	NUM
dpc-5845	98	10	(	(	PUNCT
dpc-5845	98	11	3.21	3.21	NUM
dpc-5845	98	12	%	%	NOUN
dpc-5845	98	13	)	)	PUNCT
dpc-5845	98	14	patients	patient	NOUN
dpc-5845	98	15	:	:	PUNCT
dpc-5845	98	16	4/70	4/70	NUM
dpc-5845	98	17	(	(	PUNCT
dpc-5845	98	18	5.71	5.71	NUM
dpc-5845	98	19	%	%	NOUN
dpc-5845	98	20	)	)	PUNCT
dpc-5845	98	21	in	in	ADP
dpc-5845	98	22	il-17i	il-17i	PROPN
dpc-5845	98	23	group	group	NOUN
dpc-5845	98	24	and	and	CCONJ
dpc-5845	98	25	1/86	1/86	NUM
dpc-5845	98	26	(	(	PUNCT
dpc-5845	98	27	1.16	1.16	NUM
dpc-5845	98	28	%	%	NOUN
dpc-5845	98	29	)	)	PUNCT
dpc-5845	98	30	in	in	ADP
dpc-5845	98	31	il-23i	il-23i	PROPN
dpc-5845	98	32	group	group	NOUN
dpc-5845	98	33	.	.	PUNCT
dpc-5845	99	1	the	the	DET
dpc-5845	99	2	adverse	adverse	ADJ
dpc-5845	99	3	events	event	NOUN
dpc-5845	99	4	,	,	PUNCT
dpc-5845	99	5	apart	apart	ADV
dpc-5845	99	6	from	from	ADP
dpc-5845	99	7	disease	disease	NOUN
dpc-5845	99	8	flare	flare	NOUN
dpc-5845	99	9	-	-	PUNCT
dpc-5845	99	10	up	up	NOUN
dpc-5845	99	11	,	,	PUNCT
dpc-5845	99	12	included	include	VERB
dpc-5845	99	13	sacroiliitis	sacroiliitis	ADJ
dpc-5845	99	14	,	,	PUNCT
dpc-5845	99	15	arthralgia	arthralgia	NOUN
dpc-5845	99	16	,	,	PUNCT
dpc-5845	99	17	enthesitis	enthesitis	NOUN
dpc-5845	99	18	,	,	PUNCT
dpc-5845	99	19	and	and	CCONJ
dpc-5845	99	20	pruritus	pruritus	PROPN
dpc-5845	99	21	;	;	PUNCT
dpc-5845	100	1	all	all	DET
dpc-5845	100	2	adverse	adverse	ADJ
dpc-5845	100	3	events	event	NOUN
dpc-5845	100	4	resolved	resolve	VERB
dpc-5845	100	5	after	after	SCONJ
dpc-5845	100	6	il-23i	il-23i	PRON
dpc-5845	100	7	had	have	VERB
dpc-5845	100	8	higher	high	ADJ
dpc-5845	100	9	dose	dose	NOUN
dpc-5845	100	10	-	-	PUNCT
dpc-5845	100	11	reduction	reduction	NOUN
dpc-5845	100	12	survival	survival	NOUN
dpc-5845	100	13	at	at	ADP
dpc-5845	100	14	52	52	NUM
dpc-5845	100	15	weeks	week	NOUN
dpc-5845	100	16	than	than	SCONJ
dpc-5845	100	17	did	do	VERB
dpc-5845	100	18	il-17i	il-17i	X
dpc-5845	100	19	:	:	PUNCT
dpc-5845	100	20	0.83	0.83	NUM
dpc-5845	100	21	(	(	PUNCT
dpc-5845	100	22	95	95	NUM
dpc-5845	100	23	%	%	NOUN
dpc-5845	100	24	ci	ci	NOUN
dpc-5845	100	25	:	:	PUNCT
dpc-5845	100	26	0.75–0.91	0.75–0.91	NUM
dpc-5845	100	27	)	)	PUNCT
dpc-5845	100	28	and	and	CCONJ
dpc-5845	100	29	0.66	0.66	NUM
dpc-5845	100	30	(	(	PUNCT
dpc-5845	100	31	95	95	NUM
dpc-5845	100	32	%	%	NOUN
dpc-5845	100	33	ci	ci	NOUN
dpc-5845	100	34	:	:	PUNCT
dpc-5845	100	35	0.55–0.78	0.55–0.78	NUM
dpc-5845	100	36	]	]	X
dpc-5845	100	37	,	,	PUNCT
dpc-5845	100	38	respectively	respectively	ADV
dpc-5845	100	39	.	.	PUNCT
dpc-5845	101	1	this	this	DET
dpc-5845	101	2	difference	difference	NOUN
dpc-5845	101	3	was	be	AUX
dpc-5845	101	4	statistically	statistically	ADV
dpc-5845	101	5	significant	significant	ADJ
dpc-5845	101	6	(	(	PUNCT
dpc-5845	101	7	p=0.0181	p=0.0181	PROPN
dpc-5845	101	8	)	)	PUNCT
dpc-5845	101	9	based	base	VERB
dpc-5845	101	10	on	on	ADP
dpc-5845	101	11	log	log	NOUN
dpc-5845	101	12	-	-	PUNCT
dpc-5845	101	13	rank	rank	NOUN
dpc-5845	101	14	test	test	NOUN
dpc-5845	101	15	.	.	PUNCT
dpc-5845	102	1	moreover	moreover	ADV
dpc-5845	102	2	,	,	PUNCT
dpc-5845	102	3	unadjusted	unadjusted	ADJ
dpc-5845	102	4	and	and	CCONJ
dpc-5845	102	5	adjusted	adjusted	ADJ
dpc-5845	102	6	estimates	estimate	NOUN
dpc-5845	102	7	of	of	ADP
dpc-5845	102	8	cox	cox	PROPN
dpc-5845	102	9	models	model	NOUN
dpc-5845	102	10	indicate	indicate	VERB
dpc-5845	102	11	that	that	SCONJ
dpc-5845	102	12	patients	patient	NOUN
dpc-5845	102	13	treated	treat	VERB
dpc-5845	102	14	with	with	ADP
dpc-5845	102	15	il-23i	il-23i	PRON
dpc-5845	102	16	had	have	VERB
dpc-5845	102	17	a	a	DET
dpc-5845	102	18	significant	significant	ADJ
dpc-5845	102	19	(	(	PUNCT
dpc-5845	102	20	p=0.0309	p=0.0309	NOUN
dpc-5845	102	21	,	,	PUNCT
dpc-5845	102	22	p=0.0244	p=0.0244	NOUN
dpc-5845	102	23	,	,	PUNCT
dpc-5845	102	24	respectively	respectively	ADV
dpc-5845	102	25	)	)	PUNCT
dpc-5845	102	26	lower	low	ADJ
dpc-5845	102	27	risk	risk	NOUN
dpc-5845	102	28	of	of	ADP
dpc-5845	102	29	dr	dr	PROPN
dpc-5845	102	30	discontinuation	discontinuation	NOUN
dpc-5845	102	31	compared	compare	VERB
dpc-5845	102	32	with	with	ADP
dpc-5845	102	33	il-17i	il-17i	PROPN
dpc-5845	102	34	,	,	PUNCT
dpc-5845	102	35	with	with	ADP
dpc-5845	102	36	a	a	DET
dpc-5845	102	37	hazard	hazard	NOUN
dpc-5845	102	38	ratio	ratio	NOUN
dpc-5845	102	39	of	of	ADP
dpc-5845	102	40	0.49	0.49	NUM
dpc-5845	102	41	(	(	PUNCT
dpc-5845	102	42	95	95	NUM
dpc-5845	102	43	%	%	NOUN
dpc-5845	102	44	ci	ci	NOUN
dpc-5845	102	45	:	:	PUNCT
dpc-5845	102	46	0.26–0.94	0.26–0.94	NUM
dpc-5845	102	47	]	]	X
dpc-5845	102	48	and	and	CCONJ
dpc-5845	102	49	0.48	0.48	NUM
dpc-5845	102	50	(	(	PUNCT
dpc-5845	102	51	95	95	NUM
dpc-5845	102	52	%	%	NOUN
dpc-5845	102	53	ci	ci	NOUN
dpc-5845	102	54	:	:	PUNCT
dpc-5845	102	55	0.25–0.91	0.25–0.91	NOUN
dpc-5845	102	56	)	)	PUNCT
dpc-5845	102	57	,	,	PUNCT
dpc-5845	102	58	respectively	respectively	ADV
dpc-5845	102	59	.	.	PUNCT
dpc-5845	103	1	kaplan	kaplan	PROPN
dpc-5845	103	2	-	-	PUNCT
dpc-5845	103	3	meier	meier	PROPN
dpc-5845	103	4	curves	curve	NOUN
dpc-5845	103	5	are	be	AUX
dpc-5845	103	6	also	also	ADV
dpc-5845	103	7	reported	report	VERB
dpc-5845	103	8	for	for	ADP
dpc-5845	103	9	different	different	ADJ
dpc-5845	103	10	treatments	treatment	NOUN
dpc-5845	103	11	(	(	PUNCT
dpc-5845	103	12	figure	figure	NOUN
dpc-5845	103	13	2	2	NUM
dpc-5845	103	14	)	)	PUNCT
dpc-5845	103	15	.	.	PUNCT
dpc-5845	104	1	il-23i	il-23i	PROPN
dpc-5845	104	2	had	have	VERB
dpc-5845	104	3	the	the	DET
dpc-5845	104	4	highest	high	ADJ
dpc-5845	104	5	dose	dose	NOUN
dpc-5845	104	6	-	-	PUNCT
dpc-5845	104	7	reduction	reduction	NOUN
dpc-5845	104	8	survival	survival	NOUN
dpc-5845	104	9	rate	rate	NOUN
dpc-5845	104	10	;	;	PUNCT
dpc-5845	104	11	in	in	ADP
dpc-5845	104	12	particular	particular	ADJ
dpc-5845	104	13	,	,	PUNCT
dpc-5845	104	14	at	at	ADP
dpc-5845	104	15	52	52	NUM
dpc-5845	104	16	weeks	week	NOUN
dpc-5845	104	17	,	,	PUNCT
dpc-5845	104	18	dr	dr	PROPN
dpc-5845	104	19	survival	survival	PROPN
dpc-5845	104	20	for	for	ADP
dpc-5845	104	21	guselkumab	guselkumab	NOUN
dpc-5845	104	22	was	be	AUX
dpc-5845	104	23	0.84	0.84	NUM
dpc-5845	104	24	(	(	PUNCT
dpc-5845	104	25	95	95	NUM
dpc-5845	104	26	%	%	NOUN
dpc-5845	104	27	ci	ci	NOUN
dpc-5845	104	28	:	:	PUNCT
dpc-5845	104	29	0.74–0.95	0.74–0.95	NUM
dpc-5845	104	30	)	)	PUNCT
dpc-5845	104	31	,	,	PUNCT
dpc-5845	104	32	followed	follow	VERB
dpc-5845	104	33	closely	closely	ADV
dpc-5845	104	34	by	by	ADP
dpc-5845	104	35	risankizumab	risankizumab	NOUN
dpc-5845	104	36	with	with	ADP
dpc-5845	104	37	0.81	0.81	NUM
dpc-5845	104	38	(	(	PUNCT
dpc-5845	104	39	95	95	NUM
dpc-5845	104	40	%	%	NOUN
dpc-5845	104	41	ci	ci	NOUN
dpc-5845	104	42	:	:	PUNCT
dpc-5845	104	43	0.69–0.95	0.69–0.95	NOUN
dpc-5845	104	44	)	)	PUNCT
dpc-5845	104	45	.	.	PUNCT
dpc-5845	105	1	otherwise	otherwise	ADV
dpc-5845	105	2	,	,	PUNCT
dpc-5845	105	3	the	the	DET
dpc-5845	105	4	dr	dr	PROPN
dpc-5845	105	5	table	table	NOUN
dpc-5845	105	6	3	3	NUM
dpc-5845	105	7	.	.	PUNCT
dpc-5845	105	8	pasi	pasi	NOUN
dpc-5845	105	9	and	and	CCONJ
dpc-5845	105	10	dlqi	dlqi	ADJ
dpc-5845	105	11	values	value	NOUN
dpc-5845	105	12	,	,	PUNCT
dpc-5845	105	13	overall	overall	ADJ
dpc-5845	105	14	and	and	CCONJ
dpc-5845	105	15	by	by	ADP
dpc-5845	105	16	treatment	treatment	NOUN
dpc-5845	105	17	.	.	PUNCT
dpc-5845	106	1	mean	mean	VERB
dpc-5845	106	2	and	and	CCONJ
dpc-5845	106	3	standard	standard	ADJ
dpc-5845	106	4	deviation	deviation	NOUN
dpc-5845	106	5	scores	score	NOUN
dpc-5845	106	6	were	be	AUX
dpc-5845	106	7	calculated	calculate	VERB
dpc-5845	106	8	at	at	ADP
dpc-5845	106	9	treatment	treatment	NOUN
dpc-5845	106	10	start	start	NOUN
dpc-5845	106	11	,	,	PUNCT
dpc-5845	106	12	at	at	ADP
dpc-5845	106	13	dose	dose	NOUN
dpc-5845	106	14	reduction	reduction	NOUN
dpc-5845	106	15	,	,	PUNCT
dpc-5845	106	16	and	and	CCONJ
dpc-5845	106	17	at	at	ADP
dpc-5845	106	18	different	different	ADJ
dpc-5845	106	19	follow	follow	NOUN
dpc-5845	106	20	-	-	PUNCT
dpc-5845	106	21	up	up	ADP
dpc-5845	106	22	appointments	appointment	NOUN
dpc-5845	106	23	.	.	PUNCT
dpc-5845	107	1	variables	variable	NOUN
dpc-5845	107	2	all	all	PRON
dpc-5845	107	3	il-17i	il-17i	PROPN
dpc-5845	107	4	il-23i	il-23i	NOUN
dpc-5845	107	5	n	n	PRON
dpc-5845	107	6	mean	mean	VERB
dpc-5845	107	7	(	(	PUNCT
dpc-5845	107	8	sd	sd	NOUN
dpc-5845	107	9	)	)	PUNCT
dpc-5845	107	10	n	n	CCONJ
dpc-5845	107	11	mean	mean	VERB
dpc-5845	107	12	(	(	PUNCT
dpc-5845	107	13	sd	sd	NOUN
dpc-5845	107	14	)	)	PUNCT
dpc-5845	107	15	n	n	CCONJ
dpc-5845	107	16	mean	mean	VERB
dpc-5845	107	17	(	(	PUNCT
dpc-5845	107	18	sd	sd	NOUN
dpc-5845	107	19	)	)	PUNCT
dpc-5845	107	20	pasi	pasi	NOUN
dpc-5845	107	21	treatment	treatment	NOUN
dpc-5845	107	22	start	start	VERB
dpc-5845	107	23	156	156	NUM
dpc-5845	107	24	15.12	15.12	NUM
dpc-5845	107	25	(	(	PUNCT
dpc-5845	107	26	7.14	7.14	NUM
dpc-5845	107	27	)	)	PUNCT
dpc-5845	107	28	70	70	NUM
dpc-5845	107	29	14.93	14.93	NUM
dpc-5845	107	30	(	(	PUNCT
dpc-5845	107	31	7.19	7.19	NUM
dpc-5845	107	32	)	)	PUNCT
dpc-5845	107	33	86	86	NUM
dpc-5845	107	34	15.28	15.28	NUM
dpc-5845	107	35	(	(	PUNCT
dpc-5845	107	36	7.14	7.14	NUM
dpc-5845	107	37	)	)	PUNCT
dpc-5845	107	38	dose	dose	NOUN
dpc-5845	107	39	reduction	reduction	NOUN
dpc-5845	107	40	156	156	NUM
dpc-5845	107	41	0.15	0.15	NUM
dpc-5845	107	42	(	(	PUNCT
dpc-5845	107	43	0.38	0.38	NUM
dpc-5845	107	44	)	)	PUNCT
dpc-5845	107	45	70	70	NUM
dpc-5845	107	46	0.16	0.16	NUM
dpc-5845	107	47	(	(	PUNCT
dpc-5845	107	48	0.4	0.4	NUM
dpc-5845	107	49	)	)	PUNCT
dpc-5845	107	50	86	86	NUM
dpc-5845	107	51	0.15	0.15	NUM
dpc-5845	107	52	(	(	PUNCT
dpc-5845	107	53	0.36	0.36	NUM
dpc-5845	107	54	)	)	PUNCT
dpc-5845	107	55	26	26	NUM
dpc-5845	107	56	±	±	NUM
dpc-5845	107	57	2	2	NUM
dpc-5845	107	58	weeks	week	NOUN
dpc-5845	107	59	152	152	NUM
dpc-5845	107	60	0.8	0.8	NUM
dpc-5845	107	61	(	(	PUNCT
dpc-5845	107	62	1.59	1.59	NUM
dpc-5845	107	63	)	)	PUNCT
dpc-5845	107	64	68	68	NUM
dpc-5845	107	65	0.91	0.91	NUM
dpc-5845	107	66	(	(	PUNCT
dpc-5845	107	67	1.65	1.65	NUM
dpc-5845	107	68	)	)	PUNCT
dpc-5845	107	69	84	84	NUM
dpc-5845	107	70	0.71	0.71	NUM
dpc-5845	107	71	(	(	PUNCT
dpc-5845	107	72	1.55	1.55	NUM
dpc-5845	107	73	)	)	PUNCT
dpc-5845	107	74	52	52	NUM
dpc-5845	107	75	±	±	NUM
dpc-5845	107	76	2	2	NUM
dpc-5845	107	77	weeks	week	NOUN
dpc-5845	107	78	124	124	NUM
dpc-5845	107	79	0.4	0.4	NUM
dpc-5845	107	80	(	(	PUNCT
dpc-5845	107	81	0.99	0.99	NUM
dpc-5845	107	82	)	)	PUNCT
dpc-5845	107	83	51	51	NUM
dpc-5845	107	84	0.55	0.55	NUM
dpc-5845	107	85	(	(	PUNCT
dpc-5845	107	86	1.05	1.05	NUM
dpc-5845	107	87	)	)	PUNCT
dpc-5845	107	88	73	73	NUM
dpc-5845	107	89	0.3	0.3	NUM
dpc-5845	107	90	(	(	PUNCT
dpc-5845	107	91	0.94	0.94	NUM
dpc-5845	107	92	)	)	PUNCT
dpc-5845	108	1	dlqi	dlqi	ADJ
dpc-5845	109	1	treatment	treatment	NOUN
dpc-5845	109	2	start	start	VERB
dpc-5845	109	3	156	156	NUM
dpc-5845	109	4	12.84	12.84	NUM
dpc-5845	109	5	(	(	PUNCT
dpc-5845	109	6	6.08	6.08	NUM
dpc-5845	109	7	)	)	PUNCT
dpc-5845	109	8	70	70	NUM
dpc-5845	109	9	14.71	14.71	NUM
dpc-5845	109	10	(	(	PUNCT
dpc-5845	109	11	7.44	7.44	NUM
dpc-5845	109	12	)	)	PUNCT
dpc-5845	109	13	86	86	NUM
dpc-5845	109	14	11.31	11.31	NUM
dpc-5845	109	15	(	(	PUNCT
dpc-5845	109	16	4.14	4.14	NUM
dpc-5845	109	17	)	)	PUNCT
dpc-5845	109	18	dose	dose	NOUN
dpc-5845	109	19	reduction	reduction	NOUN
dpc-5845	109	20	156	156	NUM
dpc-5845	109	21	0.04	0.04	NUM
dpc-5845	109	22	(	(	PUNCT
dpc-5845	109	23	0.21	0.21	NUM
dpc-5845	109	24	)	)	PUNCT
dpc-5845	109	25	70	70	NUM
dpc-5845	109	26	0.06	0.06	NUM
dpc-5845	109	27	(	(	PUNCT
dpc-5845	109	28	0.23	0.23	NUM
dpc-5845	109	29	)	)	PUNCT
dpc-5845	109	30	86	86	NUM
dpc-5845	109	31	0.03	0.03	NUM
dpc-5845	109	32	(	(	PUNCT
dpc-5845	109	33	0.18	0.18	NUM
dpc-5845	109	34	)	)	PUNCT
dpc-5845	109	35	26	26	NUM
dpc-5845	109	36	±	±	NUM
dpc-5845	109	37	2	2	NUM
dpc-5845	109	38	weeks	week	NOUN
dpc-5845	109	39	152	152	NUM
dpc-5845	109	40	0.72	0.72	NUM
dpc-5845	109	41	(	(	PUNCT
dpc-5845	109	42	1.94	1.94	NUM
dpc-5845	109	43	)	)	PUNCT
dpc-5845	109	44	68	68	NUM
dpc-5845	109	45	0.93	0.93	NUM
dpc-5845	109	46	(	(	PUNCT
dpc-5845	109	47	2.19	2.19	NUM
dpc-5845	109	48	)	)	PUNCT
dpc-5845	109	49	84	84	NUM
dpc-5845	109	50	0.56	0.56	NUM
dpc-5845	109	51	(	(	PUNCT
dpc-5845	109	52	1.71	1.71	NUM
dpc-5845	109	53	)	)	PUNCT
dpc-5845	109	54	52	52	NUM
dpc-5845	109	55	±	±	NUM
dpc-5845	109	56	2	2	NUM
dpc-5845	109	57	weeks	week	NOUN
dpc-5845	109	58	124	124	NUM
dpc-5845	109	59	0.35	0.35	NUM
dpc-5845	109	60	(	(	PUNCT
dpc-5845	109	61	1.55	1.55	NUM
dpc-5845	109	62	)	)	PUNCT
dpc-5845	109	63	51	51	NUM
dpc-5845	109	64	0.69	0.69	NUM
dpc-5845	109	65	(	(	PUNCT
dpc-5845	109	66	2.28	2.28	NUM
dpc-5845	109	67	)	)	PUNCT
dpc-5845	109	68	73	73	NUM
dpc-5845	109	69	0.12	0.12	NUM
dpc-5845	109	70	(	(	PUNCT
dpc-5845	109	71	0.58	0.58	NUM
dpc-5845	109	72	)	)	PUNCT
dpc-5845	109	73	figure	figure	NOUN
dpc-5845	109	74	1	1	NUM
dpc-5845	109	75	.	.	PUNCT
dpc-5845	109	76	dose	dose	NOUN
dpc-5845	109	77	reduction	reduction	NOUN
dpc-5845	109	78	survival	survival	NOUN
dpc-5845	109	79	overall	overall	ADV
dpc-5845	109	80	(	(	PUNCT
dpc-5845	109	81	left	left	ADJ
dpc-5845	109	82	panel	panel	NOUN
dpc-5845	109	83	)	)	PUNCT
dpc-5845	109	84	and	and	CCONJ
dpc-5845	109	85	separately	separately	ADV
dpc-5845	109	86	by	by	ADP
dpc-5845	109	87	class	class	NOUN
dpc-5845	109	88	of	of	ADP
dpc-5845	109	89	treatment	treatment	NOUN
dpc-5845	109	90	(	(	PUNCT
dpc-5845	109	91	right	right	ADJ
dpc-5845	109	92	panel	panel	NOUN
dpc-5845	109	93	)	)	PUNCT
dpc-5845	109	94	.	.	PUNCT
dpc-5845	110	1	p	p	X
dpc-5845	110	2	-	-	PUNCT
dpc-5845	110	3	value	value	NOUN
dpc-5845	110	4	iss	iss	NOUN
dpc-5845	110	5	the	the	DET
dpc-5845	110	6	result	result	NOUN
dpc-5845	110	7	of	of	ADP
dpc-5845	110	8	log	log	NOUN
dpc-5845	110	9	-	-	PUNCT
dpc-5845	110	10	rank	rank	NOUN
dpc-5845	110	11	test	test	NOUN
dpc-5845	110	12	.	.	PUNCT
dpc-5845	111	1	6	6	NUM
dpc-5845	111	2	original	original	ADJ
dpc-5845	111	3	article	article	NOUN
dpc-5845	111	4	|	|	ADV
dpc-5845	111	5	dermatol	dermatol	ADJ
dpc-5845	111	6	pract	pract	NOUN
dpc-5845	111	7	concept	concept	NOUN
dpc-5845	111	8	.	.	PUNCT
dpc-5845	112	1	2025;15(3):5845	2025;15(3):5845	NUM
dpc-5845	112	2	in	in	ADP
dpc-5845	112	3	contrast	contrast	NOUN
dpc-5845	112	4	,	,	PUNCT
dpc-5845	112	5	a	a	DET
dpc-5845	112	6	recent	recent	ADJ
dpc-5845	112	7	study	study	NOUN
dpc-5845	112	8	by	by	ADP
dpc-5845	112	9	daudén	daudén	PROPN
dpc-5845	112	10	et	et	PROPN
dpc-5845	112	11	al	al	PROPN
dpc-5845	112	12	.	.	PROPN
dpc-5845	112	13	proposed	propose	VERB
dpc-5845	112	14	a	a	DET
dpc-5845	112	15	dr	dr	PROPN
dpc-5845	112	16	strategy	strategy	NOUN
dpc-5845	112	17	for	for	ADP
dpc-5845	112	18	patients	patient	NOUN
dpc-5845	112	19	who	who	PRON
dpc-5845	112	20	had	have	AUX
dpc-5845	112	21	achieved	achieve	VERB
dpc-5845	112	22	prolonged	prolonged	ADJ
dpc-5845	112	23	remission	remission	NOUN
dpc-5845	112	24	with	with	ADP
dpc-5845	112	25	secukinumab	secukinumab	NOUN
dpc-5845	113	1	[	[	X
dpc-5845	113	2	9	9	NUM
dpc-5845	113	3	]	]	PUNCT
dpc-5845	113	4	.	.	PUNCT
dpc-5845	114	1	most	most	ADJ
dpc-5845	114	2	patients	patient	NOUN
dpc-5845	114	3	in	in	ADP
dpc-5845	114	4	that	that	DET
dpc-5845	114	5	study	study	NOUN
dpc-5845	114	6	simply	simply	ADV
dpc-5845	114	7	extended	extend	VERB
dpc-5845	114	8	the	the	DET
dpc-5845	114	9	interval	interval	NOUN
dpc-5845	114	10	between	between	ADP
dpc-5845	114	11	administrations	administration	NOUN
dpc-5845	114	12	—	—	PUNCT
dpc-5845	114	13	some	some	PRON
dpc-5845	114	14	also	also	ADV
dpc-5845	114	15	halved	halve	VERB
dpc-5845	114	16	the	the	DET
dpc-5845	114	17	dose	dose	NOUN
dpc-5845	114	18	—	—	PUNCT
dpc-5845	114	19	and	and	CCONJ
dpc-5845	114	20	77.8	77.8	NUM
dpc-5845	114	21	%	%	NOUN
dpc-5845	114	22	maintained	maintain	VERB
dpc-5845	114	23	therapeutic	therapeutic	ADJ
dpc-5845	114	24	success	success	NOUN
dpc-5845	114	25	without	without	ADP
dpc-5845	114	26	compromising	compromise	VERB
dpc-5845	114	27	safety	safety	NOUN
dpc-5845	114	28	.	.	PUNCT
dpc-5845	115	1	meanwhile	meanwhile	ADV
dpc-5845	115	2	,	,	PUNCT
dpc-5845	115	3	the	the	DET
dpc-5845	115	4	phase	phase	NOUN
dpc-5845	115	5	ii	ii	PROPN
dpc-5845	115	6	ole	ole	NOUN
dpc-5845	115	7	study	study	NOUN
dpc-5845	115	8	evaluated	evaluate	VERB
dpc-5845	115	9	the	the	DET
dpc-5845	115	10	efficacy	efficacy	NOUN
dpc-5845	115	11	and	and	CCONJ
dpc-5845	115	12	safety	safety	NOUN
dpc-5845	115	13	of	of	ADP
dpc-5845	115	14	brodalumab	brodalumab	NOUN
dpc-5845	115	15	in	in	ADP
dpc-5845	115	16	patients	patient	NOUN
dpc-5845	115	17	with	with	ADP
dpc-5845	115	18	moderate	moderate	ADJ
dpc-5845	115	19	-	-	PUNCT
dpc-5845	115	20	severe	severe	ADJ
dpc-5845	115	21	plaque	plaque	NOUN
dpc-5845	115	22	psoriasis	psoriasis	NOUN
dpc-5845	115	23	,	,	PUNCT
dpc-5845	115	24	revealing	reveal	VERB
dpc-5845	115	25	that	that	SCONJ
dpc-5845	115	26	individuals	individual	NOUN
dpc-5845	115	27	weighing	weigh	VERB
dpc-5845	115	28	≤	≤	NUM
dpc-5845	115	29	100	100	NUM
dpc-5845	115	30	kg	kg	NOUN
dpc-5845	115	31	who	who	PRON
dpc-5845	115	32	received	receive	VERB
dpc-5845	115	33	brodalumab	brodalumab	NOUN
dpc-5845	115	34	140	140	NUM
dpc-5845	115	35	mg	mg	NOUN
dpc-5845	115	36	q2w	q2w	NOUN
dpc-5845	115	37	achieved	achieve	VERB
dpc-5845	115	38	comparable	comparable	ADJ
dpc-5845	115	39	response	response	NOUN
dpc-5845	115	40	to	to	ADP
dpc-5845	115	41	those	those	PRON
dpc-5845	115	42	receiving	receive	VERB
dpc-5845	115	43	210	210	NUM
dpc-5845	115	44	mg	mg	NOUN
dpc-5845	116	1	[	[	X
dpc-5845	116	2	15	15	NUM
dpc-5845	116	3	]	]	PUNCT
dpc-5845	116	4	.	.	PUNCT
dpc-5845	117	1	a	a	DET
dpc-5845	117	2	cohort	cohort	NOUN
dpc-5845	117	3	of	of	ADP
dpc-5845	117	4	“	"	PUNCT
dpc-5845	117	5	long	long	ADJ
dpc-5845	117	6	term	term	NOUN
dpc-5845	117	7	responders	responder	NOUN
dpc-5845	117	8	”	"	PUNCT
dpc-5845	117	9	was	be	AUX
dpc-5845	117	10	selected	select	VERB
dpc-5845	117	11	to	to	PART
dpc-5845	117	12	initiate	initiate	VERB
dpc-5845	117	13	the	the	DET
dpc-5845	117	14	reduced	reduce	VERB
dpc-5845	117	15	dose	dose	NOUN
dpc-5845	117	16	in	in	ADP
dpc-5845	117	17	our	our	PRON
dpc-5845	117	18	study	study	NOUN
dpc-5845	117	19	.	.	PUNCT
dpc-5845	118	1	to	to	ADP
dpc-5845	118	2	the	the	DET
dpc-5845	118	3	best	good	ADJ
dpc-5845	118	4	of	of	ADP
dpc-5845	118	5	our	our	PRON
dpc-5845	118	6	knowledge	knowledge	NOUN
dpc-5845	118	7	,	,	PUNCT
dpc-5845	118	8	this	this	PRON
dpc-5845	118	9	is	be	AUX
dpc-5845	118	10	the	the	DET
dpc-5845	118	11	first	first	ADJ
dpc-5845	118	12	multicenter	multicenter	ADJ
dpc-5845	118	13	study	study	NOUN
dpc-5845	118	14	evaluating	evaluate	VERB
dpc-5845	118	15	the	the	DET
dpc-5845	118	16	effectiveness	effectiveness	NOUN
dpc-5845	118	17	of	of	ADP
dpc-5845	118	18	ds	ds	NOUN
dpc-5845	118	19	in	in	ADP
dpc-5845	118	20	maintaining	maintain	VERB
dpc-5845	118	21	the	the	DET
dpc-5845	118	22	clinical	clinical	ADJ
dpc-5845	118	23	response	response	NOUN
dpc-5845	118	24	achieved	achieve	VERB
dpc-5845	118	25	with	with	ADP
dpc-5845	118	26	il-17	il-17	ADV
dpc-5845	118	27	/	/	SYM
dpc-5845	118	28	il-23	il-23	NOUN
dpc-5845	118	29	inhibitors	inhibitor	NOUN
dpc-5845	118	30	in	in	ADP
dpc-5845	118	31	patients	patient	NOUN
dpc-5845	118	32	affected	affect	VERB
dpc-5845	118	33	by	by	ADP
dpc-5845	118	34	moderate/	moderate/	ADV
dpc-5845	118	35	severe	severe	ADJ
dpc-5845	118	36	psoriasis	psoriasis	NOUN
dpc-5845	118	37	.	.	PUNCT
dpc-5845	119	1	the	the	DET
dpc-5845	119	2	rationale	rationale	NOUN
dpc-5845	119	3	for	for	ADP
dpc-5845	119	4	the	the	DET
dpc-5845	119	5	off	off	ADP
dpc-5845	119	6	-	-	PUNCT
dpc-5845	119	7	label	label	NOUN
dpc-5845	119	8	use	use	NOUN
dpc-5845	119	9	of	of	ADP
dpc-5845	119	10	spaced	space	VERB
dpc-5845	119	11	doses	dose	NOUN
dpc-5845	119	12	of	of	ADP
dpc-5845	119	13	il-17	il-17	NOUN
dpc-5845	119	14	/	/	SYM
dpc-5845	119	15	il-23	il-23	NOUN
dpc-5845	119	16	inhibitors	inhibitor	NOUN
dpc-5845	119	17	in	in	ADP
dpc-5845	119	18	treating	treat	VERB
dpc-5845	119	19	moderate	moderate	ADJ
dpc-5845	119	20	to	to	ADP
dpc-5845	119	21	-	-	PUNCT
dpc-5845	119	22	severe	severe	ADJ
dpc-5845	119	23	psoriasis	psoriasis	NOUN
dpc-5845	119	24	lies	lie	VERB
dpc-5845	119	25	in	in	ADP
dpc-5845	119	26	identifying	identify	VERB
dpc-5845	119	27	the	the	DET
dpc-5845	119	28	minimal	minimal	ADJ
dpc-5845	119	29	effective	effective	ADJ
dpc-5845	119	30	dose	dose	NOUN
dpc-5845	119	31	needed	need	VERB
dpc-5845	119	32	to	to	PART
dpc-5845	119	33	sustain	sustain	VERB
dpc-5845	119	34	response	response	NOUN
dpc-5845	119	35	,	,	PUNCT
dpc-5845	119	36	thereby	thereby	ADV
dpc-5845	119	37	preserving	preserve	VERB
dpc-5845	119	38	the	the	DET
dpc-5845	119	39	treatment	treatment	NOUN
dpc-5845	119	40	’s	’s	PART
dpc-5845	119	41	safety	safety	NOUN
dpc-5845	119	42	profile	profile	NOUN
dpc-5845	119	43	while	while	SCONJ
dpc-5845	119	44	alleviating	alleviate	VERB
dpc-5845	119	45	healthcare	healthcare	NOUN
dpc-5845	119	46	costs	cost	NOUN
dpc-5845	119	47	.	.	PUNCT
dpc-5845	120	1	this	this	DET
dpc-5845	120	2	cost	cost	NOUN
dpc-5845	120	3	-	-	PUNCT
dpc-5845	120	4	saving	save	VERB
dpc-5845	120	5	objective	objective	NOUN
dpc-5845	120	6	is	be	AUX
dpc-5845	120	7	particularly	particularly	ADV
dpc-5845	120	8	pertinent	pertinent	ADJ
dpc-5845	120	9	given	give	VERB
dpc-5845	120	10	psoriasis	psoriasis	NOUN
dpc-5845	120	11	’s	’s	PART
dpc-5845	120	12	high	high	ADJ
dpc-5845	120	13	prevalence	prevalence	NOUN
dpc-5845	120	14	and	and	CCONJ
dpc-5845	120	15	associated	associate	VERB
dpc-5845	120	16	economic	economic	ADJ
dpc-5845	120	17	and	and	CCONJ
dpc-5845	120	18	social	social	ADJ
dpc-5845	120	19	impact	impact	NOUN
dpc-5845	120	20	[	[	X
dpc-5845	120	21	16	16	NUM
dpc-5845	120	22	-	-	SYM
dpc-5845	120	23	18	18	NUM
dpc-5845	120	24	]	]	PUNCT
dpc-5845	120	25	.	.	PUNCT
dpc-5845	121	1	consistent	consistent	ADJ
dpc-5845	121	2	with	with	ADP
dpc-5845	121	3	prior	prior	ADJ
dpc-5845	121	4	research	research	NOUN
dpc-5845	121	5	[	[	X
dpc-5845	121	6	6	6	NUM
dpc-5845	121	7	]	]	PUNCT
dpc-5845	121	8	,	,	PUNCT
dpc-5845	121	9	our	our	PRON
dpc-5845	121	10	finding	finding	NOUN
dpc-5845	121	11	indicates	indicate	VERB
dpc-5845	121	12	potential	potential	ADJ
dpc-5845	121	13	cost	cost	NOUN
dpc-5845	121	14	savings	saving	NOUN
dpc-5845	121	15	of	of	ADP
dpc-5845	121	16	up	up	ADP
dpc-5845	121	17	to	to	PART
dpc-5845	121	18	30	30	NUM
dpc-5845	121	19	%	%	NOUN
dpc-5845	121	20	,	,	PUNCT
dpc-5845	121	21	although	although	SCONJ
dpc-5845	121	22	further	further	ADJ
dpc-5845	121	23	tailoring	tailoring	NOUN
dpc-5845	121	24	of	of	ADP
dpc-5845	121	25	individual	individual	ADJ
dpc-5845	121	26	dosing	dose	VERB
dpc-5845	121	27	schedules	schedule	NOUN
dpc-5845	121	28	may	may	AUX
dpc-5845	121	29	enhance	enhance	VERB
dpc-5845	121	30	the	the	DET
dpc-5845	121	31	long	long	ADJ
dpc-5845	121	32	-	-	PUNCT
dpc-5845	121	33	term	term	NOUN
dpc-5845	121	34	sustainability	sustainability	NOUN
dpc-5845	121	35	of	of	ADP
dpc-5845	121	36	this	this	DET
dpc-5845	121	37	approach	approach	NOUN
dpc-5845	121	38	;	;	PUNCT
dpc-5845	121	39	a	a	DET
dpc-5845	121	40	more	more	ADV
dpc-5845	121	41	comprehensive	comprehensive	ADJ
dpc-5845	121	42	and	and	CCONJ
dpc-5845	121	43	accurate	accurate	ADJ
dpc-5845	121	44	pharmacoeconomic	pharmacoeconomic	ADJ
dpc-5845	121	45	analysis	analysis	NOUN
dpc-5845	121	46	has	have	AUX
dpc-5845	121	47	been	be	AUX
dpc-5845	121	48	planned	plan	VERB
dpc-5845	121	49	for	for	ADP
dpc-5845	121	50	an	an	DET
dpc-5845	121	51	upcoming	upcoming	ADJ
dpc-5845	121	52	dedicated	dedicated	ADJ
dpc-5845	121	53	article	article	NOUN
dpc-5845	121	54	.	.	PUNCT
dpc-5845	122	1	both	both	DET
dpc-5845	122	2	il-17i	il-17i	PROPN
dpc-5845	122	3	and	and	CCONJ
dpc-5845	122	4	il-23i	il-23i	PRON
dpc-5845	122	5	showed	show	VERB
dpc-5845	122	6	sustained	sustained	ADJ
dpc-5845	122	7	efficacy	efficacy	NOUN
dpc-5845	122	8	after	after	ADP
dpc-5845	122	9	one	one	NUM
dpc-5845	122	10	year	year	NOUN
dpc-5845	122	11	of	of	ADP
dpc-5845	122	12	follow	follow	NOUN
dpc-5845	122	13	-	-	PUNCT
dpc-5845	122	14	up	up	NOUN
dpc-5845	122	15	;	;	PUNCT
dpc-5845	122	16	however	however	ADV
dpc-5845	122	17	,	,	PUNCT
dpc-5845	122	18	a	a	DET
dpc-5845	122	19	comparison	comparison	NOUN
dpc-5845	122	20	of	of	ADP
dpc-5845	122	21	the	the	DET
dpc-5845	122	22	two	two	NUM
dpc-5845	122	23	cohorts	cohort	NOUN
dpc-5845	122	24	revealed	reveal	VERB
dpc-5845	122	25	a	a	DET
dpc-5845	122	26	reintroducing	reintroduce	VERB
dpc-5845	122	27	the	the	DET
dpc-5845	122	28	standard	standard	ADJ
dpc-5845	122	29	treatment	treatment	NOUN
dpc-5845	122	30	dose	dose	NOUN
dpc-5845	122	31	.	.	PUNCT
dpc-5845	123	1	a	a	DET
dpc-5845	123	2	single	single	ADJ
dpc-5845	123	3	case	case	NOUN
dpc-5845	123	4	of	of	ADP
dpc-5845	123	5	diplopia	diplopia	PROPN
dpc-5845	123	6	due	due	ADP
dpc-5845	123	7	to	to	ADP
dpc-5845	123	8	meningioma	meningioma	NOUN
dpc-5845	123	9	was	be	AUX
dpc-5845	123	10	observed	observe	VERB
dpc-5845	123	11	in	in	ADP
dpc-5845	123	12	this	this	DET
dpc-5845	123	13	patient	patient	ADJ
dpc-5845	123	14	cohort	cohort	NOUN
dpc-5845	123	15	.	.	PUNCT
dpc-5845	124	1	this	this	DET
dpc-5845	124	2	adverse	adverse	ADJ
dpc-5845	124	3	event	event	NOUN
dpc-5845	124	4	is	be	AUX
dpc-5845	124	5	not	not	PART
dpc-5845	124	6	considered	consider	VERB
dpc-5845	124	7	related	related	ADJ
dpc-5845	124	8	to	to	ADP
dpc-5845	124	9	the	the	DET
dpc-5845	124	10	dr	dr	PROPN
dpc-5845	124	11	protocol	protocol	PROPN
dpc-5845	124	12	.	.	PUNCT
dpc-5845	125	1	discussion	discussion	NOUN
dpc-5845	125	2	based	base	VERB
dpc-5845	125	3	on	on	ADP
dpc-5845	125	4	our	our	PRON
dpc-5845	125	5	experience	experience	NOUN
dpc-5845	125	6	,	,	PUNCT
dpc-5845	125	7	implementing	implement	VERB
dpc-5845	125	8	dr	dr	PROPN
dpc-5845	125	9	through	through	ADP
dpc-5845	125	10	extended	extend	VERB
dpc-5845	125	11	dosing	dosing	NOUN
dpc-5845	125	12	intervals	interval	NOUN
dpc-5845	125	13	for	for	ADP
dpc-5845	125	14	il-17	il-17	ADV
dpc-5845	125	15	and	and	CCONJ
dpc-5845	125	16	il-23	il-23	VERB
dpc-5845	125	17	inhibitors	inhibitor	NOUN
dpc-5845	125	18	appears	appear	VERB
dpc-5845	125	19	to	to	PART
dpc-5845	125	20	be	be	AUX
dpc-5845	125	21	an	an	DET
dpc-5845	125	22	effective	effective	ADJ
dpc-5845	125	23	therapeutic	therapeutic	ADJ
dpc-5845	125	24	strategy	strategy	NOUN
dpc-5845	125	25	for	for	ADP
dpc-5845	125	26	many	many	ADJ
dpc-5845	125	27	patients	patient	NOUN
dpc-5845	125	28	with	with	ADP
dpc-5845	125	29	stable	stable	ADJ
dpc-5845	125	30	plaque	plaque	NOUN
dpc-5845	125	31	psoriasis	psoriasis	NOUN
dpc-5845	125	32	.	.	PUNCT
dpc-5845	126	1	at	at	ADP
dpc-5845	126	2	both	both	DET
dpc-5845	126	3	26	26	NUM
dpc-5845	126	4	and	and	CCONJ
dpc-5845	126	5	52	52	NUM
dpc-5845	126	6	weeks	week	NOUN
dpc-5845	126	7	,	,	PUNCT
dpc-5845	126	8	most	most	ADJ
dpc-5845	126	9	patients	patient	NOUN
dpc-5845	126	10	maintained	maintain	VERB
dpc-5845	126	11	disease	disease	NOUN
dpc-5845	126	12	control	control	NOUN
dpc-5845	126	13	indicated	indicate	VERB
dpc-5845	126	14	by	by	ADP
dpc-5845	126	15	pasi	pasi	NOUN
dpc-5845	126	16	and	and	CCONJ
dpc-5845	126	17	dlqi	dlqi	ADJ
dpc-5845	126	18	scores	score	NOUN
dpc-5845	126	19	≤	≤	ADJ
dpc-5845	126	20	3	3	NUM
dpc-5845	126	21	,	,	PUNCT
dpc-5845	126	22	while	while	SCONJ
dpc-5845	126	23	only	only	ADV
dpc-5845	126	24	a	a	DET
dpc-5845	126	25	small	small	ADJ
dpc-5845	126	26	percentage	percentage	NOUN
dpc-5845	126	27	experienced	experience	VERB
dpc-5845	126	28	flare	flare	NOUN
dpc-5845	126	29	-	-	PUNCT
dpc-5845	126	30	ups	up	NOUN
dpc-5845	126	31	requiring	require	VERB
dpc-5845	126	32	a	a	DET
dpc-5845	126	33	return	return	NOUN
dpc-5845	126	34	to	to	ADP
dpc-5845	126	35	the	the	DET
dpc-5845	126	36	standard	standard	NOUN
dpc-5845	126	37	dose	dose	PROPN
dpc-5845	126	38	(	(	PUNCT
dpc-5845	126	39	std	std	PROPN
dpc-5845	126	40	)	)	PUNCT
dpc-5845	126	41	or	or	CCONJ
dpc-5845	126	42	a	a	DET
dpc-5845	126	43	change	change	NOUN
dpc-5845	126	44	in	in	ADP
dpc-5845	126	45	therapy	therapy	NOUN
dpc-5845	126	46	.	.	PUNCT
dpc-5845	127	1	the	the	DET
dpc-5845	127	2	feasibility	feasibility	NOUN
dpc-5845	127	3	of	of	ADP
dpc-5845	127	4	administering	administer	VERB
dpc-5845	127	5	reduced	reduce	VERB
dpc-5845	127	6	or	or	CCONJ
dpc-5845	127	7	spaced	space	VERB
dpc-5845	127	8	doses	dose	NOUN
dpc-5845	127	9	or	or	CCONJ
dpc-5845	127	10	ds	ds	NOUN
dpc-5845	127	11	was	be	AUX
dpc-5845	127	12	already	already	ADV
dpc-5845	127	13	explored	explore	VERB
dpc-5845	127	14	with	with	ADP
dpc-5845	127	15	these	these	DET
dpc-5845	127	16	therapies	therapy	NOUN
dpc-5845	127	17	,	,	PUNCT
dpc-5845	127	18	with	with	ADP
dpc-5845	127	19	good	good	ADJ
dpc-5845	127	20	results	result	NOUN
dpc-5845	127	21	.	.	PUNCT
dpc-5845	128	1	notably	notably	ADV
dpc-5845	128	2	,	,	PUNCT
dpc-5845	128	3	the	the	DET
dpc-5845	128	4	il-23i	il-23i	NOUN
dpc-5845	128	5	risankizumab	risankizumab	NOUN
dpc-5845	128	6	has	have	AUX
dpc-5845	128	7	shown	show	VERB
dpc-5845	128	8	the	the	DET
dpc-5845	128	9	capacity	capacity	NOUN
dpc-5845	128	10	to	to	PART
dpc-5845	128	11	sustain	sustain	VERB
dpc-5845	128	12	clinical	clinical	ADJ
dpc-5845	128	13	improvement	improvement	NOUN
dpc-5845	128	14	for	for	ADP
dpc-5845	128	15	up	up	ADP
dpc-5845	128	16	to	to	PART
dpc-5845	128	17	66	66	NUM
dpc-5845	128	18	weeks	week	NOUN
dpc-5845	128	19	following	follow	VERB
dpc-5845	128	20	a	a	DET
dpc-5845	128	21	single	single	ADJ
dpc-5845	128	22	intravenous	intravenous	ADJ
dpc-5845	128	23	administration	administration	NOUN
dpc-5845	128	24	[	[	X
dpc-5845	128	25	14	14	NUM
dpc-5845	128	26	]	]	PUNCT
dpc-5845	128	27	.	.	PUNCT
dpc-5845	129	1	furthermore	furthermore	ADV
dpc-5845	129	2	,	,	PUNCT
dpc-5845	129	3	an	an	DET
dpc-5845	129	4	asneeded	asneede	VERB
dpc-5845	129	5	dosing	dose	VERB
dpc-5845	129	6	approach	approach	NOUN
dpc-5845	129	7	has	have	AUX
dpc-5845	129	8	proven	prove	VERB
dpc-5845	129	9	viable	viable	ADJ
dpc-5845	129	10	in	in	ADP
dpc-5845	129	11	maintaining	maintain	VERB
dpc-5845	129	12	response	response	NOUN
dpc-5845	129	13	,	,	PUNCT
dpc-5845	129	14	as	as	SCONJ
dpc-5845	129	15	evidenced	evidence	VERB
dpc-5845	129	16	by	by	ADP
dpc-5845	129	17	a	a	DET
dpc-5845	129	18	successive	successive	ADJ
dpc-5845	129	19	study	study	NOUN
dpc-5845	129	20	of	of	ADP
dpc-5845	129	21	64	64	NUM
dpc-5845	129	22	patients	patient	NOUN
dpc-5845	129	23	that	that	PRON
dpc-5845	129	24	progressively	progressively	ADV
dpc-5845	129	25	extended	extend	VERB
dpc-5845	129	26	dosing	dosing	NOUN
dpc-5845	129	27	intervals	interval	NOUN
dpc-5845	129	28	to	to	ADP
dpc-5845	129	29	an	an	DET
dpc-5845	129	30	average	average	NOUN
dpc-5845	129	31	of	of	ADP
dpc-5845	129	32	over	over	ADP
dpc-5845	129	33	38	38	NUM
dpc-5845	129	34	weeks	week	NOUN
dpc-5845	130	1	[	[	X
dpc-5845	130	2	11	11	NUM
dpc-5845	130	3	]	]	PUNCT
dpc-5845	130	4	.	.	PUNCT
dpc-5845	131	1	the	the	DET
dpc-5845	131	2	guide	guide	NOUN
dpc-5845	131	3	randomized	randomize	VERB
dpc-5845	131	4	clinical	clinical	ADJ
dpc-5845	131	5	trial	trial	NOUN
dpc-5845	131	6	demonstrated	demonstrate	VERB
dpc-5845	131	7	noninferiority	noninferiority	NOUN
dpc-5845	131	8	of	of	ADP
dpc-5845	131	9	treatment	treatment	NOUN
dpc-5845	131	10	with	with	ADP
dpc-5845	131	11	guselkumab	guselkumab	NOUN
dpc-5845	131	12	every	every	DET
dpc-5845	131	13	16	16	NUM
dpc-5845	131	14	weeks	week	NOUN
dpc-5845	131	15	vs	vs	ADP
dpc-5845	131	16	8	8	NUM
dpc-5845	131	17	-	-	PUNCT
dpc-5845	131	18	weeks	week	NOUN
dpc-5845	131	19	in	in	ADP
dpc-5845	131	20	super	super	ADJ
dpc-5845	131	21	-	-	ADJ
dpc-5845	131	22	responder	responder	ADJ
dpc-5845	131	23	patients	patient	NOUN
dpc-5845	131	24	(	(	PUNCT
dpc-5845	131	25	those	those	PRON
dpc-5845	131	26	who	who	PRON
dpc-5845	131	27	achieved	achieve	VERB
dpc-5845	131	28	and	and	CCONJ
dpc-5845	131	29	maintained	maintain	VERB
dpc-5845	131	30	pasi	pasi	NOUN
dpc-5845	131	31	0	0	PUNCT
dpc-5845	131	32	at	at	ADP
dpc-5845	131	33	both	both	DET
dpc-5845	131	34	week	week	NOUN
dpc-5845	131	35	20	20	NUM
dpc-5845	131	36	and	and	CCONJ
dpc-5845	131	37	week	week	NOUN
dpc-5845	131	38	28	28	NUM
dpc-5845	131	39	)	)	PUNCT
dpc-5845	132	1	[	[	X
dpc-5845	132	2	12	12	NUM
dpc-5845	132	3	]	]	PUNCT
dpc-5845	132	4	.	.	PUNCT
dpc-5845	133	1	in	in	ADP
dpc-5845	133	2	the	the	DET
dpc-5845	133	3	optimise	optimise	ADJ
dpc-5845	133	4	study	study	NOUN
dpc-5845	133	5	[	[	X
dpc-5845	133	6	13	13	NUM
dpc-5845	133	7	]	]	PUNCT
dpc-5845	133	8	,	,	PUNCT
dpc-5845	133	9	the	the	DET
dpc-5845	133	10	il-17	il-17	NUM
dpc-5845	133	11	inhibitor	inhibitor	NOUN
dpc-5845	133	12	secukinumab	secukinumab	NOUN
dpc-5845	133	13	was	be	AUX
dpc-5845	133	14	prescribed	prescribe	VERB
dpc-5845	133	15	every	every	DET
dpc-5845	133	16	six	six	NUM
dpc-5845	133	17	weeks	week	NOUN
dpc-5845	133	18	during	during	ADP
dpc-5845	133	19	the	the	DET
dpc-5845	133	20	maintenance	maintenance	NOUN
dpc-5845	133	21	phase	phase	NOUN
dpc-5845	133	22	,	,	PUNCT
dpc-5845	133	23	although	although	SCONJ
dpc-5845	133	24	the	the	DET
dpc-5845	133	25	final	final	ADJ
dpc-5845	133	26	results	result	NOUN
dpc-5845	133	27	favored	favor	VERB
dpc-5845	133	28	the	the	DET
dpc-5845	133	29	superiority	superiority	NOUN
dpc-5845	133	30	of	of	ADP
dpc-5845	133	31	the	the	DET
dpc-5845	133	32	standard	standard	ADJ
dpc-5845	133	33	four	four	NUM
dpc-5845	133	34	-	-	PUNCT
dpc-5845	133	35	week	week	NOUN
dpc-5845	133	36	dosing	dose	VERB
dpc-5845	133	37	schedule	schedule	NOUN
dpc-5845	133	38	.	.	PUNCT
dpc-5845	134	1	figure	figure	NOUN
dpc-5845	134	2	2	2	NUM
dpc-5845	134	3	.	.	PUNCT
dpc-5845	134	4	discontinuation	discontinuation	NOUN
dpc-5845	134	5	survival	survival	NOUN
dpc-5845	134	6	by	by	ADP
dpc-5845	134	7	different	different	ADJ
dpc-5845	134	8	treatments	treatment	NOUN
dpc-5845	134	9	.	.	PUNCT
dpc-5845	135	1	p	p	X
dpc-5845	135	2	-	-	PUNCT
dpc-5845	135	3	value	value	NOUN
dpc-5845	135	4	is	be	AUX
dpc-5845	135	5	the	the	DET
dpc-5845	135	6	result	result	NOUN
dpc-5845	135	7	of	of	ADP
dpc-5845	135	8	log	log	NOUN
dpc-5845	135	9	-	-	PUNCT
dpc-5845	135	10	rank	rank	NOUN
dpc-5845	135	11	test	test	NOUN
dpc-5845	135	12	.	.	PUNCT
dpc-5845	136	1	original	original	ADJ
dpc-5845	136	2	article	article	NOUN
dpc-5845	136	3	|	|	ADV
dpc-5845	136	4	dermatol	dermatol	ADJ
dpc-5845	136	5	pract	pract	NOUN
dpc-5845	136	6	concept	concept	NOUN
dpc-5845	136	7	.	.	PUNCT
dpc-5845	137	1	2025;15(3):5845	2025;15(3):5845	NUM
dpc-5845	137	2	7	7	NUM
dpc-5845	137	3	our	our	PRON
dpc-5845	137	4	findings	finding	NOUN
dpc-5845	137	5	,	,	PUNCT
dpc-5845	137	6	underscoring	underscore	VERB
dpc-5845	137	7	the	the	DET
dpc-5845	137	8	need	need	NOUN
dpc-5845	137	9	for	for	ADP
dpc-5845	137	10	additional	additional	ADJ
dpc-5845	137	11	research	research	NOUN
dpc-5845	137	12	.	.	PUNCT
dpc-5845	138	1	future	future	ADJ
dpc-5845	138	2	research	research	NOUN
dpc-5845	138	3	direction	direction	NOUN
dpc-5845	138	4	can	can	AUX
dpc-5845	138	5	be	be	AUX
dpc-5845	138	6	represented	represent	VERB
dpc-5845	138	7	by	by	ADP
dpc-5845	138	8	larger	large	ADJ
dpc-5845	138	9	randomized	randomized	ADJ
dpc-5845	138	10	controlled	control	VERB
dpc-5845	138	11	trials	trial	NOUN
dpc-5845	138	12	to	to	PART
dpc-5845	138	13	confirm	confirm	VERB
dpc-5845	138	14	the	the	DET
dpc-5845	138	15	efficacy	efficacy	NOUN
dpc-5845	138	16	and	and	CCONJ
dpc-5845	138	17	safety	safety	NOUN
dpc-5845	138	18	of	of	ADP
dpc-5845	138	19	dr	dr	PROPN
dpc-5845	138	20	strategies	strategy	NOUN
dpc-5845	138	21	and	and	CCONJ
dpc-5845	138	22	by	by	ADP
dpc-5845	138	23	longitudinal	longitudinal	ADJ
dpc-5845	138	24	studies	study	NOUN
dpc-5845	138	25	to	to	PART
dpc-5845	138	26	assess	assess	VERB
dpc-5845	138	27	the	the	DET
dpc-5845	138	28	long	long	ADJ
dpc-5845	138	29	-	-	PUNCT
dpc-5845	138	30	term	term	NOUN
dpc-5845	138	31	outcomes	outcome	NOUN
dpc-5845	138	32	and	and	CCONJ
dpc-5845	138	33	sustainability	sustainability	NOUN
dpc-5845	138	34	of	of	ADP
dpc-5845	138	35	dr	dr	PROPN
dpc-5845	138	36	.	.	PROPN
dpc-5845	139	1	moreover	moreover	ADV
dpc-5845	139	2	,	,	PUNCT
dpc-5845	139	3	biologic	biologic	NOUN
dpc-5845	139	4	mechanisms	mechanism	NOUN
dpc-5845	139	5	underlying	underlie	VERB
dpc-5845	139	6	successful	successful	ADJ
dpc-5845	139	7	dr	dr	PROPN
dpc-5845	139	8	must	must	AUX
dpc-5845	139	9	be	be	AUX
dpc-5845	139	10	explored	explore	VERB
dpc-5845	139	11	in	in	ADP
dpc-5845	139	12	depth	depth	NOUN
dpc-5845	139	13	to	to	PART
dpc-5845	139	14	identify	identify	VERB
dpc-5845	139	15	appropriate	appropriate	ADJ
dpc-5845	139	16	biomarkers	biomarker	NOUN
dpc-5845	139	17	useful	useful	ADJ
dpc-5845	139	18	for	for	ADP
dpc-5845	139	19	patient	patient	ADJ
dpc-5845	139	20	selection	selection	NOUN
dpc-5845	139	21	.	.	PUNCT
dpc-5845	140	1	currently	currently	ADV
dpc-5845	140	2	,	,	PUNCT
dpc-5845	140	3	prolonged	prolonged	ADJ
dpc-5845	140	4	remission	remission	NOUN
dpc-5845	140	5	is	be	AUX
dpc-5845	140	6	the	the	DET
dpc-5845	140	7	main	main	ADJ
dpc-5845	140	8	criterion	criterion	NOUN
dpc-5845	140	9	for	for	ADP
dpc-5845	140	10	dose	dose	NOUN
dpc-5845	140	11	reduction	reduction	NOUN
dpc-5845	140	12	eligibility	eligibility	NOUN
dpc-5845	140	13	[	[	X
dpc-5845	140	14	22	22	NUM
dpc-5845	140	15	]	]	PUNCT
dpc-5845	140	16	,	,	PUNCT
dpc-5845	140	17	but	but	CCONJ
dpc-5845	140	18	the	the	DET
dpc-5845	140	19	identification	identification	NOUN
dpc-5845	140	20	of	of	ADP
dpc-5845	140	21	more	more	ADJ
dpc-5845	140	22	specific	specific	ADJ
dpc-5845	140	23	criteria	criterion	NOUN
dpc-5845	140	24	could	could	AUX
dpc-5845	140	25	further	far	ADV
dpc-5845	140	26	improve	improve	VERB
dpc-5845	140	27	the	the	DET
dpc-5845	140	28	results	result	NOUN
dpc-5845	140	29	obtained	obtain	VERB
dpc-5845	140	30	through	through	ADP
dpc-5845	140	31	this	this	DET
dpc-5845	140	32	strategy	strategy	NOUN
dpc-5845	140	33	.	.	PUNCT
dpc-5845	141	1	conclusions	conclusion	NOUN
dpc-5845	141	2	the	the	DET
dpc-5845	141	3	disease	disease	NOUN
dpc-5845	141	4	activity	activity	NOUN
dpc-5845	141	5	-	-	PUNCT
dpc-5845	141	6	guided	guide	VERB
dpc-5845	141	7	dr	dr	PROPN
dpc-5845	141	8	of	of	ADP
dpc-5845	141	9	il-17	il-17	NUM
dpc-5845	141	10	and	and	CCONJ
dpc-5845	141	11	il-23	il-23	VERB
dpc-5845	141	12	inhibitors	inhibitor	NOUN
dpc-5845	141	13	appears	appear	VERB
dpc-5845	141	14	to	to	PART
dpc-5845	141	15	be	be	AUX
dpc-5845	141	16	a	a	DET
dpc-5845	141	17	feasible	feasible	ADJ
dpc-5845	141	18	and	and	CCONJ
dpc-5845	141	19	effective	effective	ADJ
dpc-5845	141	20	strategy	strategy	NOUN
dpc-5845	141	21	for	for	ADP
dpc-5845	141	22	selected	select	VERB
dpc-5845	141	23	patients	patient	NOUN
dpc-5845	141	24	with	with	ADP
dpc-5845	141	25	plaque	plaque	NOUN
dpc-5845	141	26	psoriasis	psoriasis	NOUN
dpc-5845	141	27	.	.	PUNCT
dpc-5845	142	1	it	it	PRON
dpc-5845	142	2	allows	allow	VERB
dpc-5845	142	3	for	for	ADP
dpc-5845	142	4	the	the	DET
dpc-5845	142	5	optimization	optimization	NOUN
dpc-5845	142	6	of	of	ADP
dpc-5845	142	7	treatment	treatment	NOUN
dpc-5845	142	8	regimens	regimen	NOUN
dpc-5845	142	9	,	,	PUNCT
dpc-5845	142	10	improving	improve	VERB
dpc-5845	142	11	patient	patient	ADJ
dpc-5845	142	12	quality	quality	NOUN
dpc-5845	142	13	of	of	ADP
dpc-5845	142	14	life	life	NOUN
dpc-5845	142	15	and	and	CCONJ
dpc-5845	142	16	reducing	reduce	VERB
dpc-5845	142	17	healthcare	healthcare	NOUN
dpc-5845	142	18	costs	cost	NOUN
dpc-5845	142	19	.	.	PUNCT
dpc-5845	143	1	based	base	VERB
dpc-5845	143	2	on	on	ADP
dpc-5845	143	3	our	our	PRON
dpc-5845	143	4	experience	experience	NOUN
dpc-5845	143	5	,	,	PUNCT
dpc-5845	143	6	we	we	PRON
dpc-5845	143	7	encourage	encourage	VERB
dpc-5845	143	8	clinicians	clinician	NOUN
dpc-5845	143	9	to	to	PART
dpc-5845	143	10	consider	consider	VERB
dpc-5845	143	11	dr	dr	PROPN
dpc-5845	143	12	for	for	ADP
dpc-5845	143	13	patients	patient	NOUN
dpc-5845	143	14	who	who	PRON
dpc-5845	143	15	have	have	AUX
dpc-5845	143	16	maintained	maintain	VERB
dpc-5845	143	17	low	low	ADJ
dpc-5845	143	18	disease	disease	NOUN
dpc-5845	143	19	activity	activity	NOUN
dpc-5845	143	20	over	over	ADP
dpc-5845	143	21	an	an	DET
dpc-5845	143	22	extended	extended	ADJ
dpc-5845	143	23	period	period	NOUN
dpc-5845	143	24	,	,	PUNCT
dpc-5845	143	25	while	while	SCONJ
dpc-5845	143	26	emphasizing	emphasize	VERB
dpc-5845	143	27	the	the	DET
dpc-5845	143	28	importance	importance	NOUN
dpc-5845	143	29	of	of	ADP
dpc-5845	143	30	regular	regular	ADJ
dpc-5845	143	31	monitoring	monitoring	NOUN
dpc-5845	143	32	for	for	ADP
dpc-5845	143	33	early	early	ADJ
dpc-5845	143	34	detection	detection	NOUN
dpc-5845	143	35	of	of	ADP
dpc-5845	143	36	flare	flare	NOUN
dpc-5845	143	37	-	-	PUNCT
dpc-5845	143	38	ups	up	NOUN
dpc-5845	143	39	.	.	PUNCT
dpc-5845	144	1	future	future	ADJ
dpc-5845	144	2	studies	study	NOUN
dpc-5845	144	3	should	should	AUX
dpc-5845	144	4	include	include	VERB
dpc-5845	144	5	randomized	randomize	VERB
dpc-5845	144	6	controlled	control	VERB
dpc-5845	144	7	trials	trial	NOUN
dpc-5845	144	8	and	and	CCONJ
dpc-5845	144	9	long	long	ADJ
dpc-5845	144	10	-	-	PUNCT
dpc-5845	144	11	term	term	NOUN
dpc-5845	144	12	follow	follow	NOUN
dpc-5845	144	13	-	-	PUNCT
dpc-5845	144	14	up	up	NOUN
dpc-5845	144	15	to	to	PART
dpc-5845	144	16	confirm	confirm	VERB
dpc-5845	144	17	these	these	DET
dpc-5845	144	18	results	result	NOUN
dpc-5845	144	19	and	and	CCONJ
dpc-5845	144	20	assess	assess	VERB
dpc-5845	144	21	their	their	PRON
dpc-5845	144	22	implications	implication	NOUN
dpc-5845	144	23	for	for	ADP
dpc-5845	144	24	clinical	clinical	ADJ
dpc-5845	144	25	practice	practice	NOUN
dpc-5845	144	26	.	.	PUNCT
dpc-5845	145	1	finally	finally	ADV
dpc-5845	145	2	,	,	PUNCT
dpc-5845	145	3	clear	clear	ADJ
dpc-5845	145	4	communication	communication	NOUN
dpc-5845	145	5	and	and	CCONJ
dpc-5845	145	6	patient	patient	ADJ
dpc-5845	145	7	education	education	NOUN
dpc-5845	145	8	are	be	AUX
dpc-5845	145	9	essential	essential	ADJ
dpc-5845	145	10	to	to	PART
dpc-5845	145	11	ensuring	ensure	VERB
dpc-5845	145	12	that	that	SCONJ
dpc-5845	145	13	patients	patient	NOUN
dpc-5845	145	14	are	be	AUX
dpc-5845	145	15	actively	actively	ADV
dpc-5845	145	16	involved	involve	VERB
dpc-5845	145	17	in	in	ADP
dpc-5845	145	18	the	the	DET
dpc-5845	145	19	decision	decision	NOUN
dpc-5845	145	20	-	-	PUNCT
dpc-5845	145	21	making	make	VERB
dpc-5845	145	22	process	process	NOUN
dpc-5845	145	23	of	of	ADP
dpc-5845	145	24	a	a	DET
dpc-5845	145	25	valuable	valuable	ADJ
dpc-5845	145	26	yet	yet	ADV
dpc-5845	145	27	off	off	ADP
dpc-5845	145	28	-	-	PUNCT
dpc-5845	145	29	label	label	NOUN
dpc-5845	145	30	protocol	protocol	NOUN
dpc-5845	145	31	and	and	CCONJ
dpc-5845	145	32	to	to	ADP
dpc-5845	145	33	knowing	know	VERB
dpc-5845	145	34	when	when	SCONJ
dpc-5845	145	35	to	to	PART
dpc-5845	145	36	report	report	VERB
dpc-5845	145	37	any	any	DET
dpc-5845	145	38	concerning	concern	VERB
dpc-5845	145	39	symptoms	symptom	NOUN
dpc-5845	145	40	.	.	PUNCT
dpc-5845	146	1	references	reference	NOUN
dpc-5845	146	2	1	1	NUM
dpc-5845	146	3	.	.	PUNCT
dpc-5845	147	1	nast	nast	PROPN
dpc-5845	147	2	a	a	PROPN
dpc-5845	147	3	,	,	PUNCT
dpc-5845	147	4	smith	smith	PROPN
dpc-5845	147	5	c	c	PROPN
dpc-5845	147	6	,	,	PUNCT
dpc-5845	147	7	spuls	spuls	PROPN
dpc-5845	147	8	pi	pi	PROPN
dpc-5845	147	9	,	,	PUNCT
dpc-5845	147	10	et	et	PROPN
dpc-5845	147	11	al	al	PROPN
dpc-5845	147	12	.	.	PROPN
dpc-5845	148	1	euroguiderm	euroguiderm	PROPN
dpc-5845	148	2	guideline	guideline	NOUN
dpc-5845	148	3	on	on	ADP
dpc-5845	148	4	the	the	DET
dpc-5845	148	5	systemic	systemic	ADJ
dpc-5845	148	6	treatment	treatment	NOUN
dpc-5845	148	7	of	of	ADP
dpc-5845	148	8	psoriasis	psoriasis	NOUN
dpc-5845	148	9	vulgaris	vulgaris	NOUN
dpc-5845	148	10	part	part	NOUN
dpc-5845	148	11	1	1	NUM
dpc-5845	148	12	:	:	PUNCT
dpc-5845	148	13	treatment	treatment	NOUN
dpc-5845	148	14	and	and	CCONJ
dpc-5845	148	15	monitoring	monitoring	NOUN
dpc-5845	148	16	recommendations	recommendation	NOUN
dpc-5845	148	17	.	.	PUNCT
dpc-5845	149	1	j	j	PROPN
dpc-5845	149	2	eur	eur	PROPN
dpc-5845	149	3	acad	acad	PROPN
dpc-5845	149	4	dermatol	dermatol	NOUN
dpc-5845	149	5	venereol	venereol	NOUN
dpc-5845	149	6	.	.	PUNCT
dpc-5845	150	1	2020	2020	NUM
dpc-5845	150	2	nov;34(11):2461	nov;34(11):2461	X
dpc-5845	150	3	-	-	X
dpc-5845	150	4	2498	2498	NUM
dpc-5845	150	5	.	.	PUNCT
dpc-5845	151	1	doi	doi	NOUN
dpc-5845	151	2	:	:	PUNCT
dpc-5845	151	3	10.1111	10.1111	NUM
dpc-5845	151	4	/	/	SYM
dpc-5845	151	5	jdv.16915	jdv.16915	NOUN
dpc-5845	151	6	.	.	PUNCT
dpc-5845	152	1	pmid	pmid	NOUN
dpc-5845	152	2	:	:	PUNCT
dpc-5845	152	3	33349983	33349983	NUM
dpc-5845	152	4	.	.	PUNCT
dpc-5845	153	1	2	2	X
dpc-5845	153	2	.	.	NUM
dpc-5845	153	3	gisondi	gisondi	PROPN
dpc-5845	153	4	p	p	NOUN
dpc-5845	153	5	,	,	PUNCT
dpc-5845	153	6	fargnoli	fargnoli	PROPN
dpc-5845	153	7	mc	mc	PROPN
dpc-5845	153	8	,	,	PUNCT
dpc-5845	153	9	amerio	amerio	ADP
dpc-5845	153	10	p	p	X
dpc-5845	153	11	,	,	PUNCT
dpc-5845	153	12	et	et	PROPN
dpc-5845	153	13	al	al	PROPN
dpc-5845	153	14	.	.	PUNCT
dpc-5845	154	1	italian	italian	ADJ
dpc-5845	154	2	adaptation	adaptation	NOUN
dpc-5845	154	3	of	of	ADP
dpc-5845	154	4	euroguiderm	euroguiderm	NOUN
dpc-5845	154	5	guideline	guideline	NOUN
dpc-5845	154	6	on	on	ADP
dpc-5845	154	7	the	the	DET
dpc-5845	154	8	systemic	systemic	ADJ
dpc-5845	154	9	treatment	treatment	NOUN
dpc-5845	154	10	of	of	ADP
dpc-5845	154	11	chronic	chronic	ADJ
dpc-5845	154	12	plaque	plaque	NOUN
dpc-5845	154	13	psoriasis	psoriasis	NOUN
dpc-5845	154	14	.	.	PUNCT
dpc-5845	155	1	ital	ital	PROPN
dpc-5845	155	2	j	j	PROPN
dpc-5845	155	3	dermatol	dermatol	PROPN
dpc-5845	155	4	venerol	venerol	PROPN
dpc-5845	155	5	.	.	PUNCT
dpc-5845	156	1	2022	2022	NUM
dpc-5845	156	2	feb;157(suppl	feb;157(suppl	PROPN
dpc-5845	156	3	.	.	PUNCT
dpc-5845	157	1	1	1	NUM
dpc-5845	157	2	to	to	ADP
dpc-5845	157	3	no	no	NOUN
dpc-5845	157	4	.	.	PUNCT
dpc-5845	158	1	1):1	1):1	NUM
dpc-5845	158	2	-	-	SYM
dpc-5845	158	3	78	78	NUM
dpc-5845	158	4	.	.	PUNCT
dpc-5845	159	1	doi	doi	NOUN
dpc-5845	159	2	:	:	PUNCT
dpc-5845	159	3	10.23736	10.23736	NUM
dpc-5845	159	4	/	/	SYM
dpc-5845	159	5	s2784	s2784	PROPN
dpc-5845	159	6	-	-	PUNCT
dpc-5845	159	7	8671.21.07132	8671.21.07132	NUM
dpc-5845	159	8	-	-	SYM
dpc-5845	159	9	2	2	NUM
dpc-5845	159	10	.	.	PUNCT
dpc-5845	160	1	pmid	pmid	NOUN
dpc-5845	160	2	:	:	PUNCT
dpc-5845	160	3	35262308	35262308	NUM
dpc-5845	160	4	.	.	PUNCT
dpc-5845	161	1	3	3	X
dpc-5845	161	2	.	.	X
dpc-5845	161	3	atalay	atalay	PROPN
dpc-5845	161	4	s	s	PROPN
dpc-5845	161	5	,	,	PUNCT
dpc-5845	161	6	van	van	PROPN
dpc-5845	161	7	den	den	PROPN
dpc-5845	161	8	reek	reek	PROPN
dpc-5845	161	9	jmpa	jmpa	PROPN
dpc-5845	161	10	,	,	PUNCT
dpc-5845	161	11	groenewoud	groenewoud	PROPN
dpc-5845	161	12	jmm	jmm	PROPN
dpc-5845	161	13	,	,	PUNCT
dpc-5845	161	14	van	van	PROPN
dpc-5845	161	15	de	de	X
dpc-5845	161	16	kerkhof	kerkhof	PROPN
dpc-5845	161	17	pcm	pcm	PROPN
dpc-5845	161	18	,	,	PUNCT
dpc-5845	161	19	kievit	kievit	PROPN
dpc-5845	161	20	w	w	PROPN
dpc-5845	161	21	,	,	PUNCT
dpc-5845	161	22	de	de	PROPN
dpc-5845	161	23	jong	jong	PROPN
dpc-5845	161	24	emgj	emgj	PROPN
dpc-5845	161	25	.	.	PUNCT
dpc-5845	162	1	two	two	NUM
dpc-5845	162	2	-	-	PUNCT
dpc-5845	162	3	year	year	NOUN
dpc-5845	162	4	follow	follow	NOUN
dpc-5845	162	5	-	-	PUNCT
dpc-5845	162	6	up	up	NOUN
dpc-5845	162	7	of	of	ADP
dpc-5845	162	8	a	a	DET
dpc-5845	162	9	dose	dose	NOUN
dpc-5845	162	10	reduction	reduction	NOUN
dpc-5845	162	11	strategy	strategy	NOUN
dpc-5845	162	12	trial	trial	NOUN
dpc-5845	162	13	of	of	ADP
dpc-5845	162	14	biologics	biologic	NOUN
dpc-5845	162	15	adalimumab	adalimumab	NOUN
dpc-5845	162	16	,	,	PUNCT
dpc-5845	162	17	etanercept	etanercept	NOUN
dpc-5845	162	18	,	,	PUNCT
dpc-5845	162	19	and	and	CCONJ
dpc-5845	162	20	ustekinumab	ustekinumab	NOUN
dpc-5845	162	21	in	in	ADP
dpc-5845	162	22	psoriasis	psoriasis	NOUN
dpc-5845	162	23	patients	patient	NOUN
dpc-5845	162	24	in	in	ADP
dpc-5845	162	25	daily	daily	ADJ
dpc-5845	162	26	practice	practice	NOUN
dpc-5845	162	27	.	.	PUNCT
dpc-5845	163	1	j	j	PROPN
dpc-5845	163	2	dermatolog	dermatolog	PROPN
dpc-5845	163	3	treat	treat	NOUN
dpc-5845	163	4	.	.	PUNCT
dpc-5845	164	1	2022	2022	NUM
dpc-5845	164	2	may;33(3):1591	may;33(3):1591	PROPN
dpc-5845	164	3	-	-	PUNCT
dpc-5845	164	4	1597	1597	NUM
dpc-5845	164	5	.	.	PUNCT
dpc-5845	165	1	doi	doi	NOUN
dpc-5845	165	2	:	:	PUNCT
dpc-5845	165	3	10.1080/09546634.2020.1869147	10.1080/09546634.2020.1869147	NUM
dpc-5845	165	4	.	.	PUNCT
dpc-5845	166	1	epub	epub	NOUN
dpc-5845	166	2	2021	2021	NUM
dpc-5845	166	3	jan	jan	PROPN
dpc-5845	166	4	7	7	NUM
dpc-5845	166	5	.	.	PUNCT
dpc-5845	166	6	pmid	pmid	NOUN
dpc-5845	166	7	:	:	PUNCT
dpc-5845	166	8	33356686	33356686	NUM
dpc-5845	166	9	.	.	PUNCT
dpc-5845	167	1	4	4	X
dpc-5845	167	2	.	.	X
dpc-5845	167	3	van	van	PROPN
dpc-5845	167	4	der	der	PROPN
dpc-5845	167	5	schoot	schoot	PROPN
dpc-5845	167	6	ls	ls	PROPN
dpc-5845	167	7	,	,	PUNCT
dpc-5845	167	8	van	van	PROPN
dpc-5845	167	9	den	den	PROPN
dpc-5845	167	10	reek	reek	PROPN
dpc-5845	167	11	jmpa	jmpa	PROPN
dpc-5845	167	12	,	,	PUNCT
dpc-5845	167	13	grine	grine	PROPN
dpc-5845	167	14	l	l	PROPN
dpc-5845	167	15	,	,	PUNCT
dpc-5845	167	16	et	et	PROPN
dpc-5845	167	17	al	al	PROPN
dpc-5845	167	18	.	.	PROPN
dpc-5845	168	1	dose	dose	NOUN
dpc-5845	168	2	reduction	reduction	NOUN
dpc-5845	168	3	of	of	ADP
dpc-5845	168	4	the	the	DET
dpc-5845	168	5	new	new	ADJ
dpc-5845	168	6	generation	generation	NOUN
dpc-5845	168	7	biologics	biologic	NOUN
dpc-5845	168	8	(	(	PUNCT
dpc-5845	168	9	il-17	il-17	NUM
dpc-5845	168	10	and	and	CCONJ
dpc-5845	168	11	il-23	il-23	VERB
dpc-5845	168	12	inhibitors	inhibitor	NOUN
dpc-5845	168	13	)	)	PUNCT
dpc-5845	168	14	in	in	ADP
dpc-5845	168	15	psoriasis	psoriasis	NOUN
dpc-5845	168	16	:	:	PUNCT
dpc-5845	168	17	study	study	NOUN
dpc-5845	168	18	protocol	protocol	NOUN
dpc-5845	168	19	for	for	ADP
dpc-5845	168	20	an	an	DET
dpc-5845	168	21	international	international	ADJ
dpc-5845	168	22	,	,	PUNCT
dpc-5845	168	23	pragmatic	pragmatic	ADJ
dpc-5845	168	24	,	,	PUNCT
dpc-5845	168	25	multicenter	multicenter	NOUN
dpc-5845	168	26	,	,	PUNCT
dpc-5845	168	27	randomized	randomize	VERB
dpc-5845	168	28	,	,	PUNCT
dpc-5845	168	29	controlled	control	VERB
dpc-5845	168	30	,	,	PUNCT
dpc-5845	168	31	non	non	ADJ
dpc-5845	168	32	-	-	ADJ
dpc-5845	168	33	inferiority	inferiority	ADJ
dpc-5845	168	34	study	study	NOUN
dpc-5845	168	35	-	-	PUNCT
dpc-5845	168	36	the	the	DET
dpc-5845	168	37	benebio	benebio	NOUN
dpc-5845	168	38	study	study	NOUN
dpc-5845	168	39	.	.	PUNCT
dpc-5845	169	1	trials	trial	NOUN
dpc-5845	169	2	.	.	PUNCT
dpc-5845	170	1	2021	2021	NUM
dpc-5845	170	2	oct	oct	PROPN
dpc-5845	170	3	16;22(1):707	16;22(1):707	PROPN
dpc-5845	170	4	.	.	PUNCT
dpc-5845	171	1	doi	doi	NOUN
dpc-5845	171	2	:	:	PUNCT
dpc-5845	171	3	10.1186	10.1186	NUM
dpc-5845	171	4	/	/	SYM
dpc-5845	171	5	s13063	s13063	PROPN
dpc-5845	171	6	-	-	PUNCT
dpc-5845	171	7	021	021	NUM
dpc-5845	171	8	-	-	PUNCT
dpc-5845	171	9	05681	05681	NUM
dpc-5845	171	10	-	-	PUNCT
dpc-5845	171	11	z.	z.	PROPN
dpc-5845	171	12	pmid	pmid	PROPN
dpc-5845	171	13	:	:	PUNCT
dpc-5845	171	14	34656148	34656148	NUM
dpc-5845	171	15	;	;	PUNCT
dpc-5845	171	16	pmcid	pmcid	ADJ
dpc-5845	171	17	:	:	PUNCT
dpc-5845	171	18	pmc8520290	pmc8520290	NOUN
dpc-5845	171	19	.	.	PUNCT
dpc-5845	172	1	difference	difference	NOUN
dpc-5845	172	2	in	in	ADP
dpc-5845	172	3	therapeutic	therapeutic	ADJ
dpc-5845	172	4	maintenance	maintenance	NOUN
dpc-5845	172	5	showed	show	VERB
dpc-5845	172	6	a	a	DET
dpc-5845	172	7	trend	trend	NOUN
dpc-5845	172	8	favoring	favor	VERB
dpc-5845	172	9	il-23i	il-23i	NOUN
dpc-5845	172	10	.	.	PUNCT
dpc-5845	173	1	this	this	DET
dpc-5845	173	2	difference	difference	NOUN
dpc-5845	173	3	may	may	AUX
dpc-5845	173	4	be	be	AUX
dpc-5845	173	5	linked	link	VERB
dpc-5845	173	6	to	to	ADP
dpc-5845	173	7	the	the	DET
dpc-5845	173	8	superior	superior	ADJ
dpc-5845	173	9	drug	drug	NOUN
dpc-5845	173	10	survival	survival	NOUN
dpc-5845	173	11	of	of	ADP
dpc-5845	173	12	the	the	DET
dpc-5845	173	13	il-23i	il-23i	NOUN
dpc-5845	173	14	[	[	X
dpc-5845	173	15	19	19	NUM
dpc-5845	173	16	]	]	PUNCT
dpc-5845	173	17	,	,	PUNCT
dpc-5845	173	18	to	to	ADP
dpc-5845	173	19	il-23i	il-23i	PROPN
dpc-5845	173	20	’s	’s	PART
dpc-5845	173	21	sustained	sustained	ADJ
dpc-5845	173	22	suppression	suppression	NOUN
dpc-5845	173	23	of	of	ADP
dpc-5845	173	24	cd8	cd8	PROPN
dpc-5845	173	25	-	-	ADJ
dpc-5845	173	26	positive	positive	ADJ
dpc-5845	173	27	tissue	tissue	NOUN
dpc-5845	173	28	-	-	PUNCT
dpc-5845	173	29	resident	resident	NOUN
dpc-5845	173	30	memory	memory	NOUN
dpc-5845	173	31	t	t	NOUN
dpc-5845	173	32	cells	cell	NOUN
dpc-5845	173	33	in	in	ADP
dpc-5845	173	34	lesional	lesional	ADJ
dpc-5845	173	35	skin	skin	NOUN
dpc-5845	173	36	that	that	PRON
dpc-5845	173	37	play	play	VERB
dpc-5845	173	38	a	a	DET
dpc-5845	173	39	crucial	crucial	ADJ
dpc-5845	173	40	role	role	NOUN
dpc-5845	173	41	in	in	ADP
dpc-5845	173	42	psoriasis	psoriasis	NOUN
dpc-5845	173	43	recurrence	recurrence	NOUN
dpc-5845	173	44	[	[	X
dpc-5845	173	45	12	12	NUM
dpc-5845	173	46	]	]	PUNCT
dpc-5845	173	47	,	,	PUNCT
dpc-5845	173	48	to	to	ADP
dpc-5845	173	49	the	the	DET
dpc-5845	173	50	difference	difference	NOUN
dpc-5845	173	51	in	in	ADP
dpc-5845	173	52	patient	patient	ADJ
dpc-5845	173	53	selection	selection	NOUN
dpc-5845	173	54	(	(	PUNCT
dpc-5845	173	55	slightly	slightly	ADV
dpc-5845	173	56	higher	high	ADJ
dpc-5845	173	57	dlqi	dlqi	NOUN
dpc-5845	173	58	)	)	PUNCT
dpc-5845	173	59	,	,	PUNCT
dpc-5845	173	60	and/	and/	NOUN
dpc-5845	173	61	or	or	CCONJ
dpc-5845	173	62	to	to	ADP
dpc-5845	173	63	the	the	DET
dpc-5845	173	64	mechanism	mechanism	NOUN
dpc-5845	173	65	of	of	ADP
dpc-5845	173	66	action	action	NOUN
dpc-5845	173	67	of	of	ADP
dpc-5845	173	68	treatments	treatment	NOUN
dpc-5845	173	69	.	.	PUNCT
dpc-5845	174	1	in	in	ADP
dpc-5845	174	2	particular	particular	ADJ
dpc-5845	174	3	,	,	PUNCT
dpc-5845	174	4	brodalumab	brodalumab	NOUN
dpc-5845	174	5	,	,	PUNCT
dpc-5845	174	6	by	by	ADP
dpc-5845	174	7	its	its	PRON
dpc-5845	174	8	unique	unique	ADJ
dpc-5845	174	9	mechanism	mechanism	NOUN
dpc-5845	174	10	il-17	il-17	PRON
dpc-5845	174	11	receptor	receptor	VERB
dpc-5845	174	12	a	a	DET
dpc-5845	174	13	blockade	blockade	NOUN
dpc-5845	174	14	,	,	PUNCT
dpc-5845	174	15	provides	provide	VERB
dpc-5845	174	16	fast	fast	ADJ
dpc-5845	174	17	onset	onset	NOUN
dpc-5845	174	18	of	of	ADP
dpc-5845	174	19	action	action	NOUN
dpc-5845	174	20	but	but	CCONJ
dpc-5845	174	21	may	may	AUX
dpc-5845	174	22	also	also	ADV
dpc-5845	174	23	simultaneously	simultaneously	ADV
dpc-5845	174	24	correlate	correlate	VERB
dpc-5845	174	25	with	with	ADP
dpc-5845	174	26	a	a	DET
dpc-5845	174	27	greater	great	ADJ
dpc-5845	174	28	secondary	secondary	ADJ
dpc-5845	174	29	 	 	SPACE
dpc-5845	174	30	loss	loss	NOUN
dpc-5845	174	31	 	 	SPACE
dpc-5845	174	32	of	of	ADP
dpc-5845	174	33	efficacy	efficacy	NOUN
dpc-5845	174	34	in	in	ADP
dpc-5845	174	35	dose	dose	NOUN
dpc-5845	174	36	spacing	space	VERB
dpc-5845	174	37	regime	regime	NOUN
dpc-5845	174	38	.	.	PUNCT
dpc-5845	175	1	most	most	ADJ
dpc-5845	175	2	patients	patient	NOUN
dpc-5845	175	3	who	who	PRON
dpc-5845	175	4	reverted	revert	VERB
dpc-5845	175	5	to	to	ADP
dpc-5845	175	6	std	std	NOUN
dpc-5845	175	7	regained	regain	VERB
dpc-5845	175	8	complete	complete	ADJ
dpc-5845	175	9	control	control	NOUN
dpc-5845	175	10	of	of	ADP
dpc-5845	175	11	the	the	DET
dpc-5845	175	12	disease	disease	NOUN
dpc-5845	175	13	,	,	PUNCT
dpc-5845	175	14	with	with	ADP
dpc-5845	175	15	only	only	ADV
dpc-5845	175	16	2.56	2.56	NUM
dpc-5845	175	17	%	%	NOUN
dpc-5845	175	18	(	(	PUNCT
dpc-5845	175	19	0.64	0.64	NUM
dpc-5845	175	20	%	%	NOUN
dpc-5845	175	21	compared	compare	VERB
dpc-5845	175	22	to	to	ADP
dpc-5845	175	23	the	the	DET
dpc-5845	175	24	total	total	NOUN
dpc-5845	175	25	of	of	ADP
dpc-5845	175	26	dr	dr	PROPN
dpc-5845	175	27	)	)	PUNCT
dpc-5845	175	28	requiring	require	VERB
dpc-5845	175	29	a	a	DET
dpc-5845	175	30	therapy	therapy	NOUN
dpc-5845	175	31	switch	switch	NOUN
dpc-5845	175	32	,	,	PUNCT
dpc-5845	175	33	indicating	indicate	VERB
dpc-5845	175	34	that	that	SCONJ
dpc-5845	175	35	dr	dr	PROPN
dpc-5845	175	36	is	be	AUX
dpc-5845	175	37	both	both	CCONJ
dpc-5845	175	38	a	a	DET
dpc-5845	175	39	reversible	reversible	ADJ
dpc-5845	175	40	and	and	CCONJ
dpc-5845	175	41	manageable	manageable	ADJ
dpc-5845	175	42	strategy	strategy	NOUN
dpc-5845	175	43	.	.	PUNCT
dpc-5845	176	1	however	however	ADV
dpc-5845	176	2	,	,	PUNCT
dpc-5845	176	3	interval	interval	NOUN
dpc-5845	176	4	prolongation	prolongation	NOUN
dpc-5845	176	5	might	might	AUX
dpc-5845	176	6	increase	increase	VERB
dpc-5845	176	7	the	the	DET
dpc-5845	176	8	production	production	NOUN
dpc-5845	176	9	of	of	ADP
dpc-5845	176	10	anti	anti	ADJ
dpc-5845	176	11	-	-	ADJ
dpc-5845	176	12	drug	drug	ADJ
dpc-5845	176	13	antibodies	antibody	NOUN
dpc-5845	176	14	(	(	PUNCT
dpc-5845	176	15	ada	ada	NOUN
dpc-5845	176	16	)	)	PUNCT
dpc-5845	176	17	,	,	PUNCT
dpc-5845	176	18	thus	thus	ADV
dpc-5845	176	19	reducing	reduce	VERB
dpc-5845	176	20	the	the	DET
dpc-5845	176	21	drug	drug	NOUN
dpc-5845	176	22	’s	’s	PART
dpc-5845	176	23	effectiveness	effectiveness	NOUN
dpc-5845	176	24	[	[	X
dpc-5845	176	25	5	5	NUM
dpc-5845	176	26	]	]	PUNCT
dpc-5845	176	27	.	.	PUNCT
dpc-5845	177	1	moreover	moreover	ADV
dpc-5845	177	2	,	,	PUNCT
dpc-5845	177	3	excessive	excessive	ADJ
dpc-5845	177	4	prolongation	prolongation	NOUN
dpc-5845	177	5	between	between	ADP
dpc-5845	177	6	administrations	administration	NOUN
dpc-5845	177	7	,	,	PUNCT
dpc-5845	177	8	e.g.	e.g.	ADV
dpc-5845	177	9	,	,	PUNCT
dpc-5845	177	10	doubling	double	VERB
dpc-5845	177	11	the	the	DET
dpc-5845	177	12	therapeutic	therapeutic	ADJ
dpc-5845	177	13	window	window	NOUN
dpc-5845	177	14	,	,	PUNCT
dpc-5845	177	15	could	could	AUX
dpc-5845	177	16	likely	likely	ADV
dpc-5845	177	17	lead	lead	VERB
dpc-5845	177	18	to	to	ADP
dpc-5845	177	19	a	a	DET
dpc-5845	177	20	significant	significant	ADJ
dpc-5845	177	21	reduction	reduction	NOUN
dpc-5845	177	22	in	in	ADP
dpc-5845	177	23	therapeutic	therapeutic	ADJ
dpc-5845	177	24	response	response	NOUN
dpc-5845	177	25	,	,	PUNCT
dpc-5845	177	26	as	as	SCONJ
dpc-5845	177	27	already	already	ADV
dpc-5845	177	28	highlighted	highlight	VERB
dpc-5845	177	29	in	in	ADP
dpc-5845	177	30	the	the	DET
dpc-5845	177	31	study	study	NOUN
dpc-5845	177	32	conducted	conduct	VERB
dpc-5845	177	33	by	by	ADP
dpc-5845	177	34	blauvelt	blauvelt	PROPN
dpc-5845	177	35	et	et	PROPN
dpc-5845	177	36	al	al	PROPN
dpc-5845	177	37	.	.	PUNCT
dpc-5845	178	1	[	[	X
dpc-5845	178	2	20	20	NUM
dpc-5845	178	3	]	]	PUNCT
dpc-5845	178	4	.	.	PUNCT
dpc-5845	179	1	hence	hence	ADV
dpc-5845	179	2	,	,	PUNCT
dpc-5845	179	3	careful	careful	ADJ
dpc-5845	179	4	patient	patient	NOUN
dpc-5845	179	5	selection	selection	NOUN
dpc-5845	179	6	is	be	AUX
dpc-5845	179	7	essential	essential	ADJ
dpc-5845	179	8	to	to	ADP
dpc-5845	179	9	optimizing	optimize	VERB
dpc-5845	179	10	outcomes	outcome	NOUN
dpc-5845	179	11	.	.	PUNCT
dpc-5845	180	1	factors	factor	NOUN
dpc-5845	180	2	such	such	ADJ
dpc-5845	180	3	as	as	ADP
dpc-5845	180	4	biologic	biologic	ADJ
dpc-5845	180	5	treatment	treatment	NOUN
dpc-5845	180	6	history	history	NOUN
dpc-5845	180	7	,	,	PUNCT
dpc-5845	180	8	speed	speed	NOUN
dpc-5845	180	9	of	of	ADP
dpc-5845	180	10	response	response	NOUN
dpc-5845	180	11	to	to	ADP
dpc-5845	180	12	treatment	treatment	NOUN
dpc-5845	180	13	,	,	PUNCT
dpc-5845	180	14	disease	disease	NOUN
dpc-5845	180	15	duration	duration	NOUN
dpc-5845	180	16	,	,	PUNCT
dpc-5845	180	17	baseline	baseline	ADJ
dpc-5845	180	18	pasi	pasi	PROPN
dpc-5845	180	19	/	/	SYM
dpc-5845	180	20	dlqi	dlqi	ADJ
dpc-5845	180	21	scores	score	NOUN
dpc-5845	180	22	,	,	PUNCT
dpc-5845	180	23	bmi	bmi	NOUN
dpc-5845	180	24	,	,	PUNCT
dpc-5845	180	25	or	or	CCONJ
dpc-5845	180	26	type	type	NOUN
dpc-5845	180	27	of	of	ADP
dpc-5845	180	28	biologic	biologic	NOUN
dpc-5845	180	29	agent	agent	NOUN
dpc-5845	180	30	used	use	VERB
dpc-5845	180	31	should	should	AUX
dpc-5845	180	32	be	be	AUX
dpc-5845	180	33	considered	consider	VERB
dpc-5845	180	34	prior	prior	ADV
dpc-5845	180	35	to	to	ADP
dpc-5845	180	36	initiating	initiate	VERB
dpc-5845	180	37	dr	dr	PROPN
dpc-5845	180	38	.	.	PROPN
dpc-5845	180	39	further	further	PROPN
dpc-5845	180	40	studies	study	NOUN
dpc-5845	180	41	are	be	AUX
dpc-5845	180	42	needed	need	VERB
dpc-5845	180	43	to	to	PART
dpc-5845	180	44	identify	identify	VERB
dpc-5845	180	45	potential	potential	ADJ
dpc-5845	180	46	predictive	predictive	ADJ
dpc-5845	180	47	markers	marker	NOUN
dpc-5845	180	48	that	that	PRON
dpc-5845	180	49	can	can	AUX
dpc-5845	180	50	more	more	ADV
dpc-5845	180	51	accurately	accurately	ADV
dpc-5845	180	52	forecast	forecast	VERB
dpc-5845	180	53	successful	successful	ADJ
dpc-5845	180	54	outcomes	outcome	NOUN
dpc-5845	180	55	.	.	PUNCT
dpc-5845	181	1	the	the	DET
dpc-5845	181	2	primary	primary	ADJ
dpc-5845	181	3	clinical	clinical	ADJ
dpc-5845	181	4	implication	implication	NOUN
dpc-5845	181	5	of	of	ADP
dpc-5845	181	6	our	our	PRON
dpc-5845	181	7	study	study	NOUN
dpc-5845	181	8	is	be	AUX
dpc-5845	181	9	represented	represent	VERB
dpc-5845	181	10	by	by	ADP
dpc-5845	181	11	the	the	DET
dpc-5845	181	12	potential	potential	ADJ
dpc-5845	181	13	benefits	benefit	NOUN
dpc-5845	181	14	of	of	ADP
dpc-5845	181	15	dr	dr	PROPN
dpc-5845	181	16	in	in	ADP
dpc-5845	181	17	reducing	reduce	VERB
dpc-5845	181	18	the	the	DET
dpc-5845	181	19	economic	economic	ADJ
dpc-5845	181	20	burden	burden	NOUN
dpc-5845	181	21	on	on	ADP
dpc-5845	181	22	healthcare	healthcare	NOUN
dpc-5845	181	23	systems	system	NOUN
dpc-5845	181	24	without	without	ADP
dpc-5845	181	25	compromising	compromise	VERB
dpc-5845	181	26	treatment	treatment	NOUN
dpc-5845	181	27	efficacy	efficacy	NOUN
dpc-5845	181	28	.	.	PUNCT
dpc-5845	182	1	in	in	ADP
dpc-5845	182	2	fact	fact	NOUN
dpc-5845	182	3	,	,	PUNCT
dpc-5845	182	4	dr	dr	PROPN
dpc-5845	182	5	could	could	AUX
dpc-5845	182	6	lead	lead	VERB
dpc-5845	182	7	to	to	ADP
dpc-5845	182	8	more	more	ADV
dpc-5845	182	9	sustainable	sustainable	ADJ
dpc-5845	182	10	long	long	ADJ
dpc-5845	182	11	-	-	PUNCT
dpc-5845	182	12	term	term	NOUN
dpc-5845	182	13	management	management	NOUN
dpc-5845	182	14	of	of	ADP
dpc-5845	182	15	psoriasis	psoriasis	NOUN
dpc-5845	182	16	,	,	PUNCT
dpc-5845	182	17	especially	especially	ADV
dpc-5845	182	18	in	in	ADP
dpc-5845	182	19	healthcare	healthcare	NOUN
dpc-5845	182	20	settings	setting	NOUN
dpc-5845	182	21	with	with	ADP
dpc-5845	182	22	limited	limited	ADJ
dpc-5845	182	23	resources	resource	NOUN
dpc-5845	182	24	,	,	PUNCT
dpc-5845	182	25	and	and	CCONJ
dpc-5845	182	26	aligns	align	VERB
dpc-5845	182	27	with	with	ADP
dpc-5845	182	28	the	the	DET
dpc-5845	182	29	principles	principle	NOUN
dpc-5845	182	30	of	of	ADP
dpc-5845	182	31	personalized	personalized	ADJ
dpc-5845	182	32	medicine	medicine	NOUN
dpc-5845	182	33	.	.	PUNCT
dpc-5845	183	1	the	the	DET
dpc-5845	183	2	future	future	NOUN
dpc-5845	183	3	of	of	ADP
dpc-5845	183	4	biologic	biologic	NOUN
dpc-5845	183	5	treatments	treatment	NOUN
dpc-5845	183	6	for	for	ADP
dpc-5845	183	7	psoriasis	psoriasis	NOUN
dpc-5845	183	8	is	be	AUX
dpc-5845	183	9	promising	promise	VERB
dpc-5845	183	10	in	in	ADP
dpc-5845	183	11	this	this	DET
dpc-5845	183	12	regard	regard	NOUN
dpc-5845	183	13	.	.	PUNCT
dpc-5845	184	1	continuous	continuous	ADJ
dpc-5845	184	2	therapy	therapy	NOUN
dpc-5845	184	3	with	with	ADP
dpc-5845	184	4	the	the	DET
dpc-5845	184	5	minimal	minimal	ADJ
dpc-5845	184	6	effective	effective	ADJ
dpc-5845	184	7	dose	dose	NOUN
dpc-5845	184	8	,	,	PUNCT
dpc-5845	184	9	based	base	VERB
dpc-5845	184	10	on	on	ADP
dpc-5845	184	11	the	the	DET
dpc-5845	184	12	clinical	clinical	ADJ
dpc-5845	184	13	situation	situation	NOUN
dpc-5845	184	14	,	,	PUNCT
dpc-5845	184	15	has	have	AUX
dpc-5845	184	16	been	be	AUX
dpc-5845	184	17	considered	consider	VERB
dpc-5845	184	18	for	for	ADP
dpc-5845	184	19	other	other	ADJ
dpc-5845	184	20	psoriasis	psoriasis	NOUN
dpc-5845	184	21	treatments	treatment	NOUN
dpc-5845	184	22	,	,	PUNCT
dpc-5845	184	23	such	such	ADJ
dpc-5845	184	24	as	as	ADP
dpc-5845	184	25	cyclosporin	cyclosporin	NOUN
dpc-5845	184	26	and	and	CCONJ
dpc-5845	184	27	acitretin	acitretin	NOUN
dpc-5845	184	28	,	,	PUNCT
dpc-5845	184	29	and	and	CCONJ
dpc-5845	184	30	could	could	AUX
dpc-5845	184	31	represent	represent	VERB
dpc-5845	184	32	the	the	DET
dpc-5845	184	33	future	future	NOUN
dpc-5845	184	34	of	of	ADP
dpc-5845	184	35	biologic	biologic	ADJ
dpc-5845	184	36	treatment	treatment	NOUN
dpc-5845	184	37	[	[	X
dpc-5845	184	38	21	21	NUM
dpc-5845	184	39	]	]	PUNCT
dpc-5845	184	40	.	.	PUNCT
dpc-5845	185	1	to	to	PART
dpc-5845	185	2	optimize	optimize	VERB
dpc-5845	185	3	drug	drug	NOUN
dpc-5845	185	4	efficacy	efficacy	NOUN
dpc-5845	185	5	and	and	CCONJ
dpc-5845	185	6	minimize	minimize	VERB
dpc-5845	185	7	toxicity	toxicity	NOUN
dpc-5845	185	8	,	,	PUNCT
dpc-5845	185	9	measuring	measure	VERB
dpc-5845	185	10	drug	drug	NOUN
dpc-5845	185	11	concentrations	concentration	NOUN
dpc-5845	185	12	in	in	ADP
dpc-5845	185	13	a	a	DET
dpc-5845	185	14	patient	patient	NOUN
dpc-5845	185	15	’s	’s	PART
dpc-5845	185	16	blood	blood	NOUN
dpc-5845	185	17	could	could	AUX
dpc-5845	185	18	be	be	AUX
dpc-5845	185	19	a	a	DET
dpc-5845	185	20	possibility	possibility	NOUN
dpc-5845	185	21	.	.	PUNCT
dpc-5845	186	1	therapeutic	therapeutic	ADJ
dpc-5845	186	2	drug	drug	NOUN
dpc-5845	186	3	monitoring	monitoring	NOUN
dpc-5845	186	4	(	(	PUNCT
dpc-5845	186	5	tdm	tdm	NOUN
dpc-5845	186	6	)	)	PUNCT
dpc-5845	186	7	is	be	AUX
dpc-5845	186	8	a	a	DET
dpc-5845	186	9	clinical	clinical	ADJ
dpc-5845	186	10	practice	practice	NOUN
dpc-5845	186	11	that	that	PRON
dpc-5845	186	12	helps	help	VERB
dpc-5845	186	13	achieve	achieve	VERB
dpc-5845	186	14	this	this	DET
dpc-5845	186	15	goal	goal	NOUN
dpc-5845	186	16	by	by	ADP
dpc-5845	186	17	ensuring	ensure	VERB
dpc-5845	186	18	appropriate	appropriate	ADJ
dpc-5845	186	19	dosing	dosing	NOUN
dpc-5845	186	20	based	base	VERB
dpc-5845	186	21	on	on	ADP
dpc-5845	186	22	individual	individual	ADJ
dpc-5845	186	23	pharmacokinetics	pharmacokinetic	NOUN
dpc-5845	186	24	.	.	PUNCT
dpc-5845	187	1	particularly	particularly	ADV
dpc-5845	187	2	valuable	valuable	ADJ
dpc-5845	187	3	for	for	ADP
dpc-5845	187	4	medications	medication	NOUN
dpc-5845	187	5	with	with	ADP
dpc-5845	187	6	a	a	DET
dpc-5845	187	7	narrow	narrow	ADJ
dpc-5845	187	8	therapeutic	therapeutic	ADJ
dpc-5845	187	9	index	index	NOUN
dpc-5845	187	10	,	,	PUNCT
dpc-5845	187	11	tdm	tdm	NOUN
dpc-5845	187	12	could	could	AUX
dpc-5845	187	13	also	also	ADV
dpc-5845	187	14	guide	guide	VERB
dpc-5845	187	15	personalized	personalized	ADJ
dpc-5845	187	16	treatment	treatment	NOUN
dpc-5845	187	17	decisions	decision	NOUN
dpc-5845	187	18	in	in	ADP
dpc-5845	187	19	biologic	biologic	ADJ
dpc-5845	187	20	treatment	treatment	NOUN
dpc-5845	187	21	,	,	PUNCT
dpc-5845	187	22	enhancing	enhance	VERB
dpc-5845	187	23	patient	patient	ADJ
dpc-5845	187	24	safety	safety	NOUN
dpc-5845	187	25	and	and	CCONJ
dpc-5845	187	26	therapeutic	therapeutic	ADJ
dpc-5845	187	27	outcomes	outcome	NOUN
dpc-5845	187	28	.	.	PUNCT
dpc-5845	188	1	nevertheless	nevertheless	ADV
dpc-5845	188	2	,	,	PUNCT
dpc-5845	188	3	our	our	PRON
dpc-5845	188	4	study	study	NOUN
dpc-5845	188	5	suffers	suffer	VERB
dpc-5845	188	6	from	from	ADP
dpc-5845	188	7	several	several	ADJ
dpc-5845	188	8	limitations	limitation	NOUN
dpc-5845	188	9	.	.	PUNCT
dpc-5845	189	1	the	the	DET
dpc-5845	189	2	data	datum	NOUN
dpc-5845	189	3	are	be	AUX
dpc-5845	189	4	preliminary	preliminary	ADJ
dpc-5845	189	5	,	,	PUNCT
dpc-5845	189	6	the	the	DET
dpc-5845	189	7	sample	sample	NOUN
dpc-5845	189	8	size	size	NOUN
dpc-5845	189	9	is	be	AUX
dpc-5845	189	10	relatively	relatively	ADV
dpc-5845	189	11	small	small	ADJ
dpc-5845	189	12	,	,	PUNCT
dpc-5845	189	13	and	and	CCONJ
dpc-5845	189	14	the	the	DET
dpc-5845	189	15	observational	observational	ADJ
dpc-5845	189	16	design	design	NOUN
dpc-5845	189	17	introduces	introduce	VERB
dpc-5845	189	18	potential	potential	ADJ
dpc-5845	189	19	biases	bias	NOUN
dpc-5845	189	20	,	,	PUNCT
dpc-5845	189	21	including	include	VERB
dpc-5845	189	22	selection	selection	NOUN
dpc-5845	189	23	bias	bias	NOUN
dpc-5845	189	24	from	from	ADP
dpc-5845	189	25	the	the	DET
dpc-5845	189	26	inclusion	inclusion	NOUN
dpc-5845	189	27	criteria	criterion	NOUN
dpc-5845	189	28	and	and	CCONJ
dpc-5845	189	29	a	a	DET
dpc-5845	189	30	lack	lack	NOUN
dpc-5845	189	31	of	of	ADP
dpc-5845	189	32	randomization	randomization	NOUN
dpc-5845	189	33	.	.	PUNCT
dpc-5845	190	1	these	these	DET
dpc-5845	190	2	factors	factor	NOUN
dpc-5845	190	3	limit	limit	VERB
dpc-5845	190	4	the	the	DET
dpc-5845	190	5	generalizability	generalizability	NOUN
dpc-5845	190	6	of	of	ADP
dpc-5845	190	7	8	8	NUM
dpc-5845	190	8	original	original	ADJ
dpc-5845	190	9	article	article	NOUN
dpc-5845	190	10	|	|	ADV
dpc-5845	190	11	dermatol	dermatol	ADJ
dpc-5845	190	12	pract	pract	NOUN
dpc-5845	190	13	concept	concept	NOUN
dpc-5845	190	14	.	.	PUNCT
dpc-5845	191	1	2025;15(3):5845	2025;15(3):5845	NUM
dpc-5845	191	2	single	single	ADJ
dpc-5845	191	3	-	-	PUNCT
dpc-5845	191	4	rising	rise	VERB
dpc-5845	191	5	-	-	PUNCT
dpc-5845	191	6	dose	dose	NOUN
dpc-5845	191	7	,	,	PUNCT
dpc-5845	191	8	randomized	randomize	VERB
dpc-5845	191	9	,	,	PUNCT
dpc-5845	191	10	doubleblind	doubleblind	NOUN
dpc-5845	191	11	,	,	PUNCT
dpc-5845	191	12	placebo	placebo	NOUN
dpc-5845	191	13	-	-	PUNCT
dpc-5845	191	14	controlled	control	VERB
dpc-5845	191	15	trial	trial	NOUN
dpc-5845	191	16	.	.	PUNCT
dpc-5845	192	1	j	j	PROPN
dpc-5845	192	2	allergy	allergy	PROPN
dpc-5845	192	3	clin	clin	PROPN
dpc-5845	192	4	immunol	immunol	PROPN
dpc-5845	192	5	2015	2015	NUM
dpc-5845	192	6	;	;	PUNCT
dpc-5845	192	7	136	136	NUM
dpc-5845	192	8	:	:	SYM
dpc-5845	192	9	116	116	NUM
dpc-5845	192	10	–	–	PUNCT
dpc-5845	192	11	24.e7	24.e7	NUM
dpc-5845	192	12	15	15	NUM
dpc-5845	192	13	.	.	PUNCT
dpc-5845	192	14	papp	papp	PROPN
dpc-5845	192	15	k	k	PROPN
dpc-5845	192	16	,	,	PUNCT
dpc-5845	192	17	leonardi	leonardi	PROPN
dpc-5845	192	18	c	c	PROPN
dpc-5845	192	19	,	,	PUNCT
dpc-5845	192	20	menter	menter	X
dpc-5845	192	21	a	a	X
dpc-5845	192	22	,	,	PUNCT
dpc-5845	192	23	et	et	PROPN
dpc-5845	192	24	al	al	PROPN
dpc-5845	192	25	.	.	PROPN
dpc-5845	192	26	safety	safety	NOUN
dpc-5845	192	27	and	and	CCONJ
dpc-5845	192	28	efficacy	efficacy	NOUN
dpc-5845	192	29	of	of	ADP
dpc-5845	192	30	brodalumab	brodalumab	NOUN
dpc-5845	192	31	for	for	ADP
dpc-5845	192	32	psoriasis	psoriasis	NOUN
dpc-5845	192	33	after	after	ADP
dpc-5845	192	34	120	120	NUM
dpc-5845	192	35	weeks	week	NOUN
dpc-5845	192	36	of	of	ADP
dpc-5845	192	37	treatment	treatment	NOUN
dpc-5845	192	38	.	.	PUNCT
dpc-5845	193	1	j	j	PROPN
dpc-5845	193	2	am	be	AUX
dpc-5845	193	3	acad	acad	ADJ
dpc-5845	193	4	dermatol	dermatol	NOUN
dpc-5845	193	5	.	.	PUNCT
dpc-5845	194	1	2014	2014	NUM
dpc-5845	195	1	dec;71(6):1183	dec;71(6):1183	ADJ
dpc-5845	195	2	-	-	PUNCT
dpc-5845	195	3	1190.e3	1190.e3	PROPN
dpc-5845	195	4	.	.	PUNCT
dpc-5845	196	1	doi	doi	NOUN
dpc-5845	196	2	:	:	PUNCT
dpc-5845	196	3	10.1016	10.1016	NUM
dpc-5845	196	4	/j.jaad.2014.08.039	/j.jaad.2014.08.039	PUNCT
dpc-5845	196	5	.	.	PUNCT
dpc-5845	197	1	epub	epub	PROPN
dpc-5845	197	2	2014	2014	NUM
dpc-5845	197	3	oct	oct	NOUN
dpc-5845	197	4	11	11	NUM
dpc-5845	197	5	.	.	PUNCT
dpc-5845	198	1	pmid	pmid	NOUN
dpc-5845	198	2	:	:	PUNCT
dpc-5845	198	3	25313095	25313095	NUM
dpc-5845	198	4	.	.	PUNCT
dpc-5845	199	1	16	16	NUM
dpc-5845	199	2	.	.	PUNCT
dpc-5845	200	1	armstrong	armstrong	PROPN
dpc-5845	200	2	aw	aw	PROPN
dpc-5845	200	3	,	,	PUNCT
dpc-5845	200	4	robertson	robertson	PROPN
dpc-5845	200	5	ad	ad	NOUN
dpc-5845	200	6	,	,	PUNCT
dpc-5845	200	7	wu	wu	PROPN
dpc-5845	200	8	j	j	PROPN
dpc-5845	200	9	,	,	PUNCT
dpc-5845	200	10	schupp	schupp	PROPN
dpc-5845	200	11	c	c	PROPN
dpc-5845	200	12	,	,	PUNCT
dpc-5845	200	13	lebwohl	lebwohl	VERB
dpc-5845	200	14	mg	mg	PROPN
dpc-5845	200	15	.	.	PUNCT
dpc-5845	200	16	undertreatment	undertreatment	ADJ
dpc-5845	200	17	,	,	PUNCT
dpc-5845	200	18	treatment	treatment	NOUN
dpc-5845	200	19	trends	trend	NOUN
dpc-5845	200	20	,	,	PUNCT
dpc-5845	200	21	and	and	CCONJ
dpc-5845	200	22	treatment	treatment	NOUN
dpc-5845	200	23	dissatisfaction	dissatisfaction	NOUN
dpc-5845	200	24	among	among	ADP
dpc-5845	200	25	patients	patient	NOUN
dpc-5845	200	26	with	with	ADP
dpc-5845	200	27	psoriasis	psoriasis	NOUN
dpc-5845	200	28	and	and	CCONJ
dpc-5845	200	29	psoriatic	psoriatic	ADJ
dpc-5845	200	30	arthritis	arthritis	NOUN
dpc-5845	200	31	in	in	ADP
dpc-5845	200	32	the	the	DET
dpc-5845	200	33	united	united	PROPN
dpc-5845	200	34	states	states	PROPN
dpc-5845	200	35	:	:	PUNCT
dpc-5845	200	36	findings	finding	NOUN
dpc-5845	200	37	from	from	ADP
dpc-5845	200	38	the	the	DET
dpc-5845	200	39	national	national	ADJ
dpc-5845	200	40	psoriasis	psoriasis	NOUN
dpc-5845	200	41	foundation	foundation	NOUN
dpc-5845	200	42	surveys	survey	NOUN
dpc-5845	200	43	,	,	PUNCT
dpc-5845	200	44	2003	2003	NUM
dpc-5845	200	45	-	-	SYM
dpc-5845	200	46	2011	2011	NUM
dpc-5845	200	47	.	.	PUNCT
dpc-5845	201	1	jama	jama	PROPN
dpc-5845	201	2	dermatol	dermatol	NOUN
dpc-5845	201	3	.	.	PUNCT
dpc-5845	202	1	2013	2013	NUM
dpc-5845	202	2	oct;149(10	oct;149(10	NOUN
dpc-5845	202	3	):	):	PUNCT
dpc-5845	202	4	1180	1180	NUM
dpc-5845	202	5	-	-	SYM
dpc-5845	202	6	5	5	NUM
dpc-5845	202	7	.	.	PUNCT
dpc-5845	202	8	doi	doi	NOUN
dpc-5845	202	9	:	:	PUNCT
dpc-5845	202	10	10.1001	10.1001	NUM
dpc-5845	202	11	/	/	SYM
dpc-5845	202	12	jamadermatol.2013.5264	jamadermatol.2013.5264	NOUN
dpc-5845	202	13	.	.	PUNCT
dpc-5845	203	1	erratum	erratum	PROPN
dpc-5845	203	2	in	in	ADP
dpc-5845	203	3	:	:	PUNCT
dpc-5845	203	4	jama	jama	X
dpc-5845	203	5	dermatol	dermatol	NOUN
dpc-5845	203	6	.	.	PUNCT
dpc-5845	203	7	2014	2014	NUM
dpc-5845	203	8	jan;150(1):103	jan;150(1):103	X
dpc-5845	203	9	.	.	PUNCT
dpc-5845	204	1	erratum	erratum	PROPN
dpc-5845	204	2	in	in	ADP
dpc-5845	204	3	:	:	PUNCT
dpc-5845	204	4	jama	jama	X
dpc-5845	204	5	dermatol	dermatol	NOUN
dpc-5845	204	6	.	.	PUNCT
dpc-5845	205	1	2014	2014	NUM
dpc-5845	205	2	mar;150(3):337	mar;150(3):337	NOUN
dpc-5845	205	3	.	.	PUNCT
dpc-5845	206	1	pmid	pmid	NOUN
dpc-5845	206	2	:	:	PUNCT
dpc-5845	206	3	23945732	23945732	NUM
dpc-5845	206	4	.	.	PUNCT
dpc-5845	207	1	17	17	NUM
dpc-5845	207	2	.	.	PUNCT
dpc-5845	208	1	veronese	veronese	PROPN
dpc-5845	208	2	f	f	PROPN
dpc-5845	208	3	,	,	PUNCT
dpc-5845	208	4	graziola	graziola	PROPN
dpc-5845	208	5	f	f	PROPN
dpc-5845	208	6	,	,	PUNCT
dpc-5845	208	7	cammarata	cammarata	NOUN
dpc-5845	208	8	e	e	NOUN
dpc-5845	208	9	,	,	PUNCT
dpc-5845	208	10	et	et	PROPN
dpc-5845	208	11	al	al	PROPN
dpc-5845	208	12	.	.	PUNCT
dpc-5845	209	1	the	the	DET
dpc-5845	209	2	diagnostic	diagnostic	ADJ
dpc-5845	209	3	therapeutic	therapeutic	ADJ
dpc-5845	209	4	care	care	NOUN
dpc-5845	209	5	pathway	pathway	NOUN
dpc-5845	209	6	in	in	ADP
dpc-5845	209	7	psoriasis	psoriasis	NOUN
dpc-5845	209	8	:	:	PUNCT
dpc-5845	209	9	towards	towards	ADP
dpc-5845	209	10	iso	iso	PROPN
dpc-5845	209	11	9001:2015	9001:2015	PROPN
dpc-5845	209	12	certification	certification	NOUN
dpc-5845	209	13	.	.	PUNCT
dpc-5845	210	1	medicina	medicina	PROPN
dpc-5845	210	2	(	(	PUNCT
dpc-5845	210	3	kaunas	kaunas	PROPN
dpc-5845	210	4	)	)	PUNCT
dpc-5845	210	5	.	.	PUNCT
dpc-5845	211	1	2020	2020	NUM
dpc-5845	211	2	may	may	AUX
dpc-5845	211	3	22;56(5):253	22;56(5):253	NUM
dpc-5845	211	4	.	.	PUNCT
dpc-5845	212	1	doi	doi	NOUN
dpc-5845	212	2	:	:	PUNCT
dpc-5845	212	3	10.3390	10.3390	NUM
dpc-5845	212	4	/	/	SYM
dpc-5845	212	5	medicina56050253	medicina56050253	PROPN
dpc-5845	212	6	.	.	PUNCT
dpc-5845	213	1	pmid	pmid	NOUN
dpc-5845	213	2	:	:	PUNCT
dpc-5845	213	3	32455972	32455972	NUM
dpc-5845	213	4	;	;	PUNCT
dpc-5845	213	5	pmcid	pmcid	ADJ
dpc-5845	213	6	:	:	PUNCT
dpc-5845	213	7	pmc7279378	pmc7279378	NOUN
dpc-5845	213	8	.	.	PUNCT
dpc-5845	214	1	18	18	NUM
dpc-5845	214	2	.	.	PUNCT
dpc-5845	214	3	baniandrés	baniandrés	PROPN
dpc-5845	214	4	o	o	PROPN
dpc-5845	214	5	,	,	PUNCT
dpc-5845	214	6	rodríguez	rodríguez	PROPN
dpc-5845	214	7	-	-	PUNCT
dpc-5845	214	8	soria	soria	PROPN
dpc-5845	214	9	vj	vj	PROPN
dpc-5845	214	10	,	,	PUNCT
dpc-5845	214	11	romero	romero	PROPN
dpc-5845	214	12	-	-	PUNCT
dpc-5845	214	13	jiménez	jiménez	PROPN
dpc-5845	214	14	rm	rm	PROPN
dpc-5845	214	15	,	,	PUNCT
dpc-5845	214	16	suárez	suárez	PROPN
dpc-5845	214	17	r.	r.	PROPN
dpc-5845	214	18	dose	dose	PROPN
dpc-5845	214	19	modification	modification	NOUN
dpc-5845	214	20	in	in	ADP
dpc-5845	214	21	biologic	biologic	NOUN
dpc-5845	214	22	therapy	therapy	NOUN
dpc-5845	214	23	for	for	ADP
dpc-5845	214	24	moderate	moderate	ADJ
dpc-5845	214	25	to	to	ADP
dpc-5845	214	26	severe	severe	ADJ
dpc-5845	214	27	psoriasis	psoriasis	NOUN
dpc-5845	214	28	:	:	PUNCT
dpc-5845	214	29	a	a	DET
dpc-5845	214	30	descriptive	descriptive	ADJ
dpc-5845	214	31	analysis	analysis	NOUN
dpc-5845	214	32	in	in	ADP
dpc-5845	214	33	a	a	DET
dpc-5845	214	34	clinical	clinical	ADJ
dpc-5845	214	35	practice	practice	NOUN
dpc-5845	214	36	setting	setting	NOUN
dpc-5845	214	37	.	.	PUNCT
dpc-5845	215	1	actas	actas	PROPN
dpc-5845	215	2	dermosifiliogr	dermosifiliogr	NOUN
dpc-5845	215	3	.	.	PUNCT
dpc-5845	216	1	2015	2015	NUM
dpc-5845	216	2	sep;106(7):569	sep;106(7):569	NOUN
dpc-5845	216	3	-	-	PUNCT
dpc-5845	216	4	77	77	NUM
dpc-5845	216	5	.	.	PUNCT
dpc-5845	217	1	english	english	PROPN
dpc-5845	217	2	,	,	PUNCT
dpc-5845	217	3	spanish	spanish	PROPN
dpc-5845	217	4	.	.	PUNCT
dpc-5845	218	1	doi	doi	NOUN
dpc-5845	218	2	:	:	PUNCT
dpc-5845	218	3	10.1016	10.1016	NUM
dpc-5845	218	4	/	/	SYM
dpc-5845	218	5	j.ad.2015.02.003	j.ad.2015.02.003	PROPN
dpc-5845	218	6	.	.	PROPN
dpc-5845	218	7	epub	epub	PROPN
dpc-5845	218	8	2015	2015	NUM
dpc-5845	218	9	apr	apr	NOUN
dpc-5845	218	10	30	30	NUM
dpc-5845	218	11	.	.	PUNCT
dpc-5845	219	1	pmid	pmid	NOUN
dpc-5845	219	2	:	:	PUNCT
dpc-5845	219	3	25935194	25935194	NUM
dpc-5845	219	4	.	.	PUNCT
dpc-5845	220	1	19	19	NUM
dpc-5845	220	2	.	.	PUNCT
dpc-5845	221	1	thomas	thomas	PROPN
dpc-5845	221	2	se	se	PROPN
dpc-5845	221	3	,	,	PUNCT
dpc-5845	221	4	barenbrug	barenbrug	PROPN
dpc-5845	221	5	l	l	PROPN
dpc-5845	221	6	,	,	PUNCT
dpc-5845	221	7	hannink	hannink	VERB
dpc-5845	221	8	g	g	NOUN
dpc-5845	221	9	,	,	PUNCT
dpc-5845	221	10	et	et	PROPN
dpc-5845	221	11	al	al	PROPN
dpc-5845	221	12	.	.	PROPN
dpc-5845	221	13	drug	drug	PROPN
dpc-5845	221	14	survival	survival	NOUN
dpc-5845	221	15	of	of	ADP
dpc-5845	221	16	il-17	il-17	NUM
dpc-5845	221	17	and	and	CCONJ
dpc-5845	221	18	il-23	il-23	VERB
dpc-5845	221	19	inhibitors	inhibitor	NOUN
dpc-5845	221	20	for	for	ADP
dpc-5845	221	21	psoriasis	psoriasis	NOUN
dpc-5845	221	22	:	:	PUNCT
dpc-5845	221	23	a	a	DET
dpc-5845	221	24	systematic	systematic	ADJ
dpc-5845	221	25	review	review	NOUN
dpc-5845	221	26	and	and	CCONJ
dpc-5845	221	27	meta	meta	ADJ
dpc-5845	221	28	-	-	PUNCT
dpc-5845	221	29	analysis	analysis	NOUN
dpc-5845	221	30	.	.	PUNCT
dpc-5845	222	1	drugs	drug	NOUN
dpc-5845	222	2	.	.	PUNCT
dpc-5845	223	1	2024	2024	NUM
dpc-5845	223	2	may;84(5):565	may;84(5):565	PROPN
dpc-5845	223	3	-	-	PUNCT
dpc-5845	223	4	578	578	NUM
dpc-5845	223	5	.	.	PUNCT
dpc-5845	224	1	doi	doi	NOUN
dpc-5845	224	2	:	:	PUNCT
dpc-5845	224	3	10.1007	10.1007	NUM
dpc-5845	224	4	/s40265	/s40265	NOUN
dpc-5845	224	5	-	-	PUNCT
dpc-5845	224	6	024	024	NUM
dpc-5845	224	7	-	-	PUNCT
dpc-5845	224	8	02028	02028	NUM
dpc-5845	224	9	-	-	SYM
dpc-5845	224	10	1	1	NUM
dpc-5845	224	11	.	.	PUNCT
dpc-5845	225	1	epub	epub	NOUN
dpc-5845	225	2	2024	2024	NUM
dpc-5845	225	3	apr	apr	NOUN
dpc-5845	225	4	17	17	NUM
dpc-5845	225	5	.	.	PUNCT
dpc-5845	226	1	pmid	pmid	NOUN
dpc-5845	226	2	:	:	PUNCT
dpc-5845	226	3	38630365	38630365	NUM
dpc-5845	226	4	;	;	PUNCT
dpc-5845	226	5	pmcid	pmcid	ADJ
dpc-5845	226	6	:	:	PUNCT
dpc-5845	226	7	pmc11190018	pmc11190018	NOUN
dpc-5845	226	8	.	.	PUNCT
dpc-5845	227	1	20	20	NUM
dpc-5845	227	2	.	.	X
dpc-5845	227	3	blauvelt	blauvelt	VERB
dpc-5845	227	4	a	a	PRON
dpc-5845	227	5	,	,	PUNCT
dpc-5845	227	6	ferris	ferris	PROPN
dpc-5845	227	7	lk	lk	PROPN
dpc-5845	227	8	,	,	PUNCT
dpc-5845	227	9	yamauchi	yamauchi	PROPN
dpc-5845	227	10	ps	ps	PROPN
dpc-5845	227	11	,	,	PUNCT
dpc-5845	227	12	et	et	PROPN
dpc-5845	227	13	al	al	PROPN
dpc-5845	227	14	.	.	PUNCT
dpc-5845	227	15	extension	extension	NOUN
dpc-5845	227	16	of	of	ADP
dpc-5845	227	17	ustekinumab	ustekinumab	NOUN
dpc-5845	227	18	maintenance	maintenance	NOUN
dpc-5845	227	19	dosing	dose	VERB
dpc-5845	227	20	interval	interval	NOUN
dpc-5845	227	21	in	in	ADP
dpc-5845	227	22	moderate	moderate	ADJ
dpc-5845	227	23	-	-	PUNCT
dpc-5845	227	24	to	to	ADP
dpc-5845	227	25	-	-	PUNCT
dpc-5845	227	26	severe	severe	ADJ
dpc-5845	227	27	psoriasis	psoriasis	NOUN
dpc-5845	227	28	:	:	PUNCT
dpc-5845	227	29	results	result	NOUN
dpc-5845	227	30	of	of	ADP
dpc-5845	227	31	a	a	DET
dpc-5845	227	32	phase	phase	NOUN
dpc-5845	227	33	iiib	iiib	NOUN
dpc-5845	227	34	,	,	PUNCT
dpc-5845	227	35	randomized	randomize	VERB
dpc-5845	227	36	,	,	PUNCT
dpc-5845	227	37	double	double	ADJ
dpc-5845	227	38	-	-	PUNCT
dpc-5845	227	39	blinded	blind	VERB
dpc-5845	227	40	,	,	PUNCT
dpc-5845	227	41	active	active	ADV
dpc-5845	227	42	-	-	PUNCT
dpc-5845	227	43	controlled	control	VERB
dpc-5845	227	44	,	,	PUNCT
dpc-5845	227	45	multicentre	multicentre	NOUN
dpc-5845	227	46	study	study	NOUN
dpc-5845	227	47	(	(	PUNCT
dpc-5845	227	48	pstellar	pstellar	ADJ
dpc-5845	227	49	)	)	PUNCT
dpc-5845	227	50	.	.	PUNCT
dpc-5845	228	1	br	br	PROPN
dpc-5845	228	2	j	j	PROPN
dpc-5845	228	3	dermatol	dermatol	NOUN
dpc-5845	228	4	.	.	PUNCT
dpc-5845	229	1	2017	2017	NUM
dpc-5845	229	2	dec;177(6	dec;177(6	NUM
dpc-5845	229	3	):	):	PUNCT
dpc-5845	229	4	1552	1552	NUM
dpc-5845	229	5	-	-	SYM
dpc-5845	229	6	1561	1561	NUM
dpc-5845	229	7	.	.	PUNCT
dpc-5845	230	1	doi	doi	NOUN
dpc-5845	230	2	:	:	PUNCT
dpc-5845	230	3	10.1111	10.1111	NUM
dpc-5845	230	4	/	/	SYM
dpc-5845	230	5	bjd.15722	bjd.15722	NOUN
dpc-5845	230	6	.	.	PUNCT
dpc-5845	231	1	epub	epub	PROPN
dpc-5845	231	2	2017	2017	NUM
dpc-5845	231	3	nov	nov	PROPN
dpc-5845	231	4	16	16	NUM
dpc-5845	231	5	.	.	PUNCT
dpc-5845	232	1	pmid	pmid	NOUN
dpc-5845	232	2	:	:	PUNCT
dpc-5845	232	3	28600818	28600818	NUM
dpc-5845	232	4	.	.	PUNCT
dpc-5845	233	1	21	21	NUM
dpc-5845	233	2	.	.	PUNCT
dpc-5845	234	1	amatore	amatore	PROPN
dpc-5845	234	2	f	f	PROPN
dpc-5845	234	3	,	,	PUNCT
dpc-5845	234	4	villani	villani	PROPN
dpc-5845	234	5	ap	ap	PROPN
dpc-5845	234	6	,	,	PUNCT
dpc-5845	234	7	tauber	tauber	PROPN
dpc-5845	234	8	m	m	PROPN
dpc-5845	234	9	,	,	PUNCT
dpc-5845	234	10	et	et	PROPN
dpc-5845	234	11	al	al	PROPN
dpc-5845	234	12	.	.	PUNCT
dpc-5845	234	13	psoriasis	psoriasis	NOUN
dpc-5845	234	14	research	research	NOUN
dpc-5845	234	15	group	group	NOUN
dpc-5845	234	16	of	of	ADP
dpc-5845	234	17	the	the	DET
dpc-5845	234	18	french	french	ADJ
dpc-5845	234	19	society	society	NOUN
dpc-5845	234	20	of	of	ADP
dpc-5845	234	21	dermatology	dermatology	NOUN
dpc-5845	234	22	(	(	PUNCT
dpc-5845	234	23	groupe	groupe	X
dpc-5845	234	24	de	de	X
dpc-5845	234	25	recherche	recherche	X
dpc-5845	234	26	sur	sur	X
dpc-5845	234	27	le	le	X
dpc-5845	234	28	psoriasis	psoriasis	PROPN
dpc-5845	234	29	de	de	X
dpc-5845	234	30	la	la	X
dpc-5845	234	31	société	société	PROPN
dpc-5845	234	32	française	française	PROPN
dpc-5845	234	33	de	de	X
dpc-5845	234	34	dermatologie	dermatologie	NOUN
dpc-5845	234	35	)	)	PUNCT
dpc-5845	234	36	.	.	PUNCT
dpc-5845	235	1	french	french	ADJ
dpc-5845	235	2	guidelines	guideline	NOUN
dpc-5845	235	3	on	on	ADP
dpc-5845	235	4	the	the	DET
dpc-5845	235	5	use	use	NOUN
dpc-5845	235	6	of	of	ADP
dpc-5845	235	7	systemic	systemic	ADJ
dpc-5845	235	8	treatments	treatment	NOUN
dpc-5845	235	9	for	for	ADP
dpc-5845	235	10	moderate	moderate	ADJ
dpc-5845	235	11	-	-	PUNCT
dpc-5845	235	12	to	to	ADP
dpc-5845	235	13	severe	severe	ADJ
dpc-5845	235	14	psoriasis	psoriasis	NOUN
dpc-5845	235	15	in	in	ADP
dpc-5845	235	16	adults	adult	NOUN
dpc-5845	235	17	.	.	PUNCT
dpc-5845	236	1	j	j	PROPN
dpc-5845	236	2	eur	eur	PROPN
dpc-5845	236	3	acad	acad	PROPN
dpc-5845	236	4	dermatol	dermatol	NOUN
dpc-5845	236	5	venereol	venereol	NOUN
dpc-5845	236	6	.	.	PUNCT
dpc-5845	237	1	2019	2019	NUM
dpc-5845	237	2	mar;33(3):464	mar;33(3):464	ADV
dpc-5845	237	3	-	-	SYM
dpc-5845	237	4	483	483	NUM
dpc-5845	237	5	.	.	PUNCT
dpc-5845	238	1	doi	doi	NOUN
dpc-5845	238	2	:	:	PUNCT
dpc-5845	238	3	22	22	NUM
dpc-5845	238	4	.	.	PUNCT
dpc-5845	239	1	daudén	daudén	PROPN
dpc-5845	239	2	e	e	PROPN
dpc-5845	239	3	,	,	PUNCT
dpc-5845	239	4	escario	escario	NOUN
dpc-5845	239	5	e	e	NOUN
dpc-5845	239	6	,	,	PUNCT
dpc-5845	239	7	martos	marto	NOUN
dpc-5845	239	8	-	-	PUNCT
dpc-5845	239	9	cabrera	cabrera	NOUN
dpc-5845	239	10	l	l	PROPN
dpc-5845	239	11	,	,	PUNCT
dpc-5845	239	12	et	et	PROPN
dpc-5845	239	13	al	al	PROPN
dpc-5845	239	14	.	.	PROPN
dpc-5845	239	15	dose	dose	NOUN
dpc-5845	239	16	reduction	reduction	NOUN
dpc-5845	239	17	is	be	AUX
dpc-5845	239	18	a	a	DET
dpc-5845	239	19	feasible	feasible	ADJ
dpc-5845	239	20	strategy	strategy	NOUN
dpc-5845	239	21	in	in	ADP
dpc-5845	239	22	patients	patient	NOUN
dpc-5845	239	23	with	with	ADP
dpc-5845	239	24	plaque	plaque	NOUN
dpc-5845	239	25	psoriasis	psoriasis	NOUN
dpc-5845	239	26	who	who	PRON
dpc-5845	239	27	achieve	achieve	VERB
dpc-5845	239	28	sustained	sustained	ADJ
dpc-5845	239	29	response	response	NOUN
dpc-5845	239	30	with	with	ADP
dpc-5845	239	31	secukinumab	secukinumab	NOUN
dpc-5845	239	32	:	:	PUNCT
dpc-5845	239	33	a	a	DET
dpc-5845	239	34	retrospective	retrospective	ADJ
dpc-5845	239	35	,	,	PUNCT
dpc-5845	239	36	multicenter	multicenter	ADJ
dpc-5845	239	37	cohort	cohort	NOUN
dpc-5845	239	38	study	study	NOUN
dpc-5845	239	39	in	in	ADP
dpc-5845	239	40	daily	daily	ADJ
dpc-5845	239	41	practice	practice	NOUN
dpc-5845	239	42	setting	setting	NOUN
dpc-5845	239	43	.	.	PUNCT
dpc-5845	240	1	int	int	NOUN
dpc-5845	240	2	j	j	PROPN
dpc-5845	240	3	dermatol	dermatol	NOUN
dpc-5845	240	4	.	.	PUNCT
dpc-5845	241	1	2024	2024	NUM
dpc-5845	241	2	apr;63(4):503	apr;63(4):503	PROPN
dpc-5845	241	3	-	-	PUNCT
dpc-5845	241	4	511	511	NUM
dpc-5845	241	5	.	.	PUNCT
dpc-5845	242	1	doi	doi	NOUN
dpc-5845	242	2	:	:	PUNCT
dpc-5845	242	3	10.1111	10.1111	NUM
dpc-5845	242	4	/	/	SYM
dpc-5845	242	5	ijd.16915	ijd.16915	NUM
dpc-5845	242	6	.	.	PUNCT
dpc-5845	243	1	epub	epub	PROPN
dpc-5845	243	2	2024	2024	NUM
dpc-5845	243	3	jan	jan	PROPN
dpc-5845	243	4	2	2	NUM
dpc-5845	243	5	.	.	PUNCT
dpc-5845	243	6	pmid	pmid	NOUN
dpc-5845	243	7	:	:	PUNCT
dpc-5845	243	8	38168847	38168847	NUM
dpc-5845	243	9	.	.	PUNCT
dpc-5845	244	1	5	5	X
dpc-5845	244	2	.	.	X
dpc-5845	244	3	benzaquen	benzaquen	PROPN
dpc-5845	244	4	m	m	PROPN
dpc-5845	244	5	,	,	PUNCT
dpc-5845	244	6	munshi	munshi	PROPN
dpc-5845	244	7	m	m	PROPN
dpc-5845	244	8	,	,	PUNCT
dpc-5845	244	9	bossart	bossart	PROPN
dpc-5845	244	10	s	s	PROPN
dpc-5845	244	11	,	,	PUNCT
dpc-5845	244	12	et	et	PROPN
dpc-5845	244	13	al	al	PROPN
dpc-5845	244	14	.	.	PUNCT
dpc-5845	244	15	long	long	ADJ
dpc-5845	244	16	-	-	PUNCT
dpc-5845	244	17	term	term	NOUN
dpc-5845	244	18	dose	dose	NOUN
dpc-5845	244	19	optimization	optimization	NOUN
dpc-5845	244	20	of	of	ADP
dpc-5845	244	21	adalimumab	adalimumab	NOUN
dpc-5845	244	22	via	via	ADP
dpc-5845	244	23	dose	dose	NOUN
dpc-5845	244	24	spacing	spacing	NOUN
dpc-5845	244	25	in	in	ADP
dpc-5845	244	26	patients	patient	NOUN
dpc-5845	244	27	with	with	ADP
dpc-5845	244	28	psoriasis	psoriasis	NOUN
dpc-5845	244	29	.	.	PUNCT
dpc-5845	245	1	bioengineering	bioengineering	NOUN
dpc-5845	245	2	(	(	PUNCT
dpc-5845	245	3	basel	basel	PROPN
dpc-5845	245	4	)	)	PUNCT
dpc-5845	245	5	.	.	PUNCT
dpc-5845	246	1	2022	2022	NUM
dpc-5845	246	2	aug	aug	PROPN
dpc-5845	246	3	13;9(8):387	13;9(8):387	NUM
dpc-5845	246	4	.	.	PUNCT
dpc-5845	247	1	doi	doi	NOUN
dpc-5845	247	2	:	:	PUNCT
dpc-5845	247	3	10.3390	10.3390	NUM
dpc-5845	247	4	/	/	SYM
dpc-5845	247	5	bioengineering9080387	bioengineering9080387	PROPN
dpc-5845	247	6	.	.	PUNCT
dpc-5845	248	1	pmid	pmid	NOUN
dpc-5845	248	2	:	:	PUNCT
dpc-5845	248	3	36004912	36004912	NUM
dpc-5845	248	4	;	;	PUNCT
dpc-5845	248	5	pmcid	pmcid	NOUN
dpc-5845	248	6	:	:	PUNCT
dpc-5845	248	7	pmc9405054	pmc9405054	NOUN
dpc-5845	248	8	.	.	PUNCT
dpc-5845	249	1	6	6	X
dpc-5845	249	2	.	.	X
dpc-5845	249	3	atalay	atalay	PROPN
dpc-5845	249	4	s	s	PROPN
dpc-5845	249	5	,	,	PUNCT
dpc-5845	249	6	van	van	PROPN
dpc-5845	249	7	den	den	PROPN
dpc-5845	249	8	reek	reek	PROPN
dpc-5845	249	9	jmpa	jmpa	PROPN
dpc-5845	249	10	,	,	PUNCT
dpc-5845	249	11	den	den	PROPN
dpc-5845	249	12	broeder	broeder	NOUN
dpc-5845	249	13	aa	aa	NOUN
dpc-5845	249	14	,	,	PUNCT
dpc-5845	249	15	et	et	PROPN
dpc-5845	249	16	al	al	PROPN
dpc-5845	249	17	..	..	PROPN
dpc-5845	249	18	comparison	comparison	NOUN
dpc-5845	249	19	of	of	ADP
dpc-5845	249	20	tightly	tightly	ADV
dpc-5845	249	21	controlled	control	VERB
dpc-5845	249	22	dose	dose	NOUN
dpc-5845	249	23	reduction	reduction	NOUN
dpc-5845	249	24	of	of	ADP
dpc-5845	249	25	biologics	biologic	NOUN
dpc-5845	249	26	with	with	ADP
dpc-5845	249	27	usual	usual	ADJ
dpc-5845	249	28	care	care	NOUN
dpc-5845	249	29	for	for	ADP
dpc-5845	249	30	patients	patient	NOUN
dpc-5845	249	31	with	with	ADP
dpc-5845	249	32	psoriasis	psoriasis	NOUN
dpc-5845	249	33	:	:	PUNCT
dpc-5845	249	34	a	a	DET
dpc-5845	249	35	randomized	randomized	ADJ
dpc-5845	249	36	clinical	clinical	ADJ
dpc-5845	249	37	trial	trial	NOUN
dpc-5845	249	38	.	.	PUNCT
dpc-5845	250	1	jama	jama	PROPN
dpc-5845	250	2	dermatol	dermatol	NOUN
dpc-5845	250	3	.	.	PUNCT
dpc-5845	251	1	2020	2020	NUM
dpc-5845	251	2	apr	apr	VERB
dpc-5845	251	3	1;156(4):393	1;156(4):393	NUM
dpc-5845	251	4	-	-	PUNCT
dpc-5845	251	5	400	400	NUM
dpc-5845	251	6	.	.	PUNCT
dpc-5845	252	1	doi	doi	NOUN
dpc-5845	252	2	:	:	PUNCT
dpc-5845	252	3	10.1001	10.1001	NUM
dpc-5845	252	4	/	/	SYM
dpc-5845	252	5	jamadermatol.2019.4897	jamadermatol.2019.4897	PROPN
dpc-5845	252	6	.	.	PUNCT
dpc-5845	253	1	pmid	pmid	NOUN
dpc-5845	253	2	:	:	PUNCT
dpc-5845	253	3	32049319	32049319	NUM
dpc-5845	253	4	;	;	PUNCT
dpc-5845	253	5	pmcid	pmcid	ADJ
dpc-5845	253	6	:	:	PUNCT
dpc-5845	253	7	pmc7042801	pmc7042801	X
dpc-5845	253	8	.	.	PUNCT
dpc-5845	254	1	7	7	X
dpc-5845	254	2	.	.	NUM
dpc-5845	254	3	atalay	atalay	PROPN
dpc-5845	254	4	s	s	PROPN
dpc-5845	254	5	,	,	PUNCT
dpc-5845	254	6	van	van	PROPN
dpc-5845	254	7	der	der	PROPN
dpc-5845	254	8	schoot	schoot	PROPN
dpc-5845	254	9	ls	ls	PROPN
dpc-5845	254	10	,	,	PUNCT
dpc-5845	254	11	vandermaesen	vandermaesen	ADJ
dpc-5845	254	12	l	l	NOUN
dpc-5845	254	13	,	,	PUNCT
dpc-5845	254	14	et	et	PROPN
dpc-5845	254	15	al	al	PROPN
dpc-5845	254	16	.	.	PUNCT
dpc-5845	255	1	evaluation	evaluation	NOUN
dpc-5845	255	2	of	of	ADP
dpc-5845	255	3	a	a	DET
dpc-5845	255	4	one	one	NUM
dpc-5845	255	5	-	-	PUNCT
dpc-5845	255	6	step	step	NOUN
dpc-5845	255	7	dose	dose	NOUN
dpc-5845	255	8	reduction	reduction	NOUN
dpc-5845	255	9	strategy	strategy	NOUN
dpc-5845	255	10	of	of	ADP
dpc-5845	255	11	adalimumab	adalimumab	NOUN
dpc-5845	255	12	,	,	PUNCT
dpc-5845	255	13	etanercept	etanercept	NOUN
dpc-5845	255	14	and	and	CCONJ
dpc-5845	255	15	ustekinumab	ustekinumab	NOUN
dpc-5845	255	16	in	in	ADP
dpc-5845	255	17	patients	patient	NOUN
dpc-5845	255	18	with	with	ADP
dpc-5845	255	19	psoriasis	psoriasis	NOUN
dpc-5845	255	20	in	in	ADP
dpc-5845	255	21	daily	daily	ADJ
dpc-5845	255	22	practice	practice	NOUN
dpc-5845	255	23	.	.	PUNCT
dpc-5845	256	1	acta	acta	PROPN
dpc-5845	256	2	derm	derm	PROPN
dpc-5845	256	3	venereol	venereol	NOUN
dpc-5845	256	4	.	.	PUNCT
dpc-5845	257	1	2021	2021	NUM
dpc-5845	257	2	may	may	AUX
dpc-5845	257	3	25;101(5):adv00463	25;101(5):adv00463	NUM
dpc-5845	257	4	.	.	PUNCT
dpc-5845	258	1	doi	doi	NOUN
dpc-5845	258	2	:	:	PUNCT
dpc-5845	258	3	10.2340/00015555	10.2340/00015555	NUM
dpc-5845	258	4	-3815	-3815	NOUN
dpc-5845	258	5	.	.	PUNCT
dpc-5845	259	1	pmid	pmid	NOUN
dpc-5845	259	2	:	:	PUNCT
dpc-5845	259	3	33903920	33903920	NUM
dpc-5845	259	4	;	;	PUNCT
dpc-5845	259	5	pmcid	pmcid	NOUN
dpc-5845	259	6	:	:	PUNCT
dpc-5845	259	7	pmc9367038	pmc9367038	NOUN
dpc-5845	259	8	.	.	PUNCT
dpc-5845	260	1	8	8	X
dpc-5845	260	2	.	.	X
dpc-5845	260	3	menter	menter	PROPN
dpc-5845	260	4	a	a	PROPN
dpc-5845	260	5	,	,	PUNCT
dpc-5845	260	6	krueger	krueger	PROPN
dpc-5845	260	7	gg	gg	PROPN
dpc-5845	260	8	,	,	PUNCT
dpc-5845	260	9	paek	paek	PROPN
dpc-5845	260	10	sy	sy	PROPN
dpc-5845	260	11	,	,	PUNCT
dpc-5845	260	12	et	et	PROPN
dpc-5845	260	13	al	al	PROPN
dpc-5845	260	14	.	.	PUNCT
dpc-5845	260	15	interleukin-17	interleukin-17	PROPN
dpc-5845	260	16	and	and	CCONJ
dpc-5845	260	17	interleukin-23	interleukin-23	PROPN
dpc-5845	260	18	:	:	PUNCT
dpc-5845	260	19	a	a	DET
dpc-5845	260	20	narrative	narrative	NOUN
dpc-5845	260	21	review	review	NOUN
dpc-5845	260	22	of	of	ADP
dpc-5845	260	23	mechanisms	mechanism	NOUN
dpc-5845	260	24	of	of	ADP
dpc-5845	260	25	action	action	NOUN
dpc-5845	260	26	in	in	ADP
dpc-5845	260	27	psoriasis	psoriasis	NOUN
dpc-5845	260	28	and	and	CCONJ
dpc-5845	260	29	associated	associated	ADJ
dpc-5845	260	30	comorbidities	comorbiditie	NOUN
dpc-5845	260	31	.	.	PUNCT
dpc-5845	260	32	 	 	SPACE
dpc-5845	261	1	dermatol	dermatol	NOUN
dpc-5845	261	2	ther	ther	ADV
dpc-5845	261	3	(	(	PUNCT
dpc-5845	261	4	heidelb	heidelb	NOUN
dpc-5845	261	5	)	)	PUNCT
dpc-5845	261	6	.	.	PUNCT
dpc-5845	262	1	2021;11(2):385	2021;11(2):385	NUM
dpc-5845	262	2	-	-	SYM
dpc-5845	262	3	400	400	NUM
dpc-5845	262	4	.	.	PUNCT
dpc-5845	263	1	doi:10.1007	doi:10.1007	VERB
dpc-5845	263	2	/	/	SYM
dpc-5845	263	3	s13555	s13555	PROPN
dpc-5845	263	4	-	-	PUNCT
dpc-5845	263	5	021	021	NUM
dpc-5845	263	6	-	-	PUNCT
dpc-5845	263	7	00483	00483	NUM
dpc-5845	263	8	-	-	PUNCT
dpc-5845	263	9	2	2	NUM
dpc-5845	263	10	.	.	NOUN
dpc-5845	263	11	9	9	NUM
dpc-5845	263	12	.	.	X
dpc-5845	263	13	daudén	daudén	PROPN
dpc-5845	263	14	e	e	PROPN
dpc-5845	263	15	,	,	PUNCT
dpc-5845	263	16	escario	escario	NOUN
dpc-5845	263	17	e	e	NOUN
dpc-5845	263	18	,	,	PUNCT
dpc-5845	263	19	martos	marto	NOUN
dpc-5845	263	20	-	-	PUNCT
dpc-5845	263	21	cabrera	cabrera	NOUN
dpc-5845	263	22	l	l	PROPN
dpc-5845	263	23	,	,	PUNCT
dpc-5845	263	24	et	et	PROPN
dpc-5845	263	25	al	al	PROPN
dpc-5845	263	26	.	.	PROPN
dpc-5845	263	27	dose	dose	NOUN
dpc-5845	263	28	reduction	reduction	NOUN
dpc-5845	263	29	is	be	AUX
dpc-5845	263	30	a	a	DET
dpc-5845	263	31	feasible	feasible	ADJ
dpc-5845	263	32	strategy	strategy	NOUN
dpc-5845	263	33	in	in	ADP
dpc-5845	263	34	patients	patient	NOUN
dpc-5845	263	35	with	with	ADP
dpc-5845	263	36	plaque	plaque	NOUN
dpc-5845	263	37	psoriasis	psoriasis	NOUN
dpc-5845	263	38	who	who	PRON
dpc-5845	263	39	achieve	achieve	VERB
dpc-5845	263	40	sustained	sustained	ADJ
dpc-5845	263	41	response	response	NOUN
dpc-5845	263	42	with	with	ADP
dpc-5845	263	43	secukinumab	secukinumab	NOUN
dpc-5845	263	44	:	:	PUNCT
dpc-5845	263	45	a	a	DET
dpc-5845	263	46	retrospective	retrospective	ADJ
dpc-5845	263	47	,	,	PUNCT
dpc-5845	263	48	multicenter	multicenter	ADJ
dpc-5845	263	49	cohort	cohort	NOUN
dpc-5845	263	50	study	study	NOUN
dpc-5845	263	51	in	in	ADP
dpc-5845	263	52	daily	daily	ADJ
dpc-5845	263	53	practice	practice	NOUN
dpc-5845	263	54	setting	setting	NOUN
dpc-5845	263	55	.	.	PUNCT
dpc-5845	264	1	int	int	NOUN
dpc-5845	264	2	j	j	PROPN
dpc-5845	264	3	dermatol	dermatol	NOUN
dpc-5845	264	4	.	.	PUNCT
dpc-5845	265	1	2024	2024	NUM
dpc-5845	265	2	apr;63(4):503	apr;63(4):503	PROPN
dpc-5845	265	3	-	-	PUNCT
dpc-5845	265	4	511	511	NUM
dpc-5845	265	5	.	.	PUNCT
dpc-5845	266	1	doi	doi	NOUN
dpc-5845	266	2	:	:	PUNCT
dpc-5845	266	3	10.1111	10.1111	NUM
dpc-5845	266	4	/	/	SYM
dpc-5845	266	5	ijd.16915	ijd.16915	NUM
dpc-5845	266	6	.	.	PUNCT
dpc-5845	267	1	epub	epub	PROPN
dpc-5845	267	2	2024	2024	NUM
dpc-5845	267	3	jan	jan	PROPN
dpc-5845	267	4	2	2	NUM
dpc-5845	267	5	.	.	PUNCT
dpc-5845	267	6	pmid	pmid	NOUN
dpc-5845	267	7	:	:	PUNCT
dpc-5845	267	8	38168847	38168847	NUM
dpc-5845	267	9	.	.	PUNCT
dpc-5845	268	1	10	10	NUM
dpc-5845	268	2	.	.	PUNCT
dpc-5845	269	1	lebwohl	lebwohl	PROPN
dpc-5845	269	2	m	m	PROPN
dpc-5845	269	3	,	,	PUNCT
dpc-5845	269	4	strober	strober	ADV
dpc-5845	269	5	b	b	NUM
dpc-5845	269	6	,	,	PUNCT
dpc-5845	269	7	menter	menter	X
dpc-5845	269	8	a	a	NOUN
dpc-5845	269	9	,	,	PUNCT
dpc-5845	269	10	et	et	PROPN
dpc-5845	269	11	al	al	PROPN
dpc-5845	269	12	.	.	PROPN
dpc-5845	269	13	phase	phase	NOUN
dpc-5845	269	14	3	3	NUM
dpc-5845	269	15	studies	study	NOUN
dpc-5845	269	16	comparing	compare	VERB
dpc-5845	269	17	brodalumab	brodalumab	NOUN
dpc-5845	269	18	with	with	ADP
dpc-5845	269	19	ustekinumab	ustekinumab	NOUN
dpc-5845	269	20	in	in	ADP
dpc-5845	269	21	psoriasis	psoriasis	NOUN
dpc-5845	269	22	.	.	PUNCT
dpc-5845	270	1	n	n	CCONJ
dpc-5845	270	2	engl	engl	PROPN
dpc-5845	270	3	j	j	PROPN
dpc-5845	270	4	med	med	PROPN
dpc-5845	270	5	.	.	PROPN
dpc-5845	270	6	2015	2015	NUM
dpc-5845	270	7	oct;373(14):1318	oct;373(14):1318	PROPN
dpc-5845	270	8	-	-	PUNCT
dpc-5845	270	9	28	28	NUM
dpc-5845	270	10	.	.	PUNCT
dpc-5845	271	1	doi	doi	NOUN
dpc-5845	271	2	:	:	PUNCT
dpc-5845	271	3	10.1056	10.1056	NUM
dpc-5845	271	4	/	/	SYM
dpc-5845	271	5	nejmoa1503824	nejmoa1503824	PROPN
dpc-5845	271	6	.	.	PUNCT
dpc-5845	272	1	pmid	pmid	NOUN
dpc-5845	272	2	:	:	PUNCT
dpc-5845	272	3	26422722	26422722	NUM
dpc-5845	272	4	.	.	PUNCT
dpc-5845	273	1	11	11	NUM
dpc-5845	273	2	.	.	PUNCT
dpc-5845	274	1	gisondi	gisondi	PROPN
dpc-5845	274	2	p	p	NOUN
dpc-5845	274	3	,	,	PUNCT
dpc-5845	274	4	maurelli	maurelli	NOUN
dpc-5845	274	5	m	m	PROPN
dpc-5845	274	6	,	,	PUNCT
dpc-5845	274	7	bellinato	bellinato	PROPN
dpc-5845	274	8	f	f	X
dpc-5845	274	9	,	,	PUNCT
dpc-5845	274	10	girolomoni	girolomoni	PROPN
dpc-5845	274	11	g.	g.	PROPN
dpc-5845	274	12	is	be	AUX
dpc-5845	274	13	risankizumab	risankizumab	NOUN
dpc-5845	274	14	as	as	ADP
dpc-5845	274	15	needed	need	VERB
dpc-5845	274	16	administration	administration	NOUN
dpc-5845	274	17	a	a	DET
dpc-5845	274	18	good	good	ADJ
dpc-5845	274	19	option	option	NOUN
dpc-5845	274	20	for	for	ADP
dpc-5845	274	21	patients	patient	NOUN
dpc-5845	274	22	with	with	ADP
dpc-5845	274	23	plaque	plaque	NOUN
dpc-5845	274	24	psoriasis	psoriasis	NOUN
dpc-5845	274	25	?	?	PUNCT
dpc-5845	275	1	j	j	PROPN
dpc-5845	275	2	eur	eur	PROPN
dpc-5845	275	3	acad	acad	PROPN
dpc-5845	275	4	dermatol	dermatol	NOUN
dpc-5845	275	5	venereol	venereol	NOUN
dpc-5845	275	6	.	.	PUNCT
dpc-5845	276	1	2022	2022	NUM
dpc-5845	276	2	sep;36(9):e713	sep;36(9):e713	PROPN
dpc-5845	276	3	-	-	PUNCT
dpc-5845	276	4	e715	e715	PROPN
dpc-5845	276	5	.	.	PUNCT
dpc-5845	277	1	doi	doi	NOUN
dpc-5845	277	2	:	:	PUNCT
dpc-5845	277	3	10.1111	10.1111	NUM
dpc-5845	277	4	/	/	SYM
dpc-5845	277	5	jdv.18182	jdv.18182	PROPN
dpc-5845	277	6	.	.	PUNCT
dpc-5845	278	1	epub	epub	NOUN
dpc-5845	278	2	2022	2022	NUM
dpc-5845	278	3	may	may	AUX
dpc-5845	278	4	5	5	NUM
dpc-5845	278	5	.	.	PUNCT
dpc-5845	279	1	pmid	pmid	NOUN
dpc-5845	279	2	:	:	PUNCT
dpc-5845	279	3	35470475	35470475	NUM
dpc-5845	279	4	.	.	PUNCT
dpc-5845	280	1	12	12	NUM
dpc-5845	280	2	.	.	PUNCT
dpc-5845	281	1	eyerich	eyerich	PROPN
dpc-5845	282	1	k	k	NOUN
dpc-5845	282	2	,	,	PUNCT
dpc-5845	282	3	 	 	SPACE
dpc-5845	282	4	asadullah	asadullah	PROPN
dpc-5845	282	5	k	k	PROPN
dpc-5845	282	6	,	,	PUNCT
dpc-5845	282	7	 	 	SPACE
dpc-5845	282	8	pinter	pinter	VERB
dpc-5845	282	9	a	a	NOUN
dpc-5845	282	10	,	,	PUNCT
dpc-5845	282	11	et	et	PROPN
dpc-5845	282	12	al	al	PROPN
dpc-5845	282	13	.	.	PUNCT
dpc-5845	282	14	noninferiority	noninferiority	NOUN
dpc-5845	282	15	of	of	ADP
dpc-5845	282	16	16	16	NUM
dpc-5845	282	17	-	-	PUNCT
dpc-5845	282	18	week	week	NOUN
dpc-5845	282	19	vs	vs	ADP
dpc-5845	282	20	8	8	NUM
dpc-5845	282	21	-	-	PUNCT
dpc-5845	282	22	week	week	NOUN
dpc-5845	282	23	guselkumab	guselkumab	NOUN
dpc-5845	282	24	dosing	dose	VERB
dpc-5845	282	25	in	in	ADP
dpc-5845	282	26	super	super	ADJ
dpc-5845	282	27	responders	responder	NOUN
dpc-5845	282	28	for	for	ADP
dpc-5845	282	29	maintaining	maintain	VERB
dpc-5845	282	30	control	control	NOUN
dpc-5845	282	31	of	of	ADP
dpc-5845	282	32	psoriasis	psoriasis	NOUN
dpc-5845	282	33	:	:	PUNCT
dpc-5845	282	34	 	 	SPACE
dpc-5845	282	35	the	the	DET
dpc-5845	282	36	guide	guide	NOUN
dpc-5845	282	37	randomized	randomize	VERB
dpc-5845	282	38	clinical	clinical	ADJ
dpc-5845	282	39	trial	trial	NOUN
dpc-5845	282	40	.	.	PUNCT
dpc-5845	282	41	  	  	SPACE
dpc-5845	283	1	jama	jama	PROPN
dpc-5845	283	2	dermatol.2024;160(9):953–963	dermatol.2024;160(9):953–963	PROPN
dpc-5845	283	3	.	.	PUNCT
dpc-5845	283	4	doi:10.1001	doi:10.1001	PROPN
dpc-5845	283	5	/jamadermatol.2024.2463	/jamadermatol.2024.2463	PUNCT
dpc-5845	284	1	13	13	NUM
dpc-5845	284	2	.	.	PUNCT
dpc-5845	285	1	reich	reich	PROPN
dpc-5845	285	2	k	k	PROPN
dpc-5845	285	3	,	,	PUNCT
dpc-5845	285	4	puig	puig	PROPN
dpc-5845	285	5	l	l	PROPN
dpc-5845	285	6	,	,	PUNCT
dpc-5845	285	7	szepietowski	szepietowski	PROPN
dpc-5845	285	8	jc	jc	PROPN
dpc-5845	285	9	,	,	PUNCT
dpc-5845	286	1	et	et	PROPN
dpc-5845	286	2	al	al	PROPN
dpc-5845	286	3	.	.	PROPN
dpc-5845	286	4	secukinumab	secukinumab	PROPN
dpc-5845	286	5	dosing	dose	VERB
dpc-5845	286	6	optimization	optimization	NOUN
dpc-5845	286	7	in	in	ADP
dpc-5845	286	8	patients	patient	NOUN
dpc-5845	286	9	with	with	ADP
dpc-5845	286	10	moderate	moderate	ADJ
dpc-5845	286	11	-	-	PUNCT
dpc-5845	286	12	to	to	ADP
dpc-5845	286	13	-	-	PUNCT
dpc-5845	286	14	severe	severe	ADJ
dpc-5845	286	15	plaque	plaque	NOUN
dpc-5845	286	16	psoriasis	psoriasis	NOUN
dpc-5845	286	17	:	:	PUNCT
dpc-5845	286	18	results	result	VERB
dpc-5845	286	19	from	from	ADP
dpc-5845	286	20	the	the	DET
dpc-5845	286	21	randomized	randomized	ADJ
dpc-5845	286	22	,	,	PUNCT
dpc-5845	286	23	open	open	ADJ
dpc-5845	286	24	-	-	PUNCT
dpc-5845	286	25	label	label	NOUN
dpc-5845	286	26	optimise	optimise	ADJ
dpc-5845	286	27	study	study	NOUN
dpc-5845	286	28	.	.	PUNCT
dpc-5845	287	1	br	br	PROPN
dpc-5845	287	2	j	j	PROPN
dpc-5845	287	3	dermatol	dermatol	NOUN
dpc-5845	287	4	.	.	PUNCT
dpc-5845	288	1	2020	2020	NUM
dpc-5845	288	2	feb;182(2):304	feb;182(2):304	NUM
dpc-5845	288	3	-	-	PUNCT
dpc-5845	288	4	315	315	NUM
dpc-5845	288	5	.	.	PUNCT
dpc-5845	289	1	doi	doi	NOUN
dpc-5845	289	2	:	:	PUNCT
dpc-5845	289	3	10.1111	10.1111	NUM
dpc-5845	289	4	/	/	SYM
dpc-5845	289	5	bjd.18143	bjd.18143	NOUN
dpc-5845	289	6	.	.	PUNCT
dpc-5845	290	1	epub	epub	PROPN
dpc-5845	290	2	2019	2019	NUM
dpc-5845	290	3	sep	sep	PROPN
dpc-5845	290	4	8	8	NUM
dpc-5845	290	5	.	.	PUNCT
dpc-5845	291	1	pmid	pmid	NOUN
dpc-5845	291	2	:	:	PUNCT
dpc-5845	291	3	31102257	31102257	NUM
dpc-5845	291	4	.	.	PUNCT
dpc-5845	292	1	14	14	NUM
dpc-5845	292	2	.	.	PUNCT
dpc-5845	293	1	krueger	krueger	PROPN
dpc-5845	293	2	jg	jg	PROPN
dpc-5845	293	3	,	,	PUNCT
dpc-5845	293	4	ferris	ferris	PROPN
dpc-5845	293	5	lk	lk	PROPN
dpc-5845	293	6	,	,	PUNCT
dpc-5845	293	7	menter	menter	X
dpc-5845	293	8	a	a	PRON
dpc-5845	293	9	et	et	PROPN
dpc-5845	293	10	al	al	PROPN
dpc-5845	293	11	.	.	PUNCT
dpc-5845	294	1	anti	anti	ADJ
dpc-5845	294	2	-	-	ADJ
dpc-5845	294	3	il-23a	il-23a	ADJ
dpc-5845	294	4	mab	mab	X
dpc-5845	294	5	bi	bi	NOUN
dpc-5845	294	6	655066	655066	NUM
dpc-5845	294	7	for	for	ADP
dpc-5845	294	8	treatment	treatment	NOUN
dpc-5845	294	9	of	of	ADP
dpc-5845	294	10	moderate	moderate	ADJ
dpc-5845	294	11	-	-	PUNCT
dpc-5845	294	12	to	to	ADP
dpc-5845	294	13	severe	severe	ADJ
dpc-5845	294	14	psoriasis	psoriasis	NOUN
dpc-5845	294	15	:	:	PUNCT
dpc-5845	294	16	safety	safety	NOUN
dpc-5845	294	17	,	,	PUNCT
dpc-5845	294	18	efficacy	efficacy	NOUN
dpc-5845	294	19	,	,	PUNCT
dpc-5845	294	20	pharmacokinetics	pharmacokinetic	NOUN
dpc-5845	294	21	,	,	PUNCT
dpc-5845	294	22	and	and	CCONJ
dpc-5845	294	23	biomarker	biomarker	VERB
dpc-5845	294	24	results	result	NOUN
dpc-5845	294	25	of	of	ADP
dpc-5845	294	26	a	a	PRON